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ABSTRACT 
Carrie E. Rubel: Defining the Molecular Mechanisms of Ubiquitin Proteasome System 
Dysfunction as a Driver of Disease: CHIP mutation in SCAR16 
(Under the direction of: Gary Johnson) 
 
All cells must respond to changes in their environment including a plethora of 
physiologic and pathologic stresses in order to maintain homeostasis and survive. Protein 
homeostasis is particularly critical to cell survival and cells utilize multiple highly specialized 
and integrated methods of protein quality control (PQC) to ensure that proteins are appropriately 
folded and terminally misfolded proteins are eliminated to prevent proteotoxicity. PQC depends 
on an elegant collaboration between molecular chaperones and the ubiquitin-proteasome system 
(UPS). Disruption of PQC and subsequent proteotoxicity is an underlying molecular phenotype 
in disease pathologies in the brain and heart. Understanding the molecular mechanisms 
underlying diseases where disruption of PQC is central to disease pathology is key to our ability 
to intervene therapeutically. To this end, this thesis focuses on understanding the function of E3 
ubiquitin ligases and how mutations in these key players in the UPS can drive disease pathology 
in the heart and brain. First, I describe and validate a novel method for the identification of E3 
ubiquitin ligase substrates addressing a significant technological limitation in the field. Next, I 
describe the first discovery of human mutation in the E3 ubiquitin ligase CHIP in a form of 
spinocerebellar ataxia, Gordon Holmes Syndrome that has led to the establishment of a new 
disease designation, autosomal recessive spinocerebellar ataxia-16 (SCAR16) to describe 
spinocerebellar ataxia caused by homozygous or compound heterozygous mutation in CHIP. 
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Finally, I expanded upon this discovery to define the structural and functional consequences of 
CHIP mutation in SCAR16 and explore the deficits associated with this mutation in a genomic 
context utilizing a mouse model system providing the first in vivo, disease-relevant model of 
partial CHIP dysfunction. Together these studies provide novel tools to further our understanding 
of the UPS and reveal fascinating insight into the molecular mechanisms underlying CHIP 
mutation in SCAR16 disease that not only may facilitate the development of therapies for this 
devastating disease, but also contribute to our basic understanding of the UPS and its role in 
disease pathogenesis to drive successful investment, innovation, preclinical investigation and 
clinical study design in other disease areas.   
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 CHAPTER I  
 
INTRODUCTION1 
 
Organisms must respond to changes in their environment in order to maintain 
homeostasis and survive. These environmental changes include a plethora of physiologic and 
pathologic stresses, such as perturbations in pH, temperature, and osmotic pressure; mechanical 
strain; oxidative stress; and alterations in the genetic code. In any case, when faced with these 
challenges, every individual cell that composes each unique organ and tissue must be equipped 
with and successfully mobilize specific mechanisms corresponding to the needs of that cell type 
for the overall maintenance of the organism.  
While cellular homeostasis encompasses many types of biomolecules, protein 
homeostasis is particularly critical to cell survival because of the central role proteins play in so 
many cellular processes. Proteins are the building blocks of the cell and also perform a vast array 
of functions within living organisms, including catalyzing metabolic reactions, replicating DNA, 
responding to stimuli, and transporting molecules from one location to another. Cells utilize 
multiple highly specialized and integrated methods of protein quality control (PQC) to ensure 
that 1) proteins are appropriately folded, and that 2) terminally misfolded proteins are eliminated 
 
1All Figures Contributed by Carrie Rubel and Adapted from Jonathan Schisler 
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 both under basal conditions as well as when exposed to molecular stressors. PQC depends on an 
elegant collaboration between molecular chaperones and the ubiquitin-proteasome system (UPS). 
The UPS is largely responsible for targeted proteolysis in the cell. When a misfolded or damaged 
protein fails to be repaired by chaperone-mediated processes, it will be degraded by the UPS.  
The pathophysiological significance of proper PQC is well illustrated during 
proteotoxicity. If the UPS becomes impaired or overwhelmed, the cell is unable to sufficiently 
clear misfolded proteins. These proteins may then associate with one another to form 
sequentially higher order protein aggregates, such as soluble oligomers, soluble aggregates, and 
eventually, inclusion bodies.1 Experimental evidence in neurodegenerative diseases suggests that 
protein aggregates or any one of the preceding intermediaries, even soluble protein oligomers, 
may induce cell death, a process termed proteotoxicity.2, 3  With their very limited capacity for 
self-renewal, this can be quite detrimental to post-mitotic cells in organs such as the heart and 
brain. In fact, proteotoxicity has long been associated as an underlying molecular phenotype in 
disease pathologies in the brain, including Alzheimer’s, Parkinson’s and Huntington’s diseases, 
and is beginning to be appreciated as a driver of disease pathologies in the heart.1, 4-6 In the heart 
and brain, proteotoxicity is a common hallmark of proteinopathies – diseases associated with the 
accumulation of malformed protein. Importantly, the underlying molecular phenotype of 
proteinopathy has most commonly been attributed to the accumulation of a particular malformed 
protein, usually as the result of its genetic mutation. However, as our understanding of PQC has 
expanded, proteinopathies are increasingly appreciated to also encompass diseases that result in 
the general accumulation of abnormal proteins as a result of disruption of PQC, for example as a 
result of genetic mutation of a component of the UPS.  
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Our understanding of the molecular components and mechanisms involved in cellular 
PQC has grown deeper in recent years and will likely expand exponentially as we fully 
appreciate and even exploit the opportunities presented by the overlap between pathologies in the 
heart and brain, both pre-clinically and clinically. In the United States alone, more than 5 million 
Americans have Alzheimer’s disease, and heart disease remains the most common cause of death 
and disability in our society.1, 7 Yet, current therapies are severely limited for these and other 
diseases where disruption of PQC is central to disease pathology, and the need for additional 
therapies remains substantial.  Developing better tools for studying these pathways and 
uncovering the underlying molecular mechanisms and links between disruption of PQC and 
disease pathology in humans will undoubtedly generate translational outcomes, allowing for the 
cultivation of novel and highly specific treatment options for these cardiovascular and 
neurological conditions.  
The work of this thesis focuses on understanding the molecular mechanisms underlying 
diseases where disruption of PQC is central to disease pathology. Specifically, I focus on 
understanding the function of E3 ubiquitin ligases and how mutations in these key players in the 
UPS can drive disease pathology in the heart and brain. One limitation to our understanding of 
E3 ubiquitin ligases is that current methods to identify E3 ubiquitin ligase substrates rely heavily 
upon non-physiologic in vitro methods, impeding the unbiased discovery of physiological 
substrates in relevant model systems. In the following, I begin by describing a novel method for 
identifying ubiquitin ligase substrates utilizing the E3 ubiquitin ligase, MuRF1 (muscle RING-
finger proteins 1) because of its importance as a modulator of heart muscle protein homeostasis. 
However, this method can be applied to any E3 ubiquitin ligase, both in normal and disease 
model systems, in order to identify relevant physiological substrates under various biological 
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conditions, opening the door to a clearer mechanistic understanding of E3 ubiquitin ligase 
function and broadening their potential as therapeutic targets.  
I then focus on the protein E3 ubiquitin ligase CHIP (C-terminus of HSC70 interacting 
protein) encoded by the STUB1 gene. Loss of CHIP function has long been associated with 
protein misfolding and aggregation in several genetic mouse models of neurodegenerative 
disorders, and genetic depletion in mice results in robust hypertrophy and decreased cardiac 
function.8, 9 However, a role for CHIP in human disease had yet to be identified. Here I describe 
the first discovery of CHIP point mutation, STUB1 c.737C→T, p.Thr246Met, in a form of 
spinocerebellar ataxia, Gordon Holmes Syndrome, that has led to the establishment of a new 
disease designation, SCAR16 (Autosomal Recessive Spinocerebellar Ataxia-16) to describe 
spinocerebellar ataxia caused by homozygous or compound heterozygous mutation in the STUB1 
gene. I then expand upon this discovery to define the structural and functional consequences of 
CHIP mutation in SCAR16 and explore the deficits associated with this mutation in a mouse 
model system, providing the first definition of partial CHIP dysfunction and assignment of 
specific in vivo deficits that result as a consequence of partial (but not total) loss of CHIP 
function. By determining how CHIP mutation contributes to SCAR16 pathology, we will 
potentially identify means for modulating CHIP and/or its substrates/interactors as therapeutic 
targets for SCAR16. 
 
Disruption of PQC and Proteotoxicity in Human Disease 
Disruption of PQC and subsequent proteotoxicity is being increasingly recognized as a 
driver of disease pathology in both the heart and brain. This parallel between pathologies in the 
heart and brain is not largely surprising, given the importance of post-mitotic, terminally 
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differentiated cell types in these tissues. In these cells, misregulation of protein homeostasis may 
have more dire consequences, as post-mitotic cells cannot dilute out toxic proteins by cell 
division, and dead or dying cells cannot be readily replaced.   
The heart is a unique organ, constantly barraged with molecular stressors, such as the 
mechanical stress from perpetual contractions.10 The cardiomyocyte is well-adapted to withstand 
this level of stress. Cardiomyocytes are loaded with a huge amount of mitochondria to ensure 
that the energy demands of the cell are met and allow the heart’s perpetual motion to proceed. 
Cardiomyocytes are equipped with sophisticated and proficient mechanisms of cellular PQC, as 
discussed above, to eliminate misfolded proteins that could become deleterious if allowed to 
persist in the sarcoplasm.1 It has been recently discovered that an underlying molecular 
phenotype of many types of cardiac dysfunction is the accumulation of misfolded protein, 
suggesting that a breakdown in the fidelity of misfolded protein removal may play a causative 
role in cardiac pathologies. Protein misfolding has been suggested as a key contributor to the 
progression of heart failure, with evidence of proteotoxicity and PQC dysregulation in pathologic 
cardiac hypertrophy and dilated and ischemic cardiomyopathies.1, 5, 6 Indeed, it is thought that at 
least 30% of translated protein, for various reasons, never reaches its appropriate cellular 
location,11 so disruption of the PQC mechanisms in the heart can quickly lead to protein buildup 
and accelerate deleterious effects downstream. 
While protein accumulation in the heart has been observed for decades, desmin-related 
cardiomyopathy (DRM) is probably the best understood cardiac disease stemming from 
proteinopathy and associated proteotoxicity.12 DRM is a myofibrillar myopathy characterized by 
muscle weakness and cardiomyopathy. While the cause of the disease was unknown, histological 
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analysis showed a striking feature: electron-dense intracellular inclusion bodies that positively 
immunostained for desmin. Two papers published in 1998 showed that mutations in the 
intermediate filament protein desmin13 or its chaperone αB-crystallin (CryAB)14 can cause DRM. 
These genes were discovered in two families with DRM, demonstrating that a mutation in either 
of these genes can lead to heritable disease.  
In an attempt to understand these inclusions and how they affect cardiac function, Wang 
et al developed transgenic mouse models overexpressing DRM-related mutations in desmin 
(DesD7) or CryAB (CryABR120G) in a cardiac-specific manner.15, 16 The hearts of these mouse 
models developed hypertrophy and progressed to heart failure in early adulthood. Pathological 
analysis revealed that the hearts developed extensive fibrosis and, importantly, displayed the 
characteristic intracellular inclusions of DRM. These inclusions accumulate in the perinuclear 
region of cardiomyocytes and contained both CryAB and desmin. In addition, these inclusions 
were found to also contain proteins involved in the cardiac adaptation to stress, including heat 
shock protein 25 (Hsp25) and ubiquitin. This evidence suggests that these inclusions may be 
aggresomes, a common hallmark of neurodegenerative phenotypes. While DRM is a severe and 
unique case of cardiomyopathy derived from proteotoxicity, it is rare. However, this model 
clearly demonstrates that deficits in PQC mechanisms can have severe and devastating effects 
and are sufficient to cause heart failure.  
Like cardiomyocytes, the neurons that make up the brain are largely senescent cells, and 
numerous proteotoxic entities have been shown to affect this cell type, leading to neuronal cell 
death. In fact, disruption of PQC, accumulation of misfolded proteins, and resulting 
proteotoxicity has long been appreciated as a key underlying molecular phenotype in disease 
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pathologies in the brain.17, 18 More than 100 years ago Dr. Alois Alzheimer observed abnormal 
accumulations of protein in the brain of his patient who died from what was then described only 
as “an unusual mental disease.”19 Since this first observation, the list is ever-expanding as we 
have come to understand that misfolded proteins are central to the pathophysiology of not only 
Alzheimer’s disease, but many other neurodegenerative diseases including Huntington's disease, 
Parkinson's disease, Amyotrophic Lateral Sclerosis, and more recently polyglutamine expansion 
diseases like Spinocerebellar Ataxia Type 3 (SCA3).4 In this disease class, the proteotoxic entity 
can take many forms, including α-synuclein, beta-amyloid and tau, huntingtin, and SOD1, which 
are the molecular bases for Parkinson’s, Alzheimer’s, Huntington’s, and Amyotrophic Lateral 
Sclerosis, respectively .  
Common to all of these diseases is the presence of misfolded protein accumulated within 
the cell or within the extracellular space. However, the molecular drivers behind the toxic 
accumulation of protein in each of these disease pathologies may differ. In some cases, certain 
polypeptides, such as hyperphosphorylated tau in Alzheimer’s disease, which have a propensity 
towards misfolding, leads to their spontaneous misfolding and rapid aggregate formation.20 In 
others, genetic mutation in specific proteins, such as huntingtin in Huntington’s disease or α-
synuclein in Parkinson’s disease, disrupts their folding, leading to aggregate formation.21, 22 One 
common thread to these disease pathologies, however, is reduced UPS activity in the brain. 
Many studies have identified reduced proteasome activity associated with aging, resulting in a 
diminished capacity to clear misfolded protein, contributing to the formation of pathological 
protein aggregates.23-25 To make matters worse, the accumulation of aggregates of both mutated 
proteins and aggregation-prone proteins has been shown to further inhibit the activities of the 
UPS, including the proteasome, promoting this vicious cycle of misfolded protein accumulation 
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and subsequent aggregation.24, 26-30 For example, ubiquitinated and aggregated tau in Alzheimer’s 
disease as well as aggregated mutant α-synuclein in Parkinson’s disease can block the gate of the 
19S catalytic subunit of the proteasome by binding to its recognition site, blocking proteasome 
enzymatic activity and impairing proteasomal degradation. 24, 28, 31 
Inhibition of the proteasome is not the only disruption of PQC that is proposed to drive 
disease pathogenesis in neurodegeneration. Studies have also implicated impairments in 
ubiquitination and deubiquitination as well as substrate delivery to the proteasome. Examples 
include the mutation of the cytosolic E3 ubiquitin ligase parkin in Parkinson’s disease and the 
deubiqutinating enzyme Ataxin-3 in SCA3. Both inherited and/or sporadic mutation of either of 
these proteins not only leads to increased propensity towards aggregation of these proteins, 
potentially driving proteasome impairment and proteotoxicity, but also inhibits these proteins’ 
respective UPS functions as an E3 ubiquitin ligase and a deubiquitining enzyme (DUB).32, 33 
Under conditions of stress, parkin is normally recruited to the outer membrane of the 
mitochondria, where it polyubiqutinates and directs proteasomal degradation of outer 
mitochondrial membrane proteins, including Mitofusins 1/2.34, 35 Loss of parkin function has 
been associated with reduced polyubiquitination of these outer mitochondrial membrane 
proteins, the accumulation of damaged mitochondria and increased cell death.33  
Similarly, Ataxin-3 is a highly conserved DUB with a flexible C-terminal tail that 
features three ubiquitin-interacting motifs flanking a polyQ region of variable length. Abnormal 
expansion of the polyQ region to more than 53 glutamines is pathological and manifests in 
SCA3. Like mutant parkin, not only does accumulation of this mutant Ataxin-3 lead to its toxic 
aggregation, but may also drive proteotoxicity due to loss of DUB function, as expression of 
pathogenic Ataxin-3 in vivo has been associated with higher global levels of ubiquitinated 
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proteins than the nonexpanded form, likely due to reduced DUB activity of pathogenic Ataxin-3 
as a result or impaired substrate binding or proteolysis.36 Interestingly, Ataxin-3 has also been 
reported to regulate protein turnover of other UPS proteins, including the E3 ligase CHIP, thus 
further expanding the potential implications of Ataxin-3 mutation on UPS activity and UPS 
dysregulation as a driver of disease pathogenesis.37  
While in many cases the precise molecular mechanisms of protein aggregation, 
proteotoxicity, and the causative deficiencies in PQC that promote disease pathogenesis in the 
heart and brain remain to be elucidated, it is clear that disruption of PQC is a key driver of 
disease in both the heart and brain and modulation of PQC pathways represents a putative 
therapeutic strategy for the treatment of these devastating diseases. 
 
PQC and the UPS 
Coordinated PQC is crucial to the maintenance of the proteome both under basal 
conditions and particularly under conditions of stress. PQC encompasses both the refolding of 
misfolded proteins largely by molecular chaperones, as well as their degradation by the 
degradative machinery of the UPS. We define a molecular chaperone as any protein that interacts 
with, stabilizes, or helps another protein to acquire its functionally active conformation, without 
being present in its final structure.38 As such, molecular chaperones are responsible for not only 
promoting the proper de novo folding of newly synthesized proteins and their translocation 
across membranes, but also the refolding of stress-denatured substrates. Due to their upregulation 
during conditions of stress that result in protein denaturation, such as elevated temperature 
molecular chaperones are often referred to as heat-shock proteins (Hsps). Most Hsps are 
classified by their molecular weight and include small Hsps, Hsp40, Hsp60, Hsp70 and Hsp90.39, 
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40 With their inherent ability to recognize and bind non-native proteins, chaperones serve as the 
first line of defense against the accumulation of misfolded proteins and triage them 
appropriately. This triage occurs either directly by facilitating their refolding to a functional 
native state, or, when this is not possible or is not energetically favorable, promotes their 
degradation by the UPS. Interestingly, the activity of some Hsps, including Hsp70 and Hsp90, is 
regulated by their direct interaction with proteins termed molecular co-chaperones. These 
molecular co-chaperones, including members of the UPS such as E3 ubiquitin ligase CHIP, 
modulate chaperone function and expression and consequently regulate the molecular triage 
decision determining whether substrate proteins enter the productive folding pathway or the 
degradation pathway.41 The function of these molecular co-chaperones is particularly intriguing 
as it represents a direct link between the two mutually exclusive pathways of folding and 
degradation that are central to PQC. 
 
The UPS 
As described extensively in the previous section the UPS is critical to the regulation of 
protein homeostasis in both the heart and brain, emphasized by myriad cardiovascular and 
neurodegenerative diseases linked to altered UPS function, including cardiac hypertrophy, heart 
failure, diabetes, ischemia-reperfusion injury, Alzheimer’s, Parkinson’s and Huntington’s 
diseases.42 43  Here I focus on its role as degradative machinery, but it should be noted that the 
UPS is also increasingly being recognized for its role in non-proteolytic regulatory mechanisms, 
including membrane transport, chromatin structure and transcription, DNA repair and diverse 
signaling pathways.44-46 
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Ubiquitination is a multi-step enzymatic process that covalently links the carboxylic acid 
of the small protein ubiquitin to a substrate protein lysine to form a covalent amide bond. 
Substrate specificity of the ubiquitination reaction occurs at the level of the E3 ubiquitin ligase.47, 
48  However, prior to substrate recognition and ubiquitin transfer by the E3 ubiquitin ligase, 
ubiquitin is activated in a two-step process involving the E1 ubiquitin-activating enzyme and the 
E2 ubiquitin conjugating enzyme. First, in an ATP-dependent process, the E1 enzyme interacts 
with ubiquitin, forming a thioester linkage between the C-terminal carboxyl group of ubiquitin 
and the E1 sulfhydryl moiety. Next, the ubiquitin is transferred to the active cysteine of the E2 
enzyme. The ubiquitin molecule is now ready to be finally transferred to the substrate protein 
lysine by the E3 enzyme in a substrate-specific and highly regulated reaction. This process can 
then be repeated, adding additional ubiquitin molecules to generate a polyubiquitin chain. The 
human genome encodes >600 E3 ubiquitin ligases that are specific to particular targets, while 
just two E1 ubiquitin-activating enzymes and 38 E2 ubiquitin conjugating enzymes participate in 
different ubiquitination reactions.49 
E3 ubiquitin ligases function as distinct molecular regulators as the modulators of UPS 
specificity and so are the focus of this thesis work. At least nine E3 ubiquitin ligases have been 
identified in the heart, including CHIP; MuRF-1, MuRF-2, and MuRF-3 (muscle RING-finger 
proteins 1, 2, and 3); atrogin-1/MAFbx (muscle atrophy F-box); and MDM2 (murine double 
minute 2).50 In the brain, the list is significantly longer, but also includes CHIP and MDM2 as 
well as UBE3A (ubiquitin protein ligase E3A), Parkin and brain-specific TRIM9 (Tripartite 
Motif-Containing Protein 9).51  Ubiquitin post-translational modification can occur by the 
addition of a single ubiquitin (monoubiquitination) or as a chain of ubiquitins 
(polyubiquitination), with these chains varying in length and linkage type. Ubiquitin has seven 
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lysine (K) residues by which polyubiquitination can occur (K6, K11, K27, K29, K33, K48 and 
K63), as well as the amino-terminus. Both homogenous and heterogeneous ubiquitin chains can 
be formed, utilizing the same lysine on each ubiquitin in the former and different ubiquitin 
lysines in the latter.52 The fate of the ubiquitinated protein depends upon which lysine residue 
within the protein the ubiquitin is attached to and the length and linkage type of the added 
ubiquitin. (Fig. 1.1) Addition of canonical K48 polyubiquitin chains of at least four ubiquitin 
molecules leads to subsequent degradation of the substrate protein by the 26S proteasome. 
Monoubiquitination and non-canonical polyubiquitination via other linkage types and branched 
chains containing multiple linkage types can also occur, and generally do not target proteins for 
UPS-mediated degradation, but rather regulate substrate proteins via non-proteolytic 
mechanisms, including modulating protein localization, activity, or stability.53, 54 
The 26S ubiquitin proteasome is a cylindrical molecular machine consisting of a 
proteolytic 20S core particle capped at both ends by a 19S regulatory particle.49, 55 The center 
barrel-shaped proteolytic chamber of the 20S core particle has a narrow diameter of as little as 13 
angstroms, thus restricting the size of the entering polyubiquitinated substrate proteins.56 Thus, 
upon binding the polyubiquitinated substrate protein, the 19S particle deubiquitinates the 
substrate, recycling the ubiquitin, and unfolds the protein, feeding the now unfolded polypeptide 
chain into the center of the 20S core particle for proteolytic degradation. This proteolytic 
degradation is achieved by the combined activities of the β1, β2 and β5 subunits that have 
caspase-like, chymotrypsin-like and trypsin-like peptidase activities, respectively.57-59  
Similar to other post-translational modifications, ubiquitination is reversible. A key component 
in this process of both proteasomal degradation and non-proteolytic protein regulation by 
ubiquitin are a family of approximately 100 enzymes called DUBs. DUBs are responsible for 
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disassembly of polyubiquitin chains and removal of ubiquitin from substrates by cleavage of the 
bonds between ubiquitin and protein.60 In this role, DUBs play a critical role in regulating the 
dynamics of ubiquitination, proofreading ubiquitination and recycling ubiquitin. Functionally 
this may spare some proteins from degradation, reverse changes in cellular localization or alter 
protein-protein interactions.61 An additional layer of specificity is added to the UPS by the work 
of DUBs, as they contain varying ubiquitin binding domains which confer specificity for 
different ubiquitin chains.62, 63 
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Figure 1.1 The Ubiquitin Pathway. Ubiquitin conjugation of substrates occurs in a series of 
ATP-dependent reactions facilitated by the coordinated efforts of E1 ubiquitin-activating 
enzymes, E2 ubiquitin conjugating enzymes and E3 ubiquitin ligases. Substrate specificity of the 
ubiquitination reaction is determined by the E3 ubiquitin ligase. The fate of ubiquitinated 
substrates is dependent upon the length and type of the ubiquitin linkage.  
 
 
 
 
15 
 
MuRF1  
This work begins by focusing on the description of a novel method for the identification 
of E3 ubiquitin ligase substrates, specifically substrates of MuRF1. The development of this 
methodology addresses a significant gap in our ability to fully understand E3 ubiquitin ligases by 
creating a novel and improved method to identify relevant substrates under various biological 
conditions. MuRF1 is a muscle-specific E3 ubiquitin ligase regulating the function and stability 
of numerous proteins in multiple regions of the cardiomyocyte.64, 65, 66 It is known to be involved 
in PQC and reorganization of the cardiac sarcomere by placement of polyubiquitin chains on 
substrates, including troponin I, β/slow myosin heavy chain and myosin binding protein-C, 
targeting them for destruction by the proteasome.66-69 MuRF1 cellular localization is key to the 
specificity of substrates it regulates and the consequences of this ubiquitination. Outside the 
sarcomeric M-line, MuRF1-mediated ubiquitination can also regulate its substrates via non-
proteolytic mechanisms. For example, in the nucleus of cardiomyocytes, MuRF1 regulates the 
nuclear export of peroxisome proliferator-activated receptor-α (PPARα), and in the perinuclear 
region it interacts with the receptor for activated protein kinase C-1, inhibiting the translocation 
of protein kinase C-ϵ (PKCϵ) to focal adhesions following stimulation with G protein-coupled 
receptor agonists.64, 70 At the functional level of the myocardium, MuRF1 has been shown to be 
important in multiple cardiac disease models. In models of global ischemia-reperfusion (I-R) 
injury both in vitro and in vivo, MuRF1 demonstrates dramatic cardioprotection from I-R injury, 
in part mediating phospho-c-Jun degradation.66  Additionally, MuRF1 inhibits pathological 
cardiac hypertrophy induced by pressure overload in vivo and is required for induction of cardiac 
atrophy following transaortic constriction.71, 72 As a multi-faceted muscle-specific E3 ligase with 
well-established molecular targets and clear functional links to cardiac pathologies, MuRF1 is 
clearly a valuable test E3 ubiquitin ligase for validation of our substrate screening methodology. 
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Furthermore, given our interest in understanding how dysregulation of protein homeostasis can 
lead to disease pathology in the heart, studying MuRF1 in this capacity not only provides 
validation of our method but also has led to the identification of physiological substrates of 
MuRF1 that may provide mechanistic insight these cardiac pathologies and possible therapeutic 
targets. 
 
CHIP and Spinocerebellar Ataxia 
 
CHIP is an E3 ubiquitin ligase encoded by the STUB1 gene that is abundantly expressed 
in most tissues and plays a central role in maintaining PQC. CHIP is uniquely suited as a 
regulator of PQC due to its dual functions as both a molecular co-chaperone protein and E3 
ubiquitin ligase enzyme. As a co-chaperone, CHIP interacts with Hsp-bound proteins to aid in 
substrate stabilization and refolding.73 Conversely, as a ubiquitin ligase, CHIP ubiquitinates 
terminally-defective proteins and prepares them for degradation by the UPS (Fig. 1.2). 
Additionally, CHIP regulates activation of the stress-chaperone response through induced 
trimerization, nuclear localization and transcriptional activation of heat shock transcription factor 
1 (HSF1),74 which upregulates levels of Hsps that are then subsequently ubiquitinated and 
targeted for proteasomal degradation by CHIP after all substrates have been refolded or 
ubiquitinated.75 In addition to Hsp chaperone protein substrates,CHIP has also been reported to 
ubiquitinate numerous other substrates, including neuronal substrates α-synuclein and leucine-
rich repeat kinase-2 (LRRK2) and to regulate the proteasomal degradation of tumor suppressor 
p53.76-78  
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Figure 1.2. Traditional Roles of CHIP in PQC. CHIP  bridges two PQC functions with 
opposite purposes. Under cellular stress, CHIP interacts with Hsp chaperone proteins to 
determine the fate of misfolded proteins, preventing their accumulation and subsequent 
proteotoxicity. As an E3 ubiquitin ligase, CHIP can ubiquitinate misfolded proteins, targeting 
them for proteasomal degradation. Conversely, CHIP can act as a molecular co-chaperone, 
aiding the Hsp chaperone protein refolding and recycling of the damaged substrate proteins.   
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CHIP contains three primary functional domains: the tetracopeptide repeat (TPR) 
domain, the charged coiled-coil (CC) domain, and the U-box domain. The TPR domain is 
required for chaperone protein binding. CHIP dimerization and structural conformational 
flexibility are required for activation of the bound E2 conjugating enzyme and subsequent 
ubiquitin transfer. This dimerization and conformational flexibility are dependent upon both the 
U-box domain and CC domain.79, 80  
Since the discovery of CHIP in 1999,81 numerous reports have been published detailing 
CHIP’s co-chaperone and ubiquitin ligase activities in both the brain and heart. Loss of CHIP 
function has long been associated with protein misfolding and aggregation in several genetic 
animal models of neurodegenerative disorders.9, 77, 82 CHIP modulates the effects of 
polyglutamine-induced neurodegeneration, protecting cells from neurotoxicity by interacting 
with and ubiquitinating expanded ataxin-1 in a Drosophila model of Spinocerebellar Ataxia Type 
1 (SCA1).82 Additionally, Dickey et al. showed that genetic depletion of CHIP leads to the 
accumulation of toxic phospho-tau in mouse brain, demonstrating that polyubiquitination of tau 
by CHIP may facilitate the formation of  less cytotoxic insoluble filamentous tau lesions.9  
Furthermore, genetic depletion of CHIP in mice results significant deficits in multiple models of 
cardiac disease.8, 83-86 When CHIP-/- mice undergo ischemia/reperfusion injury, the size of 
myocardial infarction (as assessed by the ratio of infarct area to area at risk) is increased by 50% 
relative to wild type controls, and the hearts from these mice lacking CHIP are more susceptible 
to apoptosis and have a markedly increased frequency of reperfusion arrhythmias.84 
Additionally, induction of cardiac pressure overload in CHIP-/- mice results in robust 
hypertrophy and decreased cardiac function.8 Together these data suggest the particular 
importance of CHIP as a regulator of PQC in the heart under stress. In addition to these 
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important implications in models of heart disease and neurodegeneration that highlight CHIP’s 
traditional roles as an E3 ubiquitin ligase and co-chaperone, recent reports have also emerged 
detailing surprising new roles for CHIP, including involvement in cardiac metabolic homeostasis 
(as a regulator of AMP-activated protein kinase (AMPK)) and DNA damage repair (as a 
regulator of Sirtuin-6 (SirT6)).8, 87  However, until recently, a role for CHIP in human disease 
had yet to be identified.  
Here I describe the first direct association between a CHIP polymorphism and a human 
disease with the discovery of CHIP point mutation, STUB1 c.737C→T, p.Thr246Met, in a form 
of spinocerebellar ataxia, Gordon Holmes Syndrome (GHS). GHS is a rare and devastating 
neurodegenerative disorder characterized by cerebellar ataxia with hypogonadism.88 GHS 
belongs to a family of rare recessively inherited ataxia disorders known as autosomal recessive 
cerebellar ataxia (ARCA) (estimated prevalence is 7 per 100,000).89 The mutations associated 
with ARCA affect functionally diverse genes; furthermore, the underlying genetic basis and 
pathophysiological mechanisms are largely unknown, resulting in severely limited therapeutic 
options. Interestingly, this and six additional independent reports have identified 10 STUB1 
mutation genotypes in a diverse pool of ARCA patients.89  In fact, a study cohort of 167 
Caucasian ataxia patients identified STUB1 mutation in nearly 2% of ARCA patients.90  These 
reports have led to the establishment of a new disease designation, SCAR16 (Autosomal 
Recessive Spinocerebellar Ataxia-16) to describe spinocerebellar ataxia caused by homozygous 
or compound heterozygous mutation in the STUB1 gene.89 The high frequency of STUB1 
mutations in ARCA demands an investigation into the molecular mechanisms that are at play as 
a result of CHIP mutation and how they result in disease pathology in SCAR16, most 
importantly to guide therapeutic interventions for this underserved patient population. 
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This is the precise goal of the remainder of this thesis, where I expand upon our 
discovery of T246M mutation in GHS to define the structural and functional consequences of 
CHIP mutation in SCAR16 and explore the deficits associated with this mutation in a mouse 
model system providing the first definition of partial CHIP dysfunction and assignment of 
specific in vivo deficits that result as a consequence of partial (but not total) loss of CHIP 
function. Interestingly, cerebellar ataxias can also manifest as a secondary feature of 
neurodegenerative diseases associated with proteotoxicity, including Huntington’s and 
Parkinson’s diseases. Given the multifaceted roles of CHIP in PQC and cellular protein 
homeostasis as well as other cellular functions, the structural, biochemical and in vivo analysis of 
T246M CHIP provides a unique opportunity to delineate the different functions of CHIP and 
how they may contribute to specific deficits observed in cells and in vivo. Furthermore, these 
studies allow us the unique opportunity to evaluate how these different CHIP functions 
specifically contribute to proteotoxicity in the brain, heart and other tissues and whether 
proteotoxicity and/or other molecular mechanisms are the true drivers behind CHIP-associated 
disease pathology in ARCAs. Ultimately, by determining how CHIP mutation contributes to 
SCAR16 pathology, we will potentially identify means for modulating CHIP and/or its 
substrates/interactors as therapeutic targets for SCAR16 that may even have the potential to be 
applied clinically to other diseases characterized by proteotoxicity or PQC dysregulation in the 
heart and brain, areas where disruption of CHIP and/or the UPS has upset the delicate balance 
required to maintain protein homeostasis in the face of cellular stress resulting in devastating 
disease pathologies. 
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Therapeutically Targeting the UPS  
Recently there has been increasing interest in focusing on modulation of the UPS as a 
therapeutic strategy to treat many disease indications, particularly neurodegeneration, cancer and 
immunological disorders. Because of its central role in PQC, chemically modulating this cellular 
machinery provides a unique mechanism to alter protein homeostasis in diseases where it has 
become dysregulated. Specific components of the UPS have been targeted or are currently 
emerging as targets thus far, including the proteasome, E3 ubiquitin ligases and DUBs. These 
targets represent a promising therapeutic opportunity, as they provide chemical specificity but 
with the ability to alter protein homeostasis and cellular processes across a range of disease 
indications.  
The proteasome inhibitor Bortezomib was the first drug targeting the UPS in the clinic 
and was approved for treatment of multiple myeloma and mantle cell lymphoma by the FDA in 
2003.91 The success of this inhibitor has proven that the proteasome is a feasible and valuable 
anti-cancer target, and since its approval has led to the development of multiple second-
generation proteasome inhibitors with increased potency and oral bioavailability.92 These 
proteasome inhibitors are now being evaluated for additional non-cancer indications, including 
progressive muscular dystrophies and late-stage systemic lupus erythematosus.93 The success of 
Bortezeomib and these subsequent next generation proteasome inhibitors has greatly inspired 
further exploration into other potential UPS targets. However, the complexity of the UPS, 
including the ubiquitination reaction and its outcomes, has resulted in a significant lag in the 
development and approval of additional drugs targeting other specific components of the UPS, 
such as E3 ubiquitin ligases and DUBs.94 Fortunately, significant improvements in our 
understanding of the UPS as well as advances in screening technologies now make these much 
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more tractable therapeutic targets that are being actively and, in some cases successfully, pursued 
not only for the treatment of cancer but also many other disease indications. 
Multiple small-molecule inhibitors are currently in development targeting various steps in 
the ubiquitination cascade. As described above, the target specificity of the ubiquitination 
reaction occurs at the level of the E3 ubiquitin ligases. Direct inhibitors of E3 ubiquitin ligase 
enzymatic activity, E3–E2 or E3–substrate interactions therefore may enable specific targeting of 
a limited number of substrate proteins, which may translate into a better therapeutic ratio and 
fewer side effects. Structural constraints specific to each class of E3 ubiquitinating enzyme will 
likely determine whether targeting protein-protein interaction domains or catalytic sites will 
prove to be easier, more effective and have greater specificity.95 Several classes of E3 ubiquitin 
ligases are being actively targeted in the field. One interesting example of targeting protein-
protein interactions to modulate E3 ubiquitin ligase activity that is now being tested clinically for 
the treatment of cancer are inhibitors of the RING E3 ubiquitin ligase MDM2, specifically, 
inhibitors of MDM2’s interaction with tumor suppressor p53. Stabilization of p53 blocks cancer 
progression, and MDM2 is a highly selective negative regulator of p53 abundance.96  
Multiple MDM2-targeting compounds have been identified or designed, accounting for a vast 
majority of the current E3-liagse-targeting molecules, and there are currently at least four small-
molecule MDM2 antagonists in clinical development for multiple types of cancer.96, 97 Most of 
these compounds antagonize the MDM2-p53 interaction by targeting the p53 binding site of 
MDM2 as competitive inhibitors directly occupying these interaction domains or inducing 
conformational changes that alter MDM2-p53 affinity.95, 96  
Preclinical data demonstrated that these compounds induce apoptosis in human tumor 
cells with minimal toxicity to normal cells and slow the growth of tumor xenografts in mice.95, 97  
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Unfortunately, one of the first published clinical trial results revealed that the treatment of 
liposarcoma patients with MDM2 antagonist RG7112 increased p53 levels in biopsy specimens 
and reduced proliferation in tumors; however, clinical benefit in the study was modest, with only 
1 patient (out of 20) showing a partial response and 14 showing stable disease, while the 
remaining 5 patients had progressive disease. Additionally, trial patients had a high rate of 
adverse reactions, with hints that some may be the result of on-target toxicities related to 
stabilization of p53.98 Clearly, the clinical efficacy and achievable therapeutic window in the 
appropriate patient population will determine the success of these inhibitors. Success in 
modulating p53 by antagonizing MDM2 would undoubtedly not only provide real clinical 
benefit to patients with potentially many different malignancies, but also provide important 
clinical validation for targeting E3 ubiquitin ligases and specific other components of the UPS 
beyond the proteasome. This clinical validation would provide important momentum for 
continued drug development in this burgeoning field, where basic understanding of the UPS and 
its role in disease pathogenesis as is detailed in this thesis will drive successful investment, 
innovation, preclinical investigation and clinical study design.   
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CHAPTER II 
 
 
DIGGIN’ ON U(BIQUITIN): A NOVEL METHOD FOR THE IDENTIFICATION OF 
PHYSIOLOGICAL E3 UBIQUITIN LIGASE SUBSTRATES1,2 
 
 
The ubiquitin-proteasome system (UPS) plays a central role in maintaining protein 
homeostasis, emphasized by a myriad of diseases that are associated with altered UPS function 
such as cancer, muscle-wasting, and neurodegeneration. Protein ubiquitination plays a central 
role in both the promotion of proteasomal degradation as well as cellular signaling through 
regulation of the stability of transcription factors and other signaling molecules. Substrate 
specificity is a critical regulatory step of ubiquitination and is mediated by ubiquitin ligases. 
Recent studies implicate ubiquitin ligases in multiple models of cardiac diseases such as cardiac 
hypertrophy, atrophy, and ischemia/reperfusion injury, both in a cardioprotective and 
maladaptive role. Therefore, identifying physiological substrates of cardiac ubiquitin ligases 
provides both mechanistic insights into heart disease as well as possible therapeutic targets.  
Current methods identifying substrates for ubiquitin ligases rely heavily upon non-
physiologic in vitro methods, impeding the unbiased discovery of physiological substrates in 
relevant model systems. Here we describe a novel method for identifying ubiquitin ligase 
substrates utilizing Tandem Ubiquitin Binding Entities (TUBE) technology, two-dimensional 
differential in gel electrophoresis (2-D DIGE), and mass spectrometry, validated by the 
identification of both known and novel physiological substrates of the ubiquitin ligase MuRF1 in 
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primary cardiomyocytes.  This method can be applied to any ubiquitin ligase, both in normal and 
disease model systems, in order to identify relevant physiological substrates under various 
biological conditions, opening the door to a clearer mechanistic understanding of ubiquitin ligase 
function and broadening their potential as therapeutic targets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Elements of the work referenced in this chapter have been published in: Cell Biochemistry and Biophysics 
2Figures Contributed by: 
  Carrie E. Rubel: 2.1, 2.2, 2.4, 2.5 
  Jonathan C. Schisler, M.S., PhD: 2.3 
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Introduction 
Protein ubiquitination and the ubiquitin-proteasome system (UPS) play a critical role in 
the regulation of protein homeostasis, emphasized by a myriad of diseases associated with 
aberrant UPS function. Ubiquitin is added to a substrate protein through a covalent linkage to a 
lysine residue on a substrate protein catalyzed by a class of enzymes called ubiquitin ligases; as 
an additional layer of regulation, this mechanism is counter-regulated by a class of enzymes 
called de-ubiquitinating enzymes (DUBs).99, 100  The effect of protein ubiquitination depends 
upon which lysine residue within the protein the ubiquitin is attached to as well as the length and 
linkage type of the added ubiquitin. The UPS is most commonly thought of in terms of 
regulating the turnover of mis-folded and damaged proteins by the addition of canonical K48 
polyubiquitin chains and subsequent proteasomal degradation. However, non-canonical linkages, 
for example K63 polyubiquitin chains, or single ubiquitin molecules (monoubiquitination) can 
also occur and mediates non-proteolytic mechanisms such as modulating protein localization, 
protein-protein interactions, activity or stability.43, 47, 53  The essential nature of protein 
ubiquitination is well illustrated in the heart where dysfunction, of both proteolytic and non-
proteolytic mechanisms, has been associated with multiple disorders, including cardiac 
hypertrophy, heart failure, diabetes and ischemia-reperfusion injury.43 5. 
Substrate specificity of the ubiquitination reaction occurs at the level of the ubiquitin 
ligase; as such, ubiquitin ligases are attractive therapeutic targets for diseases involving aberrant 
protein ubiquitination.47, 101  Muscle-specific RING finger protein 1 (MuRF1, Trim63) is a 
striated muscle-specific ubiquitin ligase involved in PQC of the muscle sarcomere by targeting 
numerous proteins for polyubiquitin-dependent proteasomal degradation, including troponin I, 
muscle actin, β/slow myosin heavy chain and myosin binding protein-C.68, 69, 102, 103 Ubiquitin 
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ligases, including MuRF family proteins, function as distinct molecular regulators by which the 
heart controls not only sarcomeric structure, but also cellular signaling pathways implicated in 
multiple models of cardiac disease, both in maladaptive and cardioprotective roles.43, 66, 67, 102, 104-
107 Targeting ubiquitin ligases in the heart may allow for more precise, single therapy 
manipulation of a smaller, specific subset of substrate proteins that contribute to disease-causing 
mechanisms while avoiding the negative cardiovascular effects observed with global proteasome 
inhibition.108, 109 Yet the substrates targeted by MuRF1 and their DUB counterparts remain 
incompletely understood and more robust identification methods for identifying ubiquitin ligase 
substrates is required for development of successful therapies.110  
Traditional ubiquitin ligase substrate discovery utilizes protein-protein interaction based 
methods, such as yeast-two hybrid and co-immunoprecipitation paired with mass spectrometry. 
Although refined recently by several modifications to increase efficiency in substrate 
identification102, 111, 112  interaction-based methods are hindered by the transient, weak nature of 
the ubiquitin ligase-substrate interaction. To circumvent the limitations of interaction-based 
methods, high-throughput in vitro approaches, such as in vitro ubiquitination biochemistry 
coupled with protein microarrays, have proven to be successful at identifying ubiquitin ligase 
substrates.113, 114  The use of in vitro-based methods is limited, however, to the content printed on 
protein arrays, limiting the substrate candidate pool. Importantly, neither yeast-two hybrids nor 
in vitro methods for ubiquitin ligase substrate identification are performed in physiologically 
relevant conditions, thereby limiting and biasing substrate discovery.66, 75  
Given the limitations of existing ubiquitin ligase substrate screening methods, our aim 
was to develop a methodology to better identify candidate ubiquitin ligase substrates under 
physiological conditions. Tandem Ubiquitin Binding Entities (TUBE) technology allows 
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unbiased ubiquitome isolation through high affinity binding to polyubiquitinated proteins. TUBE 
also protects polyubiquitiated proteins from de-ubiquitination and degradation during processing, 
allowing for detection of even low abundant species.115 Furthermore, the use of different TUBE 
types that have higher affinities for specific polyubiquitin lysine linkages can be used to enrich 
for subsets of the ubiquitome, providing another potential level of specificity to the screen. We 
used a subtractive approach combining TUBE technology, 2-D DIGE, and mass spectrometry, to 
develop a method for ubiquitin ligase substrate identification that is translatable to 
physiologically relevant inputs, either from cells or tissues. We describe and validate this method 
demonstrated by the identification of both previously identified as well as novel physiological 
substrates of the ubiquitin ligase MuRF1 in primary cardiomyocytes. 
 
 
Results 
Outline of the methodology used to screen for ubiquitin ligase substrates. Identification of 
substrates for ubiquitin ligases have traditionally relied on either artificial systems, such as yeast 
two-hybrid screens, or inefficient candidate substrate screens. Our goal for a more robust and 
flexible substrate screen included the use of biologically relevant cell systems combined with a 
proteomic approach for identification. A key component of this method is the selection, as well 
as the lack of selection, of polyubiquitinated proteins immunoprecipitated by Tandem Ubiquitin 
Binding Entities (TUBE) conjugated to agarose beads. This allows us to compare the relative 
ratio of proteins that bind to TUBE (eluate) as well as compare proteins that did not bind 
(supernatant) across multiple conditions. We have provided a graphical overview of the method 
(Fig. 2.1) and discuss below the major components of this approach. 
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1) Protein source. Our method relies on a subtractive approach (i.e. comparing one state to 
another); therefore the starting material must include two conditions wherein the expression or 
activity of the ubiquitin ligase is manipulated. We classify systems where ubiquitin ligase 
activity is either increased or decreased as gain-of-function or loss-of-function, respectively (see 
Fig. 2.1 for examples). The starting material can range from protein isolated from animal tissues, 
primary cells, or stable cell culture models in which either the ubiquitin ligase or a counter-
regulatory de-ubiquitination enzyme is manipulated.  
2) Ubiquitome isolation. Protein extracts are isolated and quantified from each condition and an 
equal amount of protein is subsequently added to either agarose control beads or beads 
conjugated with TUBE. We used TUBE that bind equally to K48- and K63-ubiquitin linkages, 
however, there are other TUBE varieties that preferentially bind certain lysine linkages that can 
be used depending on the type of substrates desired (e.g. canonical versus non-canonical). From 
each condition we collect both the eluate from the TUBE, containing the selected ubiquitome, as 
well as the unbound supernatants from both the control agarose and TUBE, which provide an 
additional measure of the ubiquitome from each condition.  
3) 2D-DIGE and pick selection. In order to reduce the number of false positives, we established a 
three spot comparison to identify substrate picks. Within each 2D-DIGE gel, relative differences 
between the two conditions are quantified. We established three independent comparisons that 
are analyzed in parallel to increase the likelihood of positive substrate identification. The first 
comparison of the pick selection contrasts the eluted ubiquitome from the experimental and 
control condition. In the case of gain-of-function studies, a spot pick would be increased in the 
experimental condition compared to the control condition (converse for loss-of-function models). 
The second and third gels allow comparisons of the TUBE-selected ubiquitomes within the 
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experimental condition (Gel 2) or control condition (Gel 3). In these later comparisons, enriched 
ubiquitinated proteins are identified by comparing the unbound fraction from the control agarose 
beads (ubiquitin-enriched) versus the unbound fraction from the TUBE agarose (ubiquitin-
depleted). Naturally occurring ubiquitinated proteins in the control condition are identified in Gel 
3 whereas Gel 2 identifies the enriched (or depleted in the case of loss-of-function) pool of 
proteins in the experimental conditions.  
4) Spot pick identification. All of the spots that meet the pick criteria for each Gel are tabulated 
and subsequently used to identify picks that are common to all multiple comparisons (see Figure 
1 for the differences in pick criteria in gain-of-function versus loss-of-function models). These 
picks are then subjected to MALDI-TOF for protein identification and classified as potential 
ubiquitin ligase substrates. 
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Figure 2.1. Schematic model representing the ubiquitin ligase/deubiquitinating enzyme 
screening platform. 
Protein is isolated from control and experimental animal tissue or cell culture samples where the 
expression or activity of a ubiquitin ligase or deubiquitinating enzyme of interest is manipulated 
to increase or decrease, dubbed a gain-of-function or loss-of-function manipulation.  Isolated 
protein is then quantitated and incubated overnight at 4 °C with Tandem Ubiquitin Binding 
Entities (TUBE) or agarose control beads. Both the bound (eluate) and unbound (supernatant) 
fractions are collected and subjected to 2D-DIGE. Three different 2D-DIGE gels are run, each 
also including a pooled internal standard sample. Gel 1 compares the control sample ubiquitin 
enrichment to the experimental sample ubiquitin enrichment, identifying proteins whose 
ubiquitination is dependent upon the ubiquitin ligase of interest. The second and third gels allow 
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comparisons of the TUBE-selected ubiquitomes within the experimental condition (Gel 2) or 
control condition (Gel 3) by comparing the ubiquitin-depleted supernatants from the sample 
incubated with TUBE to the ubiquitin-rich sample incubated with agarose control beads. The 
comparison on Gel 2 identifies proteins whose ubiquitination is potentially dependent upon the 
ubiquitin ligase of interest. The Gel 3 comparison reveals naturally occurring ubiquitinated 
proteins, as here, the ubiquitin ligase of interest is unperturbed. Spots are identified as “picks” by 
DeCyder Analysis Software based upon the determination of relative changes in intensity 
between the two samples and picks are aligned across all three gel comparisons to select spots 
for subsequent MS/MS peptide sequencing and protein identification.  
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Figure 2.2. MuRF1 ectopic expression and TUBE-mediated ubiquitin enrichment. Fluorescent 
imaging and immunoblot verified MuRF1 ectopic expression and ubiquitin enrichment prior to 
2D-DIGE. 
A. Representative fluorescence micrographs of primary cardiomyocytes after 24 h of 
transduction with adenovirus expressing green fluorescent reporter protein alone (Ad-GFP) or in 
combination with Myc-tagged MuRF1 (Ad-MuRF1) at MOI of 10. 
B. Representative immunoblots (IB) of Myc, MuRF1, and GAPDH protein levels in extracts 
isolated from primary cardiomyocytes transduced with Ad-GFP (-) or Ad-MuRF1 (+) adenovirus 
for 24 h. The red arrow indicates endogenous MuRF1, with ectopically-expressed myc-tagged 
MuRF1 migrating at a slightly higher molecular weight.  
C. Representative immunoblot of total ubiquitin from TUBE enrichment in extracts isolated 
from primary cardiomyocytes transduced with Ad-GFP (G) or Ad-MuRF1 (M) for 24 h as 
performed in the 2D-DIGE MuRF1 substrate screen. Lanes 1 and 2: input samples; lanes 3 and 
4: unbound TUBE supernatant collected; lanes 5 and 6: ubiquitinated protein enrichment eluted 
from TUBE. From 3 independent experiments we observed an average of 30 ± 14.7% increase in 
total ubiquitinated protein with MuRF1 ectopic expression as measured by densitometry. 
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MuRF1 expression in primary cardiomyocytes. Using traditional substrate identification 
approaches, our laboratory as well as and other groups identified substrates for MuRF1, a striated 
muscle-specific ubiquitin ligase. As a proof of principle for our method, we screened for MuRF1 
substrates in primary rat cardiomyocytes and hypothesized we would identify both previously 
established substrates as well as potential novel substrates. We utilized a transient gain-of-
function model in primary cardiomyocytes as previously described through the use of 
adenoviral-mediated expression of either the reporter green fluorescent protein (GFP) alone or in 
combination with MuRF1 (mouse) at a multiplicity of infection of 10 MOI per cell (Fig. 2.2A). 
Confirmation of the expression of the MuRF1 transgene was performed via immunoblot 
detection of the myc epitope tag (Fig. 2.2B, top) that corresponded to an approximate 25-fold 
increase in MuRF1 transgene expression relative to the endogenous MuRF1 expression in 
control cells, measured by densitometry, after 18 h of adenoviral transduction. These data 
confirm the successful expression of the MuRF1 transgene in primary cardiomyocytes. 
MuRF1 ubiquitome isolation. Prior to 2D-DIGE analyses, we first confirmed that we could 
successfully isolate the TUBE-selected ubiquitome. Lysates were prepared, quantified, and 
incubated for 18 h in the presence of either control agarose or TUBE beads. Both the unbound 
(supernatant) and bound (eluate) fractions were collected and separated via SDS-PAGE. The 
bound fractions from the TUBE beads in both the Ad-GFP and Ad-MuRF1 conditions contained 
highly enriched levels of ubiquitinated proteins compared to the unbound fraction determined via 
immunoblot analysis (Fig. 2.2C). We also consistently noticed a 30% increase in the total 
densitometry of ubiquitin immunoreactivity in cells transduced with Ad-MuRF1 (Fig. 2.2C, 
right) suggesting an overall increase in total protein ubiquitination in the presence of increased 
MuRF1 expression. Given the successful selection of ubiquitinated proteins using the TUBE 
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isolation procedure, we moved forward to the differential gel analysis to attempt to identify 
specific proteins that are more readily ubiquitinated in the presence of increased MuRF1 
expression. 
2D-DIGE and selection of picks corresponding to increased MuRF1 expression. Using the three 
gel conditions outlined above (Fig. 2.1) we used 2D-DIGE to identify candidate picks from each 
of the three comparisons. The primary comparison was between the elution profiles of the GFP 
versus MuRF1 ubiquitome (Gel 1). As shown in Figure 2.3, 2D-DIGE resolved differentially 
fluorescent-labeled pools of proteins in the same gel separated by both molecular weight (MW, 
vertical) and isoelectric point (pH, horizontal). A relative ratio of protein species was determined 
by the ratio of fluorescent intensity at identified spots in the gel. The image of the Cy3-labeled 
GFP eluate (green) and Cy5-labeled MuRF1 eluate (Fig. 2.3 top left and bottom left, 
respectively) were overlaid to locate differentially expressed spots (Fig. 2.3 top right). In the 
eluate comparison, we were interested in spots that were ≥1.5-fold more red than green (yellow 
spots represent similar protein amounts) indicating potential protein species that were more 
abundant in the MuRF1 eluate sample. Differential spots in the other two gels that met both 
quality standards and were changed in the expected direction were also identified as “picks” (for 
additional gel image data, see Fig. 2.4). 
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Figure 2.3. 2D-DIGE gel of the TUBE-isolated ubiquitome. 
2D-DIGE image analysis of ubiquitin-enriched samples eluted from TUBE identified spots for 
mass spectrometry protein identification. Proteins eluted from TUBE incubated with protein 
extract from Ad-GFP or Ad-MuRF1 transduced cardiomyocytes were labeled with Cy3 and Cy5, 
respectively, and separated by molecular weight and isoelectric point (Cy3-GFPeluate and Cy5-
MuRF1eluate, top left and bottom left, respectively). Relative changes in protein spots were 
calculated using the ratio of fluorescence intensity of each fluorescent channel visualized by 
coloring and overlaying the Cy3-GFPeluate (green) and Cy5-MuRF1eluate images (top right). The 
region containing the 16 spots selected for mass spectrometry identification (top right, hashed 
white box) was magnified and used to generate a ratio image (Cy5/Cy3) to highlight the fold-
enrichement and identification of each picked spot (bottom right). 
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Figure 2.4. Full 2D-DIGE gel images for Gels 1-3. 
 Full fluorescent micrographs of either the individual Cy3 (left column, green) and Cy5 (middle 
column, red) channels or the false-colored overlay of both channels (right column) for all three 
gels used in generation of the “picks”. 
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Picks that pass all three selection criteria and subsequent protein identification by MALDI-TOF 
identify candidate MuRF1 substrates. We tabulated all of the individual spots that passed the 
selection criteria from each gel comparison; for a list of all the spots “picked” in each 
comparison, see Table 2.1. In total, there were nine spots that satisfied all three gel comparison 
criteria (highest confidence, Table 2.1), and an additional seven spots that satisfied criteria in Gel 
1 and Gel 2 (high confidence, Table 2.1) for gain-of-function substrate identification (Fig. 2.1). 
These 16 spots all fell within the intermediate to low pH range, spanning a molecular weight 
range of 20-75 x 103 Daltons (Fig. 2.3 upper right, boxed region). As a reference, we included a 
ratio image of this region to highlight the fold enrichment of these samples in the MuRF1 TUBE 
elution relative to the GFP TUBE elution as well as an annotated ratio image to highlight and 
label the 16 spots (Fig. 2.3, bottom right). The 16 spots were picked from an independently run 
“pick” gel and submitted for protein identification using MALDI-TOF. Peptide sequencing 
identified a total of 20 polypeptides identified from the 16 spots (Table 2.1, Table 2.2, Table 
2.3). Consistent with our hypothesis and validation of our proof-of-principal, three of the 20 
proteins were previously identified in our yeast two-hybrid screen102 9 or a published yeast two-
hybrid screen116 and all but one of the proteins (Coq9) have been published as an identified 
polyubiquitinated protein.116-119 Additionally, the functional classification of the proteins 
identified included both structural (sarcomeric) protein components and mitochondrial 
substrates, two known locations within the cardiomyocyte where MuRF1 is known to 
function,116, 120, 121  suggesting this approach may, in fact, identify bona-fide MuRF1 substrates. 
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Table 2.1. Alignment of 2D-DIGE picks across three gel comparisons for selection of spots for 
mass spectroscopy identification. 
Spots are identified by a common spot number (Spot #) across all three gels based on MW and 
pI. The table includes if the spot was detectable in the gel (Appearance?) and if so, the average 
ratio of the comparison (Av. Ratio) indicated in the table header. Spots that also passed 
additional quality standards as described in the methods are indicated (QualitySpot?). If the 
criteria were met for an individual spot and the direction of change satisfied the indicated 
comparison, the spot was considered a “Pick”. The last column represents a confidence threshold 
based on the presence of “Pick” calls across all three gels. 
 
 
Spot # Appearance? Av. Ratio QualitySpot? M > G ? Appearance? Av. Ratio QualitySpot? C >T ? Appearance? Av. Ratio QualitySpot? C >T ?
Hig
he
st
Gel 1: MuRF1eluate / GFPeluate Gel 2: MuRF1TUBES / MuRF1ctrl Gel 3: GFPTUBES / GFPctrl 
Co
nfi
de
nc
e
Pick = MuRF1eluate > GFPeluate Pick = MuRF1TUBES < MURF1ctrl Pick = GFPTUBES < GFPctrl 
1817 Yes 6.17 Yes Pick Yes -6.67 Yes Pick Yes -2.03 Yes Pick
1814 Yes 4.68 Yes Pick Yes -2.20 Yes Pick Yes -2.66 Yes Pick
1815 Yes 4.58 Yes Pick Yes -1.78 Yes Pick Yes -2.84 Yes Pick
941 Yes 3.41 Yes Pick Yes -1.34 Yes Pick Yes -2.00 Yes Pick
1134 Yes 3.11 Yes Pick Yes -1.75 Yes Pick Yes -1.79 Yes Pick
1425 Yes 2.72 Yes Pick Yes -1.15 Yes Pick Yes -1.66 Yes Pick
1339 Yes 2.25 Yes Pick Yes -1.16 Yes Pick Yes -2.06 Yes Pick
764 Yes 2.16 Yes Pick Yes -1.56 Yes Pick Yes -2.12 Yes Pick
972 Yes 1.82 Yes Pick Yes -1.15 Yes Pick Yes -2.63 Yes Pick
Hig
h
949 Yes 7.96 Yes Pick Yes -1.37 Yes Pick -1.85
1816 Yes 5.13 Yes Pick Yes -1.39 Yes Pick -2.42
810 Yes 4.60 Yes Pick Yes -1.15 Yes Pick Yes -1.52
1108 Yes 3.21 Yes Pick Yes -1.19 Yes Pick Yes -1.38
842 Yes 2.82 Yes Pick Yes -1.15 Yes Pick Yes -1.35
544 Yes 2.49 Yes Pick Yes -1.20 Yes Pick Yes -2.17
1022 Yes 2.41 Yes Pick Yes -1.16 Yes Pick 2.23
Me
diu
m
931 Yes 11.33 Yes Pick Yes -1.95 Yes Pick
1369 Yes 3.19 Yes Pick Yes -1.02 Yes -1.79 Yes Pick
826 Yes 3.14 Yes Pick Yes -1.08 Yes -1.78 Yes Pick
1319 Yes 2.60 Yes Pick Yes -1.11 Yes -1.96 Yes Pick
1006 Yes 2.40 Yes Pick Yes -1.00 Yes -1.74 Yes Pick
1011 Yes 2.36 Yes Pick Yes -1.02 Yes -2.90 Yes Pick
Lo
we
r
821 Yes 3.54 Yes Pick Yes -1.12 Yes 1.21
314 Yes 3.12 Yes Pick Yes -1.11 Yes 1.03
833 Yes 3.11 Yes Pick Yes -1.13 Yes 1.18
542 Yes 2.89 Yes Pick Yes -1.10 Yes -2.09
888 Yes 2.68 Yes Pick Yes -1.06 Yes 1.43
1145 Yes 2.50 Yes Pick Yes -1.08 Yes -1.48
782 Yes 2.26 Yes Pick Yes -1.00 Yes -2.23
517 Yes 1.57 Yes Pick Yes 1.06 Yes -1.40
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Table 2.2. Mass spectroscopy summary data for the 16 spots submitted for identification. 
The 2D-DIGE master spot number is listed with corresponding protein(s) identified by MALDI-
TOF (Protein Name, Species, Database Accession ID, Molecular Weight in Daltons (Da)) 
including peptide counts MS and MS/MS scores, peptide sequenced ion scores, and scoring for 
each identified protein. 
 
Master 
Number Protein Name Species
Database 
Accession ID 
MW 
(Da) 
Peptide 
Count 
MS & 
MS/MS 
Score 
Peptide 
sequenced 
Ion Score 
Scoring 
threshold 
544  Tax_Id=10116 Gene_Symbol=Hspa5 78 kDa glucose-regulated protein Rattus IPI00206624 72302.4 38 2,310 2042 59
764  Tax_Id=10116 Gene_Symbol=Hspd1 60 kDa heat shock protein, mitochondrial Rattus IPI00339148 60917.4 36 2,370 2094 59
810  Tax_Id=10116 Gene_Symbol=Vim Vimentin Rattus IPI00230941 53700 40 1,880 1526 59
 Tax_Id=10116 Gene_Symbol=Tuba1a Tubulin 
alpha-1A chain 
Rattus IPI00189795 50103.6 9 169 145 59
842  Tax_Id=10116 Gene_Symbol=Tubb5 Isoform 1 of Tubulin beta-5 chain Rattus IPI00197579 49639 25 1,460 1285 59
 Tax_Id=10116 Gene_Symbol=Tubb2c Tubulin 
beta-2C chain 
Rattus IPI00400573 49769 22 1,170 1036 59
941  Tax_Id=10116 Gene_Symbol=Atp5b ATP synthase subunit beta, mitochondrial Rattus IPI00551812 56318.5 27 1,750 1560 59
949  Tax_Id=10116 Gene_Symbol=Atp5b ATP synthase subunit beta, mitochondrial Rattus IPI00551812 56318.5 27 1,800 1607 59
972  Tax_Id=10116 Gene_Symbol=Pdia6 protein disulf ide-isomerase A6 Rattus IPI00365929 48729.6 14 1,290 1242 59
 Tax_Id=10116 Gene_Symbol=Atp5b ATP 
synthase subunit beta, mitochondrial 
Rattus IPI00551812 56318.5 15 400 354 59
 Tax_Id=10116 Gene_Symbol=Hnrnpf 
Heterogeneous nuclear ribonucleoprotein F 
Rattus IPI00210357 45700.9 7 255 241 59
1022
 RecName:MuRF-1 Full=E3 ubiquitin-protein 
ligase TRIM63; AltName: Full=Muscle-specif ic 
RING finger protein 1; Short=MuRF-1; 
Short=MuRF1; Short=Muscle RING finger 
protein 1; AltName: Full=Tripartite motif-
Mus musculus gi|84029592 39465.2 25 1,210 1032 83
 Tax_Id=10116 Gene_Symbol=Ppp1r7 Protein 
phosphatase 1 regulatory subunit 7 
Rattus IPI00358083 41271.4 9 204 180 59
1108  Tax_Id=10116 Gene_Symbol=Actc1 Actin, alpha cardiac muscle 1 Rattus IPI00194087 41991.9 22 1,660 1511 59
1134  Tax_Id=10116 Gene_Symbol=Actc1 Actin, alpha cardiac muscle 1 Rattus IPI00194087 41991.9 22 1,230 1093 59
 Tax_Id=10116 Gene_Symbol=Actb Actin, 
cytoplasmic 1 
Rattus IPI00189819 41709.7 19 805 704 59
1339  Tax_Id=10116 Gene_Symbol=Tpm1 Isoform 1 of Tropomyosin alpha-1 chain Rattus IPI00197888 32660.7 37 1,960 1649 59
1425  Tax_Id=10116 Gene_Symbol=Coq9 Ubiquinone biosynthesis protein COQ9, Rattus IPI00365149 35123.5 13 701 627 59
 Tax_Id=10116 Gene_Symbol=Actc1 Actin, 
alpha cardiac muscle 1 
Rattus IPI00194087 41991.9 8 271 252 59
 Tax_Id=10116 Gene_Symbol=Tollip Toll-
interacting protein 
Rattus IPI00366104 30294.9 9 251 218 59
1814  Tax_Id=10116 Gene_Symbol=Myl2 Myosin regulatory light chain 2, ventricular/cardiac Rattus IPI00214000 18868.4 24 1,330 1091 59
1815  Tax_Id=10116 Gene_Symbol=Myl3 Myosin light chain 3 Rattus IPI00231788 22142.1 18 1,330 1209 59
1816  Tax_Id=10116 Gene_Symbol=Ldhb L-lactate dehydrogenase B chain Rattus IPI00231783 36589.1 31 1,960 1662 59
 Tax_Id=10116 Gene_Symbol=Mdh1 Malate 
dehydrogenase, cytoplasmic 
Rattus IPI00198717 36460.1 6 103 89 59
1817  Tax_Id=10116 Gene_Symbol=Actc1 Actin, alpha cardiac muscle 1 Rattus IPI00194087 41991.9 24 1,630 1464 59
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Figure 2.5. Validation of screen-identified proteins Hspd1, Tpm1, and Atp5b as substrates of 
MuRF. 
In vitro and in vivo data demonstrate that the screen-identified proteins Hspd1, Tpm1 and Atp5b, 
are MuRF1 substrates.  
A. Representative immunoblot (IB) of Hspd1 protein levels in extracts isolated from primary 
cardiomyocytes transduced with Ad-GFP (G) or Ad-MuRF1 (M) adenovirus for 24 h. Lane 1 
and 2: input samples (light exposure, see Fig. 2.6B); lane 3 and 4: Ad-GFP samples eluted from 
either TUBE (Tu) or agarose control beads (Ag); Lane 5 and 6: Ad-MuRF1 samples eluted from 
TUBE (Tu) or agarose control beads (Ag). 
B. Immunoprecipitations (IP) of Hspd1 and Tpm1 in extracts isolated from wild-type (WT) or 
MuRF1 transgenic (TG) mouse hearts, subsequently immunoblotted (IB) for Hspd1 or Tpm1 and 
ubiquitin (Ub). Lane 1 and 2: IgG control IP; lane 3 and 4: Hspd1 (top) or Tpm1 (bottom) IP; 
Lane 5 and 6: 10% input of extract. Red arrows indicate ubiquitin-reactive Hspd1 or Tpm1 
species in MuRF1 Tg hearts (lane 4) that are not present or are of lower relative abundance in 
wild-type hearts (lane 3). The black arrow indicates a non-specific band also present in the IgG 
control IP.  
C. In vitro ubiquitination assays for MuRF1 ubiquitination of Hspd1 and Atp5b performed in 
presence or absence of purified ubiquitin or MuRF1 as indicated and detected by immunoblot 
analysis (IB) for Hspd1 (top) or Atp5b (bottom). 
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Figure 2.6. Full immunoblot images for figures 2.2C and 2.5A. 
A. Full image of total ubiquitin immunoblot from TUBE enrichment in extracts isolated from 
primary cardiomyocytes transduced with Ad-GFP or Ad-MuRF1 for 24 h as performed in the 
2D-DIGE MuRF1 substrate screen as represented in Figure 2.2C. For the figure in the 
manuscript, only lanes 1-4 and 7-8 contained samples relevant to this manuscript using an equal 
exposure (Fig. 2.2C). 
B. Full image of total Hspd1 immunoblot in extracts isolated from primary cardiomyocytes 
transduced with Ad-GFP or Ad-MuRF1 as represented in Figure 2.5A. For the figure in the 
manuscript, only lanes 1-6 contained samples relevant to this manuscript and shown here with an 
equal exposure. 
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Validation of Hspd1, Tpm1, and Atp5b as substrates of MuRF1. To determine if the candidate 
proteins identified in our 2D-DIGE method were substrates of MuRF1, we took advantage of 
available antibodies and purified recombinant proteins to validate selected candidates. First, we 
measured the pattern of Hspd1 (Fig. 2.3, spot #764) modification in primary cardiomyocytes 
transduced with either Ad-GFP or Ad-MuRF1 via SDS-PAGE/immunoblot analysis from 
independent experiments prepared with TUBE or control agarose identically as described in the 
2D-DIGE screen. As expected, in cells overexpressing MuRF1, we detected several higher 
molecular weight proteins bound to the TUBE beads that were reactive to the Hspd1 antibody 
(Fig. 2.5A), consistent with a MuRF1-dependent increase in Hspd1 polyubiquitination. To 
determine if our primary cell system of MuRF1 overexpression accurately reflected the action of 
increased MuRF1 activity in vivo, we immunoprecipitated Hspd1 as well as another MuRF1 
substrate candidate Tpm1 (Fig. 2.3, spot #1339) from heart tissue isolated from either wild-type 
or MuRF1-transgenic mice (Fig. 2.5B). Consistent with the pattern observed in primary 
cardiomyocytes (Fig. 2.5A), after successful immunoprecipitation of either candidate substrate 
protein, using immunoblot analysis we observed increases in higher molecular weight proteins 
reactive to an antibody that recognizes ubiquitin (Fig. 2.5B) in MuRF1-trangenic hearts 
compared to wild-type hearts. These data suggest that in vivo, both Hspd1 and Tpm1 are cardiac 
substrates of MuRF1; furthermore, the translatability of using this ubiquitin ligase screen in our 
primary cardiomyocyte culture model to identify in vivo cardiac substrates demonstrates the 
utility of developing methods that are performed in a biologically relevant context. Finally, we 
used a purified recombinant protein system to test if the candidate substrates Hspd1 and Atp5b 
(Fig. 2.3, spot #941, #949, #972) could be polyubiquitinated by MuRF1 in a cell-free in vitro 
system. Interestingly, in the absence of MuRF1 we observed E2-mediated monoubiquitination 
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(an emerging property of E2 enzymes; 122, 123 of both Hspd1 and Atp5b,. As expected, we found 
both Hspd1 and Atp5b to be polyubiquitinated in the presence of MuRF1, providing further 
validation that these proteins are direct substrates of MuRF1. Through the use of multiple 
approaches we demonstrated that all three candidate substrates identified by our 2D-DIGE 
method were validated as MuRF1 substrates.  
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Table 2.3. Identities and characterization of MuRF1 substrates identified by MS/MS analysis of 
selected 2D-DIGE spots. 
Symbols, descriptions and PANTHER protein classifications for each of the MuRF1 substrates 
identified by mass spectroscopy analysis are listed. Also indicated are those proteins previously 
identified as MuRF1 substrates by yeast two-hybrid screening (Y2H102, 116 and Cam Patterson – 
data not shown) and those proteins previously reported as MuRF1 substrates (or interacting 
proteins) in skeletal muscle.   
 
Symbol Protein description Reported substrate 
Identified 
by Y2H PANTHER Protein Class 
ACTB Actin, cytoplasmic 1    actin and actin related protein 
ACTC1 Actin, alpha cardiac muscle 1  skeletal 103 yes 102 actin and actin related protein 
ATP5B ATP synthase subunit beta, mitochondrial   yes 116 ATP synthase/ion channel/hydrolase 
COQ9 Ubiquinone biosynthesis protein COQ9, mitochondrial    cofactor biosynthesis* 
HNRNPF Heterogeneous nuclear ribonucleoprotein F    ribosomal protein 
HSPA5 78 kDa glucose-regulated protein    Hsp70 family chaperone 
HSPD1 60 kDa heat shock protein, mitochondrial    chaperonin 
LDHB L-lactate dehydrogenase B chain    dehydrogenase 
MDH1 Malate dehydrogenase, cytoplasmic    dehydrogenase 
MURF1 E3 ubiquitin-protein ligase TRIM63 (MuRF1)  auto Ub  ubiquitin-protein ligase 
MYL2 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform  skeletal 
118  yes 102 cytoskeletal protein 
MYL3 Myosin light chain 3  skeletal 118  yes102  actin family cytoskeletal protein/calmodulin 
PDIA6 Protein disulfide-isomerase A6    isomerase 
PPP1R7 Protein phosphatase 1 regulatory subunit 7    
phosphatase 
modulator/microtubule family 
cytoskeletal protein 
TOLLIP Toll-interacting protein    adapter protein* 
TPM1 Isoform 1 of Tropomyosin alpha-1 chain    actin binding motor protein 
TUBA1A Tubulin alpha-1A chain    tubulin 
TUBB2C Tubulin beta-2C chain    tubulin 
TUBB5 Isoform 1 of Tubulin beta-5 chain    tubulin 
VIM Vimentin    structural protein/intermediate filament 
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Discussion 
Ubiquitin ligases and their counter-regulatory deubiquitinating enzymes (DUBs) play 
unique roles in protein ubiquitination and the UPS as the regulators of substrate specificity; 
therefore, substrate identification is critical to the mechanistic understanding of the UPS as well 
as our ability to modify protein ubiquitination in order to modulate disease. Despite this, the 
available methods to identify ubiquitin ligase and DUB substrates do not provide robust or 
unbiased means to identify physiological substrates, often relying upon non-physiological in 
vitro approaches. Given the current limitations in ubiquitin substrate screens, we developed a 
novel method for the identification of physiological ubiquitin ligase/DUB substrates (Fig. 2.1). 
As a proof-of-principle for our method, we successfully utilized a transient gain-of-function 
model to screen for MuRF1 substrates in primary cardiomyocytes (Fig. 2.2) and identified both 
previously identified MuRF1 substrates as well as novel substrate proteins (Table 2.3). Not 
surprisingly, nearly all of the candidate substrates were previously identified as polyubiquitinated 
proteins;116-119 additionally, the novel candidate substrates were functionally classified in cellular 
locations where MuRF1 is known to function including the sarcomere and mitochondria, 116, 120, 
121 reflective of the physiological approach utilized by our method. Furthermore, we validated 
several novel MuRF1 substrates both in vitro (Hspd1, Atp5b) and in vivo (Hspd1, Tpm1). In fact, 
the increased in polyubiquitination of Hspd1 and Tpm1 in hearts of MuRF1 transgenic animals 
not only validates the ability of our screen to identify novel substrates but also demonstrates the 
unique translatability of this screening method performed in a biologically relevant context to an 
independent in vivo model. 
Our method circumvents major pitfalls of traditional substrate screens by: 1) using a 
physiological setting that is relevant to the ubiquitin ligase/DUB or disease model; 2) utilizing 
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TUBE technology to isolate and protect the ubiquitome,115 independent of the strength of the 
physical interaction between the ubiquitin ligase/DUB and substrate; and 3) employing 2D-
DIGE with multiple subtractive comparisons to reduce the number of false positives. For our 
proof-of-principle we used a biologically relevant primary cell culture system; however, TUBE-
based ubiquitome isolation can be used with a myriad of other protein sources including stable 
cell culture models, isolated preparations of subcellular compartments (for example, 
mitochondria, Rubel and Patterson – data not shown), and animal tissues. The flexibility in 
starting material allows the study substrates of a ubiquitin ligase, or the action of an opposing 
DUB (Fig. 2.1), under specific physiological or pathophysiological conditions. We performed 
our screen using TUBE technology that has an equal affinity to K63 and K48 ubiquitin linkages; 
however, there are other TUBE variants that bind specific lysine linkages allowing the screen to 
be biased towards non-canonical ubiquitinated substrates if desired. Moreover, we used semi-
quantitative proteomics using 2D-DIGE, allowing high resolution separation and reduction of 
sample complexity prior to mass spectrometric analysis, and enhancing accuracy of protein 
identification, while avoiding issues of gel-to-gel variability associated with traditional 1D or 2D 
gel-based proteomics.124 To minimize false positives, we coupled our 2D-DIGE strategy with a 
multi-sample cross-comparison to achieve higher confidence in spot-picking prior to MALDI-
TOF peptide identification, the stringency of which could be increased or decreased based on the 
user’s preference for confidence (Table 2.1). 
We realize that there are other modifications to this protocol that could be used to refine 
substrate identification. Although we did not include proteasome inhibition to our protocol, an 
approach that is often used in interaction-based methods, the inclusion of a proteasome inhibitor 
such as MG132 for cell-based protein sources prior to protein extraction would likely increase 
48 
 
the pool of K48-linked polyubiquitinated proteins. In addition, there are other protein 
identification methods that could be used in place of 2D-DIGE/MALDI-TOF as there are 
limitations to a gel-based approach including difficulty detecting very hydrophobic proteins, 
proteins with extreme molecular weights and pI values, as well as the potential limited 
availability of 2D-DIGE facilities and personnel with the required expertise. With minimal 
modification this method could be used with gel-free quantitative proteomics strategies such 
Tandem Mass Tags (TMT) or Isobaric Tags for Relative and Absolute Quantification (iTRAQ) 
to identify and quantitate proteins in each of the collected eluate and supernatant samples.125 It 
should be noted that, even with the use of a gel-free based approach, the same subtractive 
approach could be used to reduce false positives. With the robust, flexible nature of the protocol 
described here, we are hopeful that this method will be broadly applied to the study of both 
ubiquitin ligases and DUBs and through the identification of their substrates, aid in the 
understanding of these unique and important regulatory proteins. 
 
Experimental Procedures 
Neonatal Rat Ventricular Myocyte Isolation and Culture. Neonatal rat ventricular myocytes 
(NRVM) were isolated from day old Sprague–Dawley pups utilizing the Worthington Neonatal 
Cardiomyocyte Isolation System as previously described and according to manufacturer’s 
instructions. 126 Briefly, isolated neonatal hearts were sequentially digested at 4 °C overnight 
with trypsin and then at 37 °C for 2 h with collagenase type II. After preplating to minimize 
nonmyocyte contamination, cells were plated on tissue culture dishes precoated with laminin 
(Sigma). NRVM were cultured at 37 °C and 5% CO2 in Dulbecco's Modified Eagle Medium 
(DMEM, Invitrogen) with 10% horse serum, 5% fetal bovine serum and 100 μM 5-bromo-2'-
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deoxyuridine (BRDU) to inhibit non-myocyte growth for the first 24 h post isolation and 
subsequently in a 4:1 ratio of DMEM:Minimum Essential Medium with 100 μM BRDU.  
Freshly isolated NRVM were cultured for 72 h prior to adenoviral infection.  
Adenoviral Constructs. Full-length mouse MuRF1 was cloned into the Myc-pCMV vector. 
Adenovirus plasmids Ad-GFP and Ad-MuRF1 (the later expressing GFP and Myc-tagged 
MuRF1 bicistronically) were constructed in pADTrack-CMV and used as previously 
described.102 
Adenoviral Infection and TUBE Enrichment for Ubiquitinated Proteins. Six independent 15 cm 
plates of cultured NRVM were transduced with Ad-GFP or Ad-MuRF1 at a multiplicity of 
infection (MOI) of 10 for 18 h. Lysates were prepared by scraping, trituration and brief 
sonication of cells in cell lysis buffer containing 50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1 mM 
EDTA, 1% NP-40, 10% glycerol, 50 μM deubiquitinating enzyme inhibitor PR619 (LifeSensors) 
and 1X HALT protease/phosphatase inhibitor (Pierce) followed by clarification by centrifugation 
at 15,000 x g. Lysates from all plates transduced with Ad-GFP or Ad-MuRF1 were pooled and 
total protein concentration determined by BCA protein assay (Pierce). Lysate containing 1 mg of 
total protein was incubated for 18 h at 4 °C with 60 μl of prewashed Agarose TUBE 2 beads 
(LifeSensors) or Control Agarose beads (LifeSensors). Unbound supernatant was removed and 
frozen at -80 °C. Beads were thoroughly washed in 20 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 
0.1% Tween-20 (TBST) and ubiquitinated proteins eluted in 0.2 M glycine, pH 2.5 and 
neutralized with 1 M Tris pH9.0. Elutions were stored at -80 °C prior to 2D-DIGE and proteomic 
analysis. Alternatively, ubiquitinated proteins were eluted by resuspending the beads in 20 μl 
SDS reducing sample buffer and boiling for 5 m followed by centrifugation at 13000 x g for 5 m. 
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Beads were discarded and eluted samples analyzed by SDS-PAGE and immunoblotting for 
Hspd1 (Abcam, ab59457) or total ubiquitin (Lifesensors, VU-1). 
Two-Dimensional Differential In Gel Electrophoresis (2D-DIGE). To detect differential protein 
expression, samples were first cleaned by methanol/chloroform precipitation and dissolved in 
lysis buffer (8 M urea, 20 mM tris-HCl, pH 8.5, 4% CHAPS). Aliquots of the MuRF1 TUBE 
eluate, MuRF1 TUBE supernatant, MuRF1 agarose control supernatant, GFP TUBE eluate, GFP 
TUBE supernatant, and GFP agarose control supernatant were labeled with either Cy3 or Cy5 
fluorescent dyes. An internal control (IC) was prepared by pooling equal amounts of protein (15 
µg) from all samples, and then labeled with 200 pmol of Cy2 for every 15 µg of protein. The 
labeling reaction was carried out on ice for 30 min, protected from light. To quench the reaction, 
1 µL of 10 mM lysine was added, and the reaction was then incubated for an additional 10 m on 
ice in the dark. After labeling, corresponding samples were combined. An equal volume of 2X 
sample buffer (8 M urea, 4% CHAPS, 20 mg/mL DTT, 2% (v/v) IPG buffer 4–7 (GE 
Healthcare)) was added and the mixture was placed on ice for 15 m. Rehydration buffer (8 M 
urea, 4% CHAPS, 2 mg/mL DTT, 1% (v/v) IPG buffer 4-7) was added to a final volume of 250 
µL. For each gel IC, Cy3, and Cy5 labeled samples were mixed before applying to immobilized 
pH gradient (IPG) strips (24 cm, pI range 4–7, GE Healthcare). Isoelectric focusing and the 
subsequent SDS-PAGE (second dimension) were performed as previously described.127 37. Three 
independent gels were run: the first comparing MuRF1 TUBE eluate to GFP TUBE eluate, the 
second comparing MuRF1 TUBE supernatant to MuRF1 agarose control supernatant and the 
third comparing GFP TUBE supernatant to GFP agarose control supernatant. Gels were analyzed 
using DeCyder 7.0 software (GE Healthcare). A “spot number” of 4500 was used to generate 
spot maps using the differential in-gel analysis (DIA) component. Spot maps were filtered via 
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the built-in algorithm using a Max slope of 1.0, and manually edited to remove dust particle 
signals. Expression changes were assessed using the Volume Ratio between samples within each 
gel. 
Spot selection and MALDI-TOF.  Protein spots displaying greater than 1.5 fold expression 
changes were marked as “picks” and the list of “picks” from all three gel comparisons were 
aligned to determine spots that were identified as “picks” by all three comparisons.  Spots that 
were identified as “picks” across all multiple gels were selected for further analysis and removed 
from the 2D gels using an Ettan Spot Picker (GE Healthcare) and submitted to the Michael 
Hooker Proteomics Center (University of North Carolina) for protein identification by matrix-
assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry. With the 
aid of a Progest Protein Digestion System (Digilab), proteins were digested with trypsin, and the 
resulting peptides were extracted. Peptides were mixed with matrix (α-Cyano-4-
Hydroxycinnamic Acid) and analyzed using a MALDI-TOF/TOF mass spectrometer (Applied 
Biosystems 4800 Plus). MS spectra were obtained in reflector positive ion mode and peaks with 
signal-to-noise ratio above 10 were selected for MS/MS analysis (maximum of 45 MS/MS 
spectra per spot). All spectra were searched using GPS Explorer, Version 3.6 (AB Sciex) linked 
to the Mascot (Matrix Science, Inc.) search engine and compared to the IPI rat database 
downloaded from European Bioinformatics Institute. 
Immunofluorescence. 24 h post infection with Ad-GFP or Ad-MuRF1, cells were washed with 
PBS, fixed, and permeabilized in phosphate-buffered 2% paraformaldehyde/0.2% Triton X-100 
for 30 minutes at 4 °C. Immunofluorescence labeling was carried out with a mouse anti-GFP 
(Sigma, G6795) followed by a FITC-conjugated goat anti-mouse secondary antibody (Jackson 
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ImmunoResearch Laboratories Inc.) and DAPI (Sigma-Aldrich). Images were acquired by 
fluorescence-inverted microscopy. 
Western blotting. 24 h post infection with Ad-GFP or Ad-MuRF1, cells were washed with PBS 
and lysates prepared by scraping, trituration and brief sonication of cells in cell lysis buffer 
containing 50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1 mM EDTA, 1% NP-40, 10% glycerol, 50 
μM deubiquitinating enzyme inhibitor PR619 (LifeSensors), and 1X HALT 
protease/phosphatase inhibitor (Pierce) followed by clarification by centrifugation at 15,000 x g. 
Proteins were separated by SDS-PAGE, transferred to PVDF and detected by Western blot 
analysis with anti-myc (Sigma, C3956), anti-MuRF1 (R&D Systems, AF5366), or anti-GAPDH 
(Sigma, G8795). 
In Vitro Ubiquitination Reactions. In vitro ubiquitination reactions were performed as previously 
described.128 In brief, 2 μM human MuRF1 (LifeSensors), 0.25 μM Ube1 (Boston Biochem), 2.5 
μM UbcH5c and 10 mg/ml ubiquitin and 500 ng of recombinant Hspd1 (Enzo Life Sciences) or 
ATP5b (Abnova) were incubated in 20 μM HEPES, pH 7.4, 10 μM KCl, 5mM ATP, 5mM 
MgCl2, and 1X Energy Regeneration Solution (ERS, Boston Biochem) for 3 h at 30 °C.  Samples 
were analyzed by SDS/PAGE and immunoblotting for ATP5b (Aviva Systems Biology, 
ARP48186) or Hspd1 (Abcam, ab59457). 
Animals. The MuRF1 transgenic (MuRF1-Tg) mice used in this study were previously 
described.121 All animal protocols were reviewed and approved by the University of North 
Carolina Institutional Animal Care Advisory Committee and were in compliance with the rules 
governing animal use as published by the National Institutes of Health. 
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Immunoprecipitation from MuRF1 Transgenic Hearts. Whole heart ventricles were excised from 
anesthetized male wild-type and MuRF1-Tg mice and homogenized on ice in T-Per tissue 
protein extraction reagent (Pierce) containing 1X HALT protease/phosphatase inhibitor (Pierce), 
50uM PR619 (Lifesensors), 50uM MG132 (Millipore) and 10mM N-ethylmaleimide (Sigma) 
first in a 2 ml glass tissue grinder homogenizer followed by brief homogenization by handheld 
tissue homogenizer. Homogenates were clarified by centrifugation at 10,000 x g.  Protein G 
Dynabeads (Invitrogen) pre-conjugated to 2 μg of Hspd1 (Abcam, ab59457) or Tpm1 (Abcam, 
ab133292) antibody or appropriate IgG control were incubated for 1 h at 4 °C with clarified 
homogenates. Beads were washed five times with Tris-Buffered Saline with 0.02% Tween-20 
and subsequently, proteins were eluted in SDS-sample buffer and analyzed by SDS-PAGE and 
western blotting.  
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CHAPTER III 
 
 
ATAXIA AND HYPOGONADISM CAUSED BY THE LOSS OF UBIQUTIN LIGASE 
ACTIVITY OF THE U BOX PROTEIN CHIP1,2 
 
 
Gordon Holmes syndrome (GHS) is a rare Mendelian neurodegenerative disorder 
characterized by ataxia and hypogonadism. Despite being recognized clinically for nearly 
100years, little has been understood about the pathophysiological mechanisms or underlying 
genetic causes of GHS. However, recently there have been several reports of mutations in 
STUB1 (NM_005861), a gene that encodes the protein CHIP, (C-terminus of HSC70 interacting 
protein) in GHS. Furthermore, it was suggested that disordered ubiquitination underlies GHS 
though the discovery of exome mutations in another E3 ligase RNF216 and the deubiquitinase 
OTUD4. Here we describe the first discovery of STUB1 mutation in GHS. We performed exome 
sequencing in a family with two of three siblings afflicted with ataxia and hypogonadism and 
identified a homozygous mutation STUB1 c.737C→T, p.Thr246Met, the gene encoding CHIP. 
CHIP plays a central role in regulating PQC, in part through its ability to function as an E3 
ligase. 
Loss of CHIP function has long been associated with protein misfolding and aggregation 
in several genetic mouse models of neurodegenerative disorders; however, a role for CHIP in 
human neurological disease has yet to be identified. Introduction of the Thr246Met mutation into 
CHIP results in a loss of ubiquitin ligase activity measured directly using recombinant proteins 
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as well as in cell culture models. Loss of CHIP function in mice resulted in behavioral and 
reproductive impairments that mimic human ataxia and hypogonadism. We conclude that GHS 
can be caused by a loss of function mutation in CHIP. Our findings further highlight the role of 
disordered ubiquitination and PQC in the pathogenesis of neurodegenerative disease and 
demonstrate the utility of combining whole exome-sequencing with molecular analyses and 
animal models to define causal disease polymorphisms. Furthermore, our findings and 
subsequent reports of human STUB1 mutation in various forms of ataxia have led to the 
establishment of a new disease designation, SCAR16 (Autosomal Recessive Spinocerebellar 
Ataxia-16) to describe spinocerebellar ataxia caused by homozygous or compound heterozygous 
mutation in the STUB1 gene.  
 
 
 
 
 
 
 
 
 
 
 
1Elements of the work referenced in this chapter have been published in: Human Molecular Genetics 
2Figures Contributed by: 
 Chang-He Shi: 3.1, 3.2  
 Carrie E. Rubel: 3.3, 3.4, 3.10 
 Jonathan C. Schisler, M.S., PhD:3.5, 3.6, 3.7, 3.8, 3.9 
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 Introduction 
Gordon Holmes syndrome (GHS [MIM 212840]) is a rare neurodegenerative disorder 
characterized by ataxia with hypogonadism. 129 Generally the term ‘Ataxia’ is used to describe a 
loss of coordination and may be caused by a variety of diseases including metabolic disorders, 
vitamin deficiencies, peripheral neuropathy, cancer, or brain injuries. In the case of GHS, ataxia 
is the result of progressive deterioration of the cerebellum. As such, GHS belongs to a large 
family of disorders termed ‘cerebellar ataxias,’ (CA) all characterized by cerebellar degeneration. 
The majority of diseases caused by CA mutations, including GHS, are inherited as autosomal 
recessive CA (ARCA, estimated prevalence is 7 per 100,000). 89 Patients with GHS typically 
present in early adulthood with variable movement disorders, most notably ataxia but may also 
include chorea, dysmetria, unsteady gait and dysdiadochokinesis. These deficits are progressive 
and may be accompanied by a wide range of additional neurological features including 
dysarthria, brisk reflexes, impulsivity, aggressive behavior, nystagmus, dementia and cognitive 
impairment.130-132 As one might expect with this variability in reported neurological symptoms, 
brain imaging of GHS patients has also revealed significant clinical variability with reports of 
cortical atrophy, pronounced cerebellar degeneration, diffuse white matter lesions in the 
cerebrum, brainstem and cerebellum as well as atrophy of the putamen.131, 132   
This neurologic phenotype is accompanied by hypogonadotropic hypogonadism. In the 
normally functioning hypothalamic-pituitary axis the hypothalamus releases gonadotropin-
releasing hormone (GnRH) which stimulates the pituitary gland to release follicle-stimulating 
hormone (FSH) and leutinizing hormone (LH). These hormones then act upon the female ovaries 
or male testes to stimulate the release of estrogen, progesterone and testosterone driving normal 
sexual development in puberty. Any change in this hormone release chain causes a lack of sex 
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hormones and prevents normal sexual maturity. Concordant with hypogonadotropic 
hypogonadism, patients with GHS present with low serum levels of sex steroids and 
gonadotropins and a lack of sexual development and infertility. Hypogonadotropic refers to a 
defect in the production or release of gonadotropins by the pituitary gland. In most cases of GHS, 
the hypogonadism is hypogonadoptropic in nature.130, 132  However, in some patients extended 
treatment with physiologic doses of pulsatile GnRH is able to stimulate a gonadotropin response, 
suggesting that in these patients the pituitary is able to produce and release gonadotropins, but 
under physiological conditions does not do so normally.131 It is notable that in addition to that 
which is observed in association with ataxia in GHS, hypogonadism has a distinctive association 
with variable neurological disorders including epilepsy, dysmyelination, nerve muscle disease, 
movement disorders, mental retardation and deafness. This clearly indicates an intrinsic 
pathophysiological association between neurological function and hypogonadism yet the 
molecular mechanisms underlying this association remain unknown.133 
Despite almost 100 years of clinical recognition, there is still little understanding of the 
pathophysiological mechanisms or underlying genetic causes of GHS. Here we describe the 
discovery of the first mutation in STUB1, the gene encoding the protein CHIP, in humans 
associated with GHS. We performed exome sequencing in a family with two of three siblings 
afflicted with ataxia and hypogonadism and identified a homozygous mutation, STUB1 
c.737C→T, p.Thr246Met. CHIP is a 35 kDa protein that functions as both a molecular co-
chaperone, autonomous chaperone, and ubiquitin E3 ligase. 8, 128, 134These activities are 
facilitated by three functional domains: a tetratricopeptide repeat (TPR) domain required for 
interaction with heat shock proteins (Hsp), a charged domain that mediates CHIP’s dimerization 
and activity, and a U-box domain that confers ubiquitin ligase activity.8, 79 As a ubiquitin ligase 
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CHIP forms a homodimer and associates with ubiquitin conjugating enzymes to ubiquitinate 
substrates with canonical or noncanonical chains. In cooperation with heat shock chaperone 
proteins, including HSC70, HSP70, and HSP90, CHIP plays a crucial role in recognizing and 
modulating the degradation of numerous chaperone-bound proteins.87 CHIP can also promote the 
folding and/or activity of substrates, including the metabolic energy sensor AMPK acting 
directly as an autonomous chaperone.8, 135  
Recently the E3 ligase RNF216 and deubiquitinase OTUD4 were associated with GHS in 
multiple non-Asian families.136 Protein ubiquitination is primarily regulated through E3 ligases 
that construct covalently-linked polyubiquitin chains on protein substrates, subsequently 
resulting in the targeting of ubiquitinated proteins for degradation through the 26S proteasome. 
Together these data suggest that perhaps disordered ubiquitination in general plays an essential 
role in the pathophysiology of ataxia and hypogonadism.  
 In genetic mouse models of neurodegenerative disease, the loss of CHIP function is associated 
with the misfolding and aggregation of several proteins (such as expanded polyglutamine tracts, 
hyperphosphorylated Tau and oligomeric forms of α-Synuclein), all of which are thought to be 
associated with multiple neurodegenerative disorders such as Spinocerebellar ataxia, Alzheimer's 
disease and Parkinson's disease. 82, 137, 138 However, prior to our discovery, mutations in the 
human STUB1 gene had not been reported, and information about the physiology of CHIP 
deficiency in humans was non-existent. We demonstrate that the STUB1 mutation leads to a loss 
of function of CHIP resulting in diminished E3 ligase activity; furthermore, mice lacking the 
expression of CHIP phenocopy some aspects of human GHS, supporting a direct link between 
CHIP and GHS pathophysiology. 
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Results 
Clinical assessment of two sisters with GHS. We initially observed a pedigree characterized by 
ataxia with hypogonadism in two sisters (II-1 and II-2) with an autosomal recessive inheritance 
pattern. The initial behavioral and sexual development of the proband (II-1) appeared normal, but 
unsteady gait developed when she was 19 years old, followed by dysarthria 2 years later and 
remarkable ataxia (Table 3.1). Upon neurological examination, patient II-1 exhibited horizontal 
gaze-evoked nystagmus with no restriction of extraocular movement. Photography and fluoresce 
angiogram of the ocular fundus revealed no abnormality (data not shown). Additionally, muscle 
tone, power and deep tendon reflexes of the four limbs were normal without any overt pathology. 
Neuroelectrophysiological examination was generally normal, except for decreased amplitude of 
motor-evoked potential in the bilateral lower limbs.  
The younger sister (II-2) also had a similar illness recognized at 17 years of age with a 
progressive deterioration of balance and gait disturbance (Table 3.1). Over the next two years, 
patient II-2 developed noticeable hand tremors during activity along with coarse head tremors. 
Further examination revealed findings similar to patient II-1, in addition to increased tendon 
reflex and positive pathological signs in the four limbs, suggesting pyramidal tract lesions. 
Patients II-1 and II-2 were administered the mini-mental state examination (MMSE) resulting in 
normal cognitive scores, whereas the Montreal Cognitive Assessment (MoCA), which is more 
sensitive to subtle cognitive defects particularly in the early stages of disease, 139 did reveal 
cognitive deficiencies in both sisters (Table 3.1). Furthermore, patients II-1 and II-2 completed 
only four and eight years of schooling, respectively. The neurological phenotype consisting of 
severe ataxia with selective cognitive impairments are consistent with cerebellar ataxia. The 
diagnosis of cerebellar ataxia was confirmed with MRI brain scans that revealed remarkable 
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atrophy of the cerebellum in both sisters (Fig. 3.1A).  
In addition to the neurological defects, both sisters had poor sexual organ development. At 
22 years of age, patient II-1 had still not menstruated, had poor development of secondary sexual 
characteristics (Table 3.1) and hypoplasia of uterus and ovaries, as revealed via ultrasound 
analysis (Table 3.1). Similar to her older sister, patient II-2 did not attain menarche or any 
secondary sexual characteristics, presenting with infantile uterus and ovarian development (Table 
3.1). Along with the lack of sexual development in both patients, the serum levels of estradiol 
and progesterone were much lower than the normal reference range, leading to a diagnosis for 
both patients of hypogonadotropic hypogonadism (Table 3.1). In addition to the low circulating 
sex hormones and the lack of menses, levels of the pituitary hormones FSH and LH in both 
sisters were comparable to pre-pubescent levels (Table 3.1). The nature of the hypogonadism in 
GHS is still not clear and may derive from either hypothalamic or pituitary hypogonadotropism. 
132 Interestingly, a gonadotropin-releasing hormone (GnRH) stimulation test showed the 
pituitaries in both patients were responsive to a single intravenous dose of GnRH (100 μg) 
measured by the stimulated release of FSH and LH (Fig. 3.1B), suggesting the primary defect in 
these sisters may be due to hypothalamic versus pituitary hypogonadotropism. However, the 
pituitary response to GnRH in other GHS patients is reported to diminish over time, suggesting 
pituitary dysfunction may still be an issue in these patients,132, 136 making it difficult to pinpoint 
the primary lesion of the hypogonadotrophic hypogonadism in GHS. The two patients in this 
study were referred to a gynecological endocrinologist, and exogenous estrogen and progestin 
supplement therapy was administered in an attempt to construct an artificial menstrual cycle. 
After three weeks of therapy, their menarche came, demonstrating that the lack of reproductive 
organ maturity was due to the lack of circulating hormones. 
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Table 3.1. Clinical phenotypes of STUB1 genotypes 
 
 
 
 
 
 
 
 
 
 
  
Subject II-1 II-2 
Ataxia   
  SARA 13 15 
Cognitive measures   
  MMSE 25 27 
  MoCA 11 24 
Sexual development   
  Tanner stage II-III II-III 
  Corpus uterus (mm) 35 x 31x 25 28 x 20 x 19 
  Cervix (mm) 23 16 
  Ovaries (mm) 14 x 9 13 x 10 
Hypogonadism   
  Estradiol (pg/ml) 26 28 
  Progesterone (ng/ml) 0.31 0.33 
  FSH (mIU/ml) 6.97 6.25 
  LH (mIU/ml) 5.95 6.44 
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Figure 3.1. Clinical Manifestations in Patients Presenting with Ataxia and Hypogonadism.  
 
A. MRI scans revealed remarkable cerebellum atrophy of patient II-1 (left) and II-2 (right).  
 
B. Gonadotropin-releasing hormone (GnRH) stimulation tests measured the response in 
circulating FSH and LH serum levels to exogenous GnRH administration (at time = 0) in patient 
II-1 (left) and II-2 (right). 
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Exome sequencing reveals a mutation in Stub1 associated with GHS. In an attempt to identify the 
causative mutation in this family, we performed whole exome sequencing of the two affected 
patients (II-1, II-2) as well as the unaffected brother (II-3). Using a combination of bioinformatic 
repositories and functional algorithms, we developed a strategy to identify causal mutations 
segregating with the GHS phenotype (Fig. 3.2A). After quality control and coverage criteria were 
met, we started with a total of 98255, 96183, 98507 SNPs, and 7227, 7046, 7159 insertions or 
deletions (indels) for II-1, II-2, and II-3, respectively. Since ataxia with hypogonadism is a rare 
disorder but has a clear phenotype, there was a low likelihood that a causal mutation in our 
patients was present in wider, healthy populations. We therefore filtered for novel variants by 
comparing our exome data to dbSNP build 132, 140 the 1000 Genomes Project, 141 Hapmap, 142, 
143 YH project, 144 and the National Heart, Lung, and Blood Institute (NHLBI) Exome 
Sequencing Project, 145 further refining our target list to around 2000 SNPs and 130 indels (Fig. 
3.2A). Next, we filtered for a recessive inheritance pattern for variants that were present in the 
affected sisters, but not in the unaffected brother, which reduced the number of candidate 
variants to six, including three compound heterozygote variants and three homozygous variants 
(Fig. 3.2A and Table 3.2). 
The analysis of chromosomal regions that are identical by descent (IBD) is a form of 
homozygosity mapping, a fundamental tool in linkage analysis of pedigree data. For Mendelian 
diseases with a recessive inheritance pattern, affected family members usually share the genomic 
segment harboring the causal mutation. Therefore, variants inside the IBD regions found among 
the affected family members are of primary interest and can be exploited to identify genomic 
regions consistent with inheritance of a recessive monogenic disease. 146, 147 These regions of 
interest are indicated by an IBD score of two, signifying the intersection between paternal and 
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maternal haplotypes. 147 Using the criteria of IBD = 2 we excluded three additional variants, 
reducing the number of candidate variants to three. Finally, we carried out functional-impact 
prediction on protein mutations by PolyPhen-2, 148 Mutation Taster, 148 and SIFT. 149 
Interestingly, only one homozygous variant predicted an impact on protein function in this 
family, STUB1 (NM_005861) c.737C→T, resulting in a p.Thr246Met (T246M) amino acid 
change in the corresponding protein commonly known as CHIP (C-terminus of HSC70 
interacting protein, Figure 3.2C). As an additional control, we tested for the STUB1 c.737C→T 
mutation in 500 Chinese control individuals; consistent with our data mining of multiple SNP 
databases used in our filtering strategy (Fig. 3.2A), the c.737C→T mutation was not detected in 
the Chinese control population. 
The genetics of cerebellar ataxia has been intensely pursued over the last decade, identifying 
over 30 loci that associate with the disease.150 Therefore, we were not surprised that we did not 
detect any STUB1 mutations in an additional cohort of 32 Chinese cerebellar ataxia patients 
without hypogonadism, suggesting that mutations in STUB1, and the recently described 
mutations in RNF216/OTUD4, associate with the distinct pathophysiological phenotype of 
cerebellar ataxia with hypogonadism. We also sequenced the STUB1 gene in a cohort of five 
GHS patients that harbor a single heterozygous RNF216 mutation and eight GHS patients that do 
not have either RNF216 and OTUD4 mutations; 136 interestingly, we did not identify any 
mutations in STUB1 in any of these GHS patients, suggesting additional genetic factors likely 
remain to be identified in other GHS patient populations. We also performed copy number 
variations (CNV) analysis and did not find any CNV that co-segregated either separately with the 
disease phenotype or together with single heterozygous variations in this family,151 suggesting 
that gene dosage was not contributing to the GHS phenotype. Taken together, our genetic and 
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bioinformatics analyses demonstrate the association of the STUB1 c.737C→T mutation with 
GHS and predict the T246M in CHIP results in a functional change that directly contributes to 
the pathophysiology of cerebellar ataxia and hypogonadism.  
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Figure 3.2. Exome Sequencing Identiﬁes a p.Thr246Met Mutation in the GHS Family.  
 
A. Schematic representation of our exome data-ﬁltering approach to identify mutations with 
recessive inheritance patterns in the family.  
 
B. Posterior probabilities of IBD = 2 classiﬁcation. The logarithmic ratio (LOD) of the posterior 
probabilities of being IBD = 2 versus IBD ≠ 2 are plotted for all classiﬁed variant positions on 
chromosome 16. A disease-causing mutation in the STUB1 gene was identiﬁed in an IBD = 2 
region of high posterior probability, indicated by the red arrow. 
 
C. A pedigree of the family indicating the unaffected (open symbols) and affected (filled 
symbols) members. Sanger sequencing conﬁrmed the co-segregation of the c.737C→T resulting 
in p.Thr246Met mutation in STUB1 within the family.  
 
 
 
67 
 
Table 3.2. Six Candidate Variants from Exome Sequencing Data. 
  
Chromosome Position Reference Allele 
Variant 
Allele HET/HOM 
Gene 
Substitution IBD=2 Functional Prediction Name 
chr19 9025639 A G HOM MUC16 N12272S NO ……… 
chr1 75037091 G A HET C1orf173 G1435R NO ……… 
chr1 75039089 C G HET C1orf173 L769V NO ……… 
chr2 97914920 T A HET ANKRD36 C1893S NO ……… 
chr2 97915322 T G HET ANKRD36 I1914M NO ……… 
chr4 151769986 G T HET LRBA G94V YES TOLERATED 
chr4 151356766 G T HET LRBA S2350I YES TOLERATED 
chr22 24325095 A G HOM GSTT2 K129E YES TOLERATED 
chr16 732232 C T HOM STUB1 T246M YES DAMAGING 
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The T246M mutation in CHIP abolishes ubiquitin ligase activity. The identification of the 
homozygous c.737C→T mutation in sibling GHS subjects and the co-segregation of functional 
mutation algorithms predicting a strong impact on protein function suggested that the resulting 
T246M substitution mutation in CHIP results in a change in protein function. T246, which is 
highly conserved across CHIP homologs, is located within the U box domain of CHIP (Figure 
3.3A), the domain responsible for ubiquitin ligase activity. 128 In addition, T246 is located in the 
core of a conversed beta hairpin turn (Fig. 3.3A),152 likely contributing to the high impact scores 
of the T246M mutation identified in our functional prediction analysis. In addition to the role 
that CHIP plays as a ubiquitin ligase, CHIP can also act as a co-chaperone through its direct 
interactions with cellular chaperones including HSC70, HSP70, and HSP90 via CHIP’s 
tetratricopeptide repeat (TPR) domain (Fig. 3.3A).81, 128, 134, 153 Both a functional TPR and U box 
domain are required for CHIP’s ability to directly impact PQC and attenuate the cellular stress 
response in large part through polyubiquitiantion of HSP chaperones.75, 79 Given that the CHIP 
mutation identified in our patients resides in the U box domain, we hypothesized that the T246M 
substitution would result in a loss of CHIP’s ubiquitin ligase activity, without affecting CHIP’s 
interaction with cellular chaperones though the intact TPR domain.  
To test effect of the T246M substitution on CHIP’s ubiquitin ligase activity and its ability to 
bind to chaperones, we first expressed either wild-type CHIP (CHIP-WT) or CHIP engineered 
with a methionine substituted for threonine at residue 246 (CHIP-T246M) in COS-7 cells. As 
expected, both the WT and T246M proteins immunoprecipitated with exogenous HSP70 (Fig. 
3.3B and Fig. 3.4A), demonstrating that CHIP-chaperone interactions are not perturbed by the 
T246M substitution. In fact, more CHIP-T246M protein immunoprecipitated with HSP70 
compared to CHIP-WT (Fig. 3.3B and Fig. 3.4A). Surprisingly, the increased interaction 
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between CHIP-T246M and HSP70 did not result in robust HSP70 ubiquitination compared to 
CHIP-WT expressing cells (Fig. 3.3B and Fig. 3.4A), indicating that the T246M substitution 
deleteriously affects CHIP’s ubiquitin ligase activity. We subsequently tested both the interaction 
and ubiquitination function of CHIP-T246M on an endogenously-expressed CHIP substrate, 
HSC70, and again observed an increased interaction between CHIP-T246M and HSC70 with 
diminished polyubiquitination (Fig. 3.3C). Together, these data suggest the functional defect in 
CHIP-T246M is a loss of ubiquitin ligase activity.   
To directly test the impact of the T246M substitution on CHIP-dependent substrate 
ubiquitination we compared the T246M mutation to previously engineered point mutations of 
CHIP. To do this we used CHIP constructs with mutations located either in the TPR domain 
(CHIP-K30A) or the U box (CHIP-H260Q), that abolish either the interaction with cellular 
chaperones, such as HSC70 and HSP70, or the ubiquitin ligase activity of CHIP, respectively 
(Fig. 3.3A) using cell-free assays comprised of purified recombinant proteins. Similar to the 
results observed in cell culture models (Fig. 3.3B and 3.3C), CHIP-T246M failed to 
polyubiquitinate HSC70 in vitro, mimicking the effect of the H260Q (U box) mutant CHIP 
protein (Fig. 3.3D). To confirm that the lack of chaperone ubiquitination in vitro is due to a 
defect in the U box domain and not due to the inability to bind to the chaperone substrate, we 
measured the effect of the CHIP-T246M mutation CHIP’s intrinsic ability to autoubiquitinate, a 
phenomenon that readily occurs in vitro.79 Similar to the H260Q mutation, the CHIP-T246M 
mutant did not exhibit any autoubiquitination, in contrast to CHIP-WT and CHIP-K30A proteins 
that both contain functional U boxes (Fig. 3.3E), confirming that the T246M mutation abolishes 
CHIP’s ubiquitin ligase activity.  
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Taken together, these data suggest the CHIP-T246M mutation is, at minimum, a partial loss 
of function mutation, that results in an inability of the mutant protein to polyubiquitinate both 
chaperone-bound proteins as well as the chaperone proteins themselves, functions that are 
integral to CHIP’s role in PQC. 75, 154 
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Figure 3.3. The T246M Substitution mutation in CHIP Abolishes Ubiquitin Ligase Activity.  
 
A. CHIP is comprised of three functional domains, tetratricopeptide repeat (TPR), coiled-coil 
(CC), and U box. The arrows indicate the location and identity of point mutations used to 
measure the functional parameters of CHIP (top). The structural features of the U box include 
alpha helices (cylinders), beta strands (arrows), beta turns (TT), and alpha turns (TTT). Sequence 
alignment demonstrates the evolutionary conservation of the T246 in the U box domain of the 
CHIP protein across the indicated species. Conservation of residues are labeled as fully 
conserved (*), strongly similar (:), or non- similar ( ).  
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B. COS-7 cells were co-transfected with the indicated vectors (transgenes, CTL = pcDNA3, WT 
= pcDNA3-CHIP, T246M = pcDNA3-CHIP-T246M) in addition to HA-tagged ubiquitin. HSP70 
was immunoprecipitated (IP) with FLAG beads and the resulting precipitants as well as inputs 
were immunoblotted (IB) with the indicated antibodies.  
 
C.COS-7 cells were co-transfected with the indicated transgenes in addition to HA-tagged 
ubiquitin and immunoprecipitated with either an HSC70 antibody or rat IgG. The inputs and 
resulting precipitants (IP) were immunoblotted with the indicated antibodies. Approximate 
molecular weights in kilodaltons (kd) are also provided.  
 
D. and E. Cell-free ubiquitination reactions containing recombinant HSC70 and the indicated 
CHIP proteins resolved via SDS-PAGE and immunoblotted for an antibody recognizing HSC70 
(D) or CHIP (E). Ubiquitin (Ub) was excluded in lane 1 (E) to demonstrate the 
autoubiquitination of CHIP, arrows indicate the incomplete reduction of CHIP oligomers. 
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Figure 3.4. CHIP-T246M Interacts with Chaperones but Lacks Ubiquitin Ligase Activity.  
 
A. To confirm the effect of CHIP-T246M on the exogenous HSP70 substrate, we performed the 
reverse IP shown in Figure 3A. COS-7 cells were co-transfected with the indicated vectors 
(transgenes, CTL = pcDNA3, WT = pcDNA3-CHIP, T246M = pcDNA3-CHIP-T246M) in 
addition to HA-tagged ubiquitin. Ubiquitinated proteins was immunoprecipitated (IP) with HA 
beads and the resulting precipitants as well as inputs were immunoblotted (IB) with the indicated 
antibodies.  
 
B. Cell-free ubiquitination reactions from the experiment represented in Figure 3D containing 
recombinant HSC70 and the indicated CHIP proteins resolved via SDS-PAGE and 
immunoblotted for an antibody recognizing CHIP. 
 
  
74 
 
CHIP-deficient mice exhibit defects in motoric, sensory, cognitive and reproductive function. The 
profound cerebellar ataxia exhibited by both siblings homozygous for the CHIP-T246M 
substitution suggests that CHIP plays a critical role in maintaining cerebellar function. Given the 
autosomal recessive nature of CHIP deficiency in our GHS subjects, we first wanted to assess the 
neurological behavior of Chip-/- mice to determine if the loss of CHIP expression leads to 
impairments associated with cerebellar ataxia. Our group has previously described a line of mice 
deficient in CHIP expression.74, 155  Given the data above linking the human CHIP-T246M 
mutation with cognitive impairments, we evaluated the phenotype of Chip-/- mice using a battery 
of behavioral assessments (Fig. 3.6A). The rotarod test is extensively used in mouse models to 
detect cerebellar dysfunction by testing motor coordination and motor learning on a rotating 
dowel. The performance of Chip-/- mice on the rotarod demonstrated a severe motoric 
impairment irrespective of gender, with wild-type mice having between 2.9 ± 0.6 and 4.2 ± 1.8 
fold increase in latency to falling times in male and female mice, respectively, compared to Chip-
/- mice (Fig. 3.5A). The performance of Chip-/- mice did not improve with retesting (Fig. 3.5A), 
demonstrating a lack of motor learning. To further confirm a motoric defect and to test for 
defects in sensory gating we measured the acoustic startle response in wild-type and Chip-/- mice 
(Fig. 3.5B). Consistent with the motoric impairment observed in Chip-/- mice using the rotarod 
assessment, the magnitude of the startle response was reduced 86% in Chip-/- mice compared to 
wild-type mice (Fig. 3.5C). Additionally, the reaction time to the acoustic startle was delayed 
across all sound levels by an average of 40% ± 4% (7.8 ms) in Chip-/- mice (Fig. 3.5D), 
consistent with our hypothesis that the loss of CHIP expression results in motoric impairment 
due to cerebellar dysfunction. Interestingly, pre-pulse inhibition levels were not affected by the 
loss in CHIP expression (Fig. 3.6B), suggesting that sensory gating (as well as auditory function) 
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was not impaired. In addition to the deficits attributed to cerebellar dysfunction, Chip-/- mice also 
exhibited an aberrant pattern of exploration in a novel environment demonstrated by increased 
time in the open arms of the elevated plus maze (EPM, Fig. 3.5E) and a higher error rate in the 
acquisition of a spatial learning task in the Barnes maze (Fig. 3.5F) compared to wild-type mice, 
suggesting hippocampal function may also be impaired with the loss of CHIP function. 
Additional testing found no differences in physical activity, both in the EPM and open field (Fig. 
3.6C, 3.6D, and 3.6E), latency measures in a spatial task (Fig. 3.6F), or in social behavior (Fig. 
3.6G). In gait testing, Chip-/- mice took smaller steps relative to wild-type mice (8% to 16% 
reduction in stride length, F(1,16) = 5.515, p = 0.032) however there were no differences in 
overlap, front paw stride length, or front paw and hind paw base width (data not shown) 
suggesting that motoric synchrony is not altered. Taken together, the loss of CHIP expression 
appears to have a selective impact in motoric, sensory, and cognitive function, in particular with 
tasks attributed to cerebellar function.  
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Figure 3.5. Chip-/- Mice Have Extreme Ataxia and Other Selective Motoric and Cognitive 
Impairments.  
 
A. Latency to fall from an accelerating rotarod represented by the mean ± SEM for either Chip-/- 
or wild-type mice (n = 5 per genotype per gender). The first three trials were given on the first 
day of rotarod testing. Retest (R) indicates the highest latency across two trials given 48 hours 
after the day one trials: ** p < 0.01 comparing Chip-/- versus wild-type mice at the retest; † p < 
0.05 and †† p < 0.01 comparing the indicated time point with first trial within the genotype.  
 
B. The acoustic startle response is comprised of a prepulse followed by an acoustic stimulus (AS, 
120 decibels, dB). Both the reaction time to the AS and the magnitude of the response was 
measured.  
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C and D. Amplitude and reaction time of the startle response following AS is represented by the 
mean ± SEM for each genotype (n = 6 and 10 for Chip-/- and wild-type mice, respectively). Trials 
included no stimulus trials (No) and AS alone trials: p < 0.05 comparing Chip-/- versus wild-type 
mice across all stimulus conditions shown in (C) or as indicated by * in (D).  
 
E and F.  Time on the open and closed arms of an elevated plus maze (E) and the number of 
errors (incorrect holes explored) before finding the target hole on the Barnes maze (F) 
represented by the mean ± SEM for each genotype (n = 10): * p < 0.05 comparing Chip-/- versus 
wild-type mice.  
  
78 
 
 
 
 
Figure 3.6A. Behavioral Assessment Tests of Chip-/- Mice.  
 
The goal of these assessments was to determine the behavioral phenotype of mice with a 
deficiency in CHIP expression. Subjects were 10 wild-type mice and 10 Chip-/- mice with an 
equal number of males and females per genotype. In all tests, an observer took measures blind to 
experimental treatment (genotype). Data were analyzed using two-way ANOVAs, looking for 
effects of genotype (wild-type or Chip-/-) or sex, or when indicated, repeated measures ANOVAs. 
Fisher's protected least-significant difference (PLSD) tests were used for comparing group means 
only when a significant F value was determined.  
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Figure 3.6B-E. Prepulse Inhibition During Acoustic Startle Test and Various Measures of 
Physical Activity Throughout Behavioral Testing. 
 
B. Prepulse Inhibition During Acoustic Startle Test, depicted in Figure 3.5B. The prepulse 
inhibition was calculated as 100 - [(response amplitude for prepulse stimulus and startle stimulus 
together / response amplitude for startle stimulus alone) x 100] and represented by the mean ± 
SEM for each genotype (n = 6 and 10 for Chip-/- and wild-type mice, respectively). Four animals, 
all Chip-/- mice (three males and one female), did not show significant startle responses to the 
acoustic stimuli, suggesting auditory impairment.  Therefore, their data were removed from the 
analysis. There was no significant effect of genotype on levels of prepulse inhibition, indicating 
that the Chip deficiency did not lead to impairment in sensory gating.  This result also suggested 
that the remaining knockout mice had normal auditory function, since a prepulse stimulus only 8 
dB above background noise (the 78 dB prepulse level) decreased the startle response by more 
than 25%. These data suggest a possible motoric deficit for the decrease in startle amplitude and 
reaction time (Fig. 3.5C and 3.5D). 
 
C. The number of entries into the open and closed arms of mice in the elevated plus maze 
(EPM). There was no difference between the groups for arm entries, suggesting that wild-type 
and Chip-/- mice have equal levels of activity.  
 
D. and E. The number of crossings and rears in an open-field chamber were counted at two 
different time points (2 and 5 weeks of testing). For all data shown neither genotype nor sex had 
a significant impact on the various measures represented by the mean ± SEM for each genotype.
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Figure 6F-G: Latency in the Barnes Maze and Social Affiliation Test 
 
F. Latency in the Barnes Maze. Each mouse received one trial per day, across seven days. 
Measures were taken of latency to find the target hole until reaching the target represented by the 
mean ± SEM for each genotype (n = 10). Both wildtype and Chip-/- mice showed high latency 
scores, reflecting the performance of some animals which never left the center of the maze 
(especially on the first and second trials).  A repeated measures ANOVA did not result in any 
significant effects for genotype or gender on latency, although the significant effect for trials (the 
repeated measure) confirmed that some learning occurred in this task [F(6,108) = 10.99, p = 
.0001]. 
 
G. Social Affiliation Test. Animals were tested in a three-chambered apparatus, with the 
chambers connected by short tubes. Each mouse was first set in the middle chamber and allowed 
to explore for five minutes in the absence of another mouse (habituation period, H). Then 
measures were taken of the time each mouse spent in either and empty chamber (open squares) 
or the chamber containing an unfamiliar mouse (closed squares) for the first (1) and second (2) 
five minutes of the session. Separate repeated measures ANOVAs were performed for time spent 
in the side with the unfamiliar mouse and time in the empty side. No significant overall effects of 
either group (wild-type or Chip-/-) or gender were detected. One-way ANOVAs indicated that 
Chip-/- mice spent less time exploring during the habituation period (when both sides of the 
chamber were empty, p < 0.05), but Chip-/- mice subsequently showed normal social preference 
during the test period. These data indicate that loss of CHIP protein does not cause deficits in the 
preference for social affiliation. 
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CHIP expression in the human cerebellum and the neuropathological and reproductive 
phenotype of Chip-/- mice. In the healthy human brain, CHIP is widely expressed throughout, 
including the molecular and granular region of the cerebellum where it is abundantly expressed 
in Purkinje cells (Fig. 3.7A). A similar pattern of CHIP immunoreactivity is found in mouse 
brains.156 Histological examination of sagittal cerebellar sections from Chip-/- mice revealed 
cellular loss throughout the various lobes of the cerebellum, specifically in the Purkinje cell layer 
with noticeable degeneration and a 3-fold increase in the number of pyknotic nuclei compared to 
an intact Purkinje cell layer in wild-type cerebellum (Fig. 3.7B and Fig. 3.8A), mimicking the 
observation of Purkinje cell loss identified in the neuropathological analysis in a deceased GHS 
patient with disordered ubiquitination (RNF216 and OTUD4 mutations).136 The effect on 
Purkinje cell pathology was confirmed with the Purkinje cell-specific marker, calbindin (Fig. 
3.7C, middle). Additionally, calbindin staining revealed a mosaic expression pattern in Chip-/- 
mice where calbindin expression in the molecular layer is reduced or absent in regions with 
significant Purkinje cell loss (Fig. 3.7C, left) similar to other mouse models of cerebellar ataxia 
157. Likewise, the cerebellar regions of Chip-/- mice that do contain intact Purkinje cells exhibited 
severe dendritic swelling (Fig. 3.7C, right), a common feature in ataxias. 158, 159 Taken together, 
these data demonstrate that the complete loss of CHIP function in our mouse model results in 
behavioral and cellular phenotypes consistent with the cerebellar ataxia found in human subjects 
with the T246M mutation. 
 The profound lack of sexual development in patients II-1 and II-2 suggests that CHIP 
plays a role in neuroendocrine signaling and is necessary for proper sexual development. 
Notably, since originally deriving the Chip-/- mice,74 we have long been aware of the inability of 
Chip-/- breeding pairs to successfully mate, necessitating that the Chip-/- colony be maintained 
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through Chip+/- crossings. Not surprisingly, FSH levels in Chip-/- mice were reduced more that 
50% when compared to wild-type littermate mice, irrespective of gender (Fig. 3.9A), consistent 
with the low levels of FSH in patients II-1 and II-2 (Table 3.1). As an additional measure of 
gonadal dysfunction in Chip-/- mice, we measured testicular weight and observed a 38% decrease 
in Chip-/- testes compared to wild-type testes (Fig. 3.9B). Not surprisingly, CHIP is expressed in 
wild-type mouse testes as well as in both male and female human gonads (Fig. 3.8B and 3.8C). 
Therefore, the Chip-/- mice also appear to encompass some of the neuroendocrine deficiencies 
seen in patients II-1 and II-2 with the CHIP T246M mutation. In summary, given the likeness of 
the neurological and neuroendocrine phenotypes in the Chip-/- mice with those reported in the 
GHS patients described in this study, it is highly probably that the c.737C→T in the STUB1 gene 
results in a loss of CHIP function in these patients and directly contributes to the disease 
phenotype observed in this pedigree. 
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Figure 3.7. CHIP Expression in Human Cerebellum and the Loss of Purkinje Cells in Chip-/- 
mice. 
 
A. Immunohistochemistry of CHIP expression in adult human cerebellum from a healthy female 
(♀) and male (♂) with the major regions of the cerebellum identified: molecular layer (ML), 
Purkinje cell layer (PL), and the granular layer (GL). The colored arrows highlight intense CHIP 
immunoreactivity throughout the cerebellum including increased reactivity in Purkinje cells, 
both in the cell body (downward arrows) and dendrites (upward arrows). Scale bar represents 
100 microns.  
 
B. Representative whole cerebellar sagittal sections from wild-type and Chip-/- cerebellums 
(left) with the major regions labeled at higher power (middle) as shown in (A) stained with either 
hematoxylin and eosin (left, middle) or cresyl violet (right). The open arrows identify normal 
Purkinje cells in wild-type mice whereas the closed arrows identify the pyknotic uclei in Purkinje 
cells in Chip-/- cerebellums.  
C. Representative whole cerebellar sagittal sections from wild-type and Chip-/- cerebellums 
immunostained for calbindin (left). Magenta arrowheads (left) indicate regions with no calbindin 
immunoreactivity and the black and red boxes correspond to the higher power images (middle 
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and right, respectively). The closed arrows identify the pyknotic nuclei present in Purkinje cells 
(middle) and the cyan arrows identify swollen dendrites in Chip-/- cerebellums. (B and C) Scale 
bars for whole cerebellum and higher power images are 1 mm and 100 microns, respectively. 
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Figure 3.8. Increase in Purkinje Cell Pathology in Chip-/- Mice and CHIP Expression in Mouse 
and Human Gonads.  
 
A. Sagittal sections of whole cerebellums from either wild-type or Chip-/- mice were stained 
with crystal violet (Fig. 5B) to measure Purkinje cell pathology. Data are represented by the 
number of Purkinje cells with pyknotic nuclei per 100 health Purkinje cells with each data point 
corresponding to one sagittal section (n = 18). A two-tailed t test was used to compare the two 
genotypes. Chip-/- mice had three-fold more pyknotic Purkinje cells compared to wild-type mice 
(1079 and 324 across all 18 sections from 3 different mice per genotype, respectively) and a 
decrease in healthy Purkinje cells (3390 and 4051, respectively).  
 
B. Immunoblot confirmation of CHIP protein expression in extracts isolated from wild-type 
testes.  
 
C. CHIP is expressed in both human testes (upper) in both Leydig cells (open arrows) and 
seminiferous ductal cells (closed arrows) and throughout human ovarian stromal cells (lower). 
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Figure 3.9. Hypogonadism in Chip-/- mice.  
 
A. Serum levels of FSH in wild-type and Chip-/- mice represented by the mean ± SEM for each 
genotype (n = 10): * p < 0.05, ** p < 0.01 comparing Chip-/- versus wild-type mice. 
 
B. Representative pictographs of testes and testicle weights from wild-type and Chip-/- mice. 
Scale bar represents 20 mm. Weights are represented in mg of testicle per mm of tibia length to 
control for animal size and represented by the mean ± SEM for each genotype (n = 10 and 8, 
wild-type and Chip-/- mice, respectively). 
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Discussion 
There is considerable heterogeneity in terms of age of onset and progression of symptoms 
within groups of clinical syndromes presenting with both ataxia and hypogonadism.133 Previous 
studies have found mutations in POLR3A and GBA2 associated with both ataxia and 
hypogonadism,160, 161 but given the additional complex clinical features in these patients, they 
were not diagnosed with GHS. Immediately prior to our discovery of STUB1 mutation in GHS, 
disordered ubiquitination was proposed as a contributing factor to the etiology of GHS, 
demonstrated by the identification of mutations in the E3 ligase RNF216 and deubiquitinase 
OTUD4 associated with GHS in non-Asian populations.136 Consistent with an integral role for 
ubiquitination in GHS pathophysiology, in this study we identified a mutation in the STUB1 gene 
encoding the E3 ligase CHIP (Fig. 3.2A and 3.2C) that results in a GHS phenotype (Fig. 3.1A 
and 3.1B).  
Although both hypo- and hypergonadotropic forms of GHS have been reported, most GHS 
patients, including the RNF216-associated GHS patients, usually present with hypogonadotropic-
induced hypogonadism.132, 136 In our patients, the level of gonadotropin is low given their age, 
but is in the normal range for pre-pubescent individuals; this may indicate a more mild 
abnormality in the reproductive-endocrine axis, although the lack of sexual development remains 
remarkable. It is intriguing that deficiency in either RNF216 or CHIP can both lead to a similar 
clinical syndrome. One possible explanation is RNF216 and CHIP ubiquitin ligase substrates 
overlap or may converge to a shared pathway that contributes to GHS. Alternatively, RNF216 
may have some physiological functions that overlap with the functions of CHIP. It is notable 
however, that outside of the fundamental phenotype of GHS, ataxia and hypogonadism, there are 
some other distinct differences in the clinical features of our patients to those harboring RNF216 
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and OTUD4 mutations; most notably, we did not observe dementia or white matter lesions 
described previously.136 However, as mild cognitive impairment was observed in our patients 
(Table 3.1) and likewise in Chip-/- mice (Fig. 3.5), we speculate that cognitive impairment may 
also act as a core clinical feature in the STUB1-associated GHS patients. Long-term follow-up of 
these patients will be needed to clarify this issue.  
 Our molecular characterization of the STUB1 c.737C→T, p.Thr246Met mutation 
demonstrates a loss in ubiquitin ligase activity (Fig. 3.3D and 3.3E), while still maintaining 
chaperone interactions (Fig. 3.3B and 3.3C). The ability of CHIP-T246M to maintain its 
chaperone interaction without a functional U box may result in a dominant-negative phenotype 
versus a complete loss of CHIP function. Generation of a CHIP-T246M knock-in mouse and 
comparison of the pathophysiology related to GHS phenotypes will provide valuable insight into 
the role of CHIP in this disease. Nonetheless, Chip-/- mice share several striking physiological 
similarities to GHS patients with ataxia and hypogonadism (Fig. 3.1), including neuronal 
degeneration (Fig. 3.7B and 3.7C), pronounced ataxic motor behavior (Fig. 3.5) and reproductive 
impairments (Fig. 3.9). This strong similarity between the findings in our GHS patients and those 
in the Chip-/- mouse model establishes an important role for CHIP in the maintenance of 
cerebellar function and the reproductive-endocrine axis. Taken together, our results demonstrate 
that deficiency of the ubiquitin ligase CHIP causes ataxia with hypogonadism and further 
highlight the role of aberrant ubiquitin ligase function in the pathogenesis of GHS. 
Subsequent to our discovery there have been multiple reports utilizing clinical genomics to 
identify mutations in STUB1 in GHS as well as other related forms of ARCA. The majority of 
these mutations are nicely reviewed by Ronnebaum et al. here.89  To date, 7 independent reports 
including our own have identified 10 STUB1 mutation genotypes in a diverse pool of ARCA 
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patients.90, 162-166 These 10 genotypes feature 15 unique mutations that have led to disease 
pathology in patients harboring either compound heterozygous or homozygous mutations (Fig. 
3.10). The amino-acid substitutions reported result in nonsense, missense, frameshift and 
splicing mutations and are predicted to significantly alter protein function. The CHIP mutations 
associated with ARCAs are present in all three of CHIP’s functional domains, although 
interestingly the majority are concentrated in the charged domain and the Ubox domain (Fig. 
3.10), such that one might predict negative implications for CHIP dimerization and ubiquitin 
ligase activity. Given the clinical heterogeneity of the ARCA patients harboring these STUB1 
mutations it begs the question whether the affected protein domain may directly correlate to 
clinical phenotype. For example, cognitive impairment occurs in five out of six genetic 
signatures harboring mutations in the U-box domain, such that residual CHIP activity involving a 
defective or truncated U-box domain but intact TPR domain could directly correlate to specific 
clinical symptoms in some patients.  
As a direct result of our report and the subsequent clinical genomics reports of STUB1 
mutation in a heterogeneity of ARCAs, including GHS, a novel disease classification, Autosomal 
Recessive Spinocerebellar Ataxia-16 (SCAR16) has recently been established. SCAR16 is 
precisely defined as spinocerebellar ataxia caused by homozygous or compound heterozygous 
mutation in the STUB1 gene on chromosome 16p13. SCAR16 is described as a progressive 
neurologic disorder characterized by truncal and limb ataxia resulting in gait instability. This 
novel classification better defines the clinical symptoms specifically correlated with STUB1 
mutation in ARCAs to include ataxia, dysarthria, nystagmus, spasticity of the lower limbs, and 
mild peripheral sensory neuropathy. Additionally, this new definition encompasses those cases of 
STUB1 ataxia without hypogonadism that would not fall under the GHS terminology. While 
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STUB1 mutations in GHS may in fact be relatively rare, Synofzik et al. performed whole exome 
sequencing to evaluate the frequency of STUB1 mutations in ataxia. They screened for STUB1 
mutations in a large cohort of Caucasian degenerative ataxia (n=167) and spastic paraplegia 
patients (n=133) as well as an additional 1707 exomes from 891 index families with other 
neurological diseases and discovered STUB1 mutations have a high incidence rate of 1.8% (3 of 
167) in degenerative ataxia patients, with 0% occurring in the other two groups.90 This high 
frequency of STUB1 mutation in ataxia further highlights the importance of this new definition 
of ataxias specifically linked to STUB1 mutation. Future studies of animal models harboring the 
identified disease-causing mutations will undoubtedly allow us to better define whether the 
clinical heterogeneity seen in SCAR16 can be related to the location of the mutations as well as 
better define the molecular functions of CHIP, particularly in the brain.  Furthermore, additional 
clinical genomics studies across even larger, more diverse cohorts of ataxic patients will more 
precisely define both the spectrum of STUB1 mutations represented by SCAR16 and the 
specifically associated clinical symptoms. SCAR16 represents the first definition of human 
disease caused by dysfunctional CHIP protein, or “CHIPopathy.” Pre-clincal data has long 
implied a role for CHIP not only in neurodegenerative diseases but also cardiac pathologies and 
cancer such that as whole exome sequencing strategies are more broadly utilized clinically it may 
not be surprising if other CHIPopathies are discovered. With this increased understanding of 
clinical CHIPopathies will come an even greater opportunity to utilize the wealth of pre-clinical 
data surrounding CHIP biology to the guide the potential development of improved therapeutic 
strategies for these diseases. 
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Figure 3.10. SCAR16 human CHIP mutations 
 
A. STUB1 genomic structure and corresponding CHIP protein domains are diagramed. The 
locations (arrows) of the various mutations associated with SCAR16 and respective nucleic 
acid and amino acid changes are indicated in the inset table. Joined arrows indicate a 
compound heterozygous mutation. 
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Experimental Procedures 
Exome sequencing and candidate gene validation. Targeted exon enrichment was performed with 
the use of the NimbleGen SeqCap EZ Human Exome Library (Roche - NimbleGen Inc). The 
exon-enriched DNA libraries were subjected to paired-end sequencing with the Illumina 
Hiseq2000 platform (Illumina). Sequence data were mapped with SOAP2 167 and BWA 168 onto 
the hg18 human genome as a reference. We generated an average of 15 Gb of sequence with 90× 
average coverage for each individual as single-end, 80-bp reads, calls with variant quality less 
than 20 were filtered out and 99% of the targeted bases were covered sufficiently to pass our 
thresholds for calling SNPs and small indels (Beijing Genomic Institute, Shenzhen, China). 
Furthermore, coding regions of the STUB1, RNF216 and OTUD4 gene were amplified by 
polymerase chain reaction (PCR) for conventional direct sequencing. Purified PCR products 
were sequenced on an ABI 3500 Genetic Analyzer (Applied Biosystems, CA). Sanger 
sequencing results were analyzed by Mutation Surveyor (Softgenetics, PA) and reconfirmed by 
the same procedure. 
Expression plasmids and recombinant proteins. Mammalian expression plasmids pcDNA3-myc-
CHIP, pcDNA3-myc-CHIP-K30A, pcDNA3-myc-CHIP-H260Q, HA-Ubiquitin and FLAG-
HSP70 were used as described previously 75, 128, 135. CHIP, CHIP-H260Q, CHIP-K30A, CHIP-
T246M and HSC70 recombinant proteins were produced in Escherichia coli BL21(DE3) as His-
tagged fusion proteins by induction with 0.1mM isopropyl-1-thio-β-D-galactopyranoside 
overnight at 18 °C followed by purification with HisTrap™ HP columns (GE Healthcare), 
concentrated, and stored in in 20 mM HEPES pH 7.4 with 150 mM NaCl.   
Mutagenesis. A point mutation of threonine to methionine at position 246 of CHIP was created 
by site-directed mutagenesis using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, 
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E0554S) according to manufacturer’s instructions using previously described pcDNA3-myc-
CHIP template 128 and mutagenic primers 5’-CCGTGCATCATGCCCAGTGGC-3’ and 5’-
CTCCCGCATCAGCTCAAAGC-3’ (BaseChanger software, New England Biolabs). The myc-
CHIP-T246 expression plasmid was produced by transformation in Escherichia coli DH5α, 
purified, and the single-base pair substitution was verified by DNA sequencing.  
In vitro ubiquitination reactions. In vitro ubiquitination reactions were carried out as previously 
described 128. Briefly, 0.75 μg (1 μM) of bacterially-expressed HSC70 was incubated in the 
presence of 2.5 μM CHIP or CHIP mutants, 50 nM purified Ube1 (BostonBiochem, E305), 2.5 
μM purified UbcH5c (BostonBiochem, E2-627) and 0.25 μM ubiquitin (BostonBiochem, 
U100H) in 50 mM Tris pH 7.5, 600 μM DTT, 2.5 mM MgCl2-ATP (BostonBiochem, B20) in a 
total volume of 10 μl for 1 h at 37 °C. Samples were analyzed by 4-12% Bis-Tris SDS-PAGE 
and immunoblotting was performed with either anti-HSC70 (Enzo, ADI-SPA-815) or anti-CHIP 
(Sigma, S1073) antibodies. 
Cell culture and transfection. COS-7 cells were maintained in Dulbecco's modified Eagle's 
medium (Invitrogen) supplemented with 10% fetal bovine serum (Sigma) at 37 °C in an 
atmosphere of 5% CO2. Cell transfections were performed using X-tremeGENE 9 (Roche) with 
the indicated plasmid DNA at a 1:3 DNA to X-tremeGENE 9 ratio. 
Immunoprecipitation/Co-immunoprecipitation of FLAG-HSP70/CHIP from COS-7 cells. 1E6 
COS-7 cells were plated in normal growth media in 10 cm2 tissue culture-treated dishes and 
incubated overnight under normal growth conditions. Cells were then transiently transfected with 
pcDNA3-mycCHIP (0.5 μg), pcDNA3-mycCHIP T246M (2.5 μg), pcDNA3 (2.5 μg) and/or 
FLAG-HSP-70 (2 μg) and HA-Ubiquitin (1 μg) and incubated for 24 h under normal growth 
conditions, followed by treatment with 20 μM MG132 or DMSO for 2.5 h prior to harvest. Cells 
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were washed in cold PBS and lysed in Cell Lytic M (Sigma) containing 1X HALT 
protease/phosphatase inhibitor (Pierce) and 50uM PR619 (Lifesensors). Lysates were clarified 
by centrifugation at 15,000 x g for 10 min. Total protein concentration was determined by BCA 
protein assay (Pierce) and 1 mg total protein clarified lysate incubated overnight at 4 °C with 20 
μg of either EZview™ Red ANTI-FLAG® M2 or ANTI-HA Affinity Gel (Sigma). The gel was 
then washed five times with Tris-Buffered Saline with 0.5% Nonident P-40; subsequently, 
proteins were eluted in reducing SDS-sample buffer and analyzed by SDS-PAGE and western 
blotting was performed using anti-Hsp70 (Enzo ADI-SPA-810), anti-FLAG HRP (Sigma, 
A8592), anti-HA HRP (Sigma, A6533) and anti-myc HRP (Sigma, A5598) antibodies. 
Immunoprecipitation/Co-immunoprecipitation of HSC70/CHIP from COS-7 cells. 1E6 COS-7 
cells were plated in normal growth media in 100mm tissue culture treated dishes and incubated 
overnight under normal growth conditions. Cells were then transiently transfected with pcDNA3-
mycCHIP (1.5 μg), pcDNA3-mycCHIP T246M (4 μg) or pcDNA3 (1.5 μg) and HA-Ubiquitin 
and incubated for 24 h under normal growth conditions, followed by treatment with 20 μM 
MG132 or DMSO control for 2.5 h prior to harvest. Cells were washed 1X in cold PBS and lysed 
in Cell Lytic M (Sigma) containing 1X HALT protease/phosphatase inhibitor (Pierce) and 50 μM 
PR619 (LifeSensors). Lysates were clarified by centrifugation at 15,000 x g for 10 min. Total 
protein concentration was determined by BCA protein assay (Pierce) and 1.8 mg total protein 
clarified lysates were incubated overnight at 4 °C with 10 μg anti-Hsc70 (Enzo ADI-SPA-815) 
or rat IgG antibodies. 120 μl Protein-G Dynabeads (Invitrogen) were then added to each sample 
and incubated for 0.5 h at room temperature with rotation. Beads were washed four times with 
Phosphate-Buffered Saline with 0.05% Tween-20; subsequently, proteins were eluted in SDS-
sample buffer and analyzed by SDS-PAGE and western blotting using anti-Hsc70 (Enzo ADI-
95 
 
SPA-815), anti-CHIP (abcam, Ab4448), anti-HA HRP (Sigma, A6533) and anti-myc HRP 
(Sigma, A5598) antibodies. 
Mouse behavioral assessments.  
Home cage behavior. In the first week of testing, a bedding nestlet was added to each home cage 
of the experimental groups. 24 hours later animals were observed to note if nests had been 
formed from the bedding material and, in the case of multiply-housed mice, if the animals 
huddled together in the nest. Nests were observed in each cage, and no aberrant behavior was 
observed. 
 
Elevated plus maze test for anxiety. The elevated plus maze (EPM) test was performed as the 
first behavioral test to avoid possible confounding effects of extensive handling. Mice were 
given one five-minute trial on the plus maze, which had two walled arms (the closed arms) and 
two open arms. The maze was elevated 52 cm from the floor, and the arms were 51 cm long. 
Animals were placed on the center section (9.5 cm x 9.5 cm), and allowed to freely explore the 
maze. Measures were taken of time on, and number of entries into, the open and closed arms.  
Activity. One day following the EMP test (week two), exploratory activity in a novel 
environment was further assessed by a five-minute trial in an open field chamber (40 cm x 30 
cm). A grid of squares (10 X 6) was drawn on the floor of the chamber, and counts were taken of 
number of squares crossed and rears during the trial. A second activity test was performed during 
week five of testing.  
Neurophysiological screen and gait testing. The neurophysiological screen consisted of several 
measures to assay overall appearance and behavior of the mice. Measures included general 
observations on the animal's appearance, body posture, and normality of gait. Normal reflexive 
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reactions to a gentle touch from a Q-tip to the whiskers on each side of the face, and the 
approach of the Q-tip to the eyes, were assessed. Each mouse was placed in a small, empty 
plastic cage, and ability to remain upright when the cage was moved from side-to-side or up-and-
down was noted. Locomotor coordination was assayed by allowing the mouse to walk across an 
elevated dowel (wrapped in nylon rope to facilitate grasping) and to climb a similar pole.  Each 
subject was also placed on a wire grid and allowed to hang for two minutes. Reaction to 20 
seconds of tail-suspension was observed. For the gait test, a footprint record was generated by 
painting the paws of the mice and letting the animals run down a narrow alley into a small box. 
Front paws were painted yellow and hind paws were painted blue with a nontoxic poster paint. 
Each mouse was given two trials, and measures of front paw and hind paw stride lengths, and 
front paw and hind paw base widths, were taken. In addition, measures were also taken for paw-
print overlap. 
Rotarod. Mice were tested on an accelerating rotarod (IITC Inc., Woodland Hills, CA) to assess 
motor coordination. For the first test session, animals were given three trials, with 45 seconds 
between each trial. Two additional trials were given 48 hours later. RPM (revolutions per 
minute) was set at an initial value of three, with a progressive increase to a maximum of 30 RPM 
across three minutes (the maximum trial length).  Measures were taken for latency to fall from 
the top of the rotating barrel. 
Acoustic startle. This test is based on the measurement of the reflexive whole-body flinch, or 
startle response, that follows exposure to a sudden noise.  Assessments included startle 
magnitude and prepulse inhibition, which occurs when a weak prestimulus leads to a reduced 
startle in response to a subsequent louder noise.  Animals were tested with a San Diego 
Instruments SR-Lab system, using the procedure as described in 169. Briefly, mice were placed in 
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a small Plexiglas cylinder within a larger, sound-attenuating chamber (San Diego Instruments). 
The cylinder was seated upon a piezoelectric transducer, which allowed vibrations to be 
quantified and displayed on a computer. The chamber included a houselight, fan, and a 
loudspeaker for the acoustic stimuli. Background sound levels (70 dB) and calibration of the 
acoustic stimuli were confirmed with a digital sound level meter (San Diego Instruments). Each 
mouse was given one session, consisting of 42 trials that began with a five-minute habituation 
period. There were seven different types of trials: the no-stimulus trials, trials with the acoustic 
startle stimulus (120 dB) alone, and trials in which a prepulse stimulus (either 74, 78, 82, 86, or 
90 dB) occurred 100 ms before the onset of the startle stimulus. Measures were taken of the 
startle amplitude for each trial, and an overall analysis was performed for each animal’s data for 
levels of prepulse inhibition at each prepulse sound level. 
Spatial learning on the Barnes maze. The Barnes maze consisted of a large, brightly lit, circular 
platform (diameter = 122 cm), elevated 96.5 cm from the floor and positioned like a table, with 
40 holes (diameter = 5 cm) drilled along the perimeter. An escape box containing fresh nesting 
material was placed under one of the holes, and the task required that the animal learn which 
hole allowed escape from the maze surface. Each mouse was assigned a particular "target" hole, 
which remained constant across trials, and was different for each subject. At the beginning of 
each trial, the animal was placed in the center of the maze and allowed 5 minutes to find and 
enter the escape box. Subjects received one trial per day, across seven days. Measures were taken 
of latency to find the target hole and number of errors (incorrect holes investigated) until 
reaching the target. 
Social affiliation test. Animals were tested in a three-chambered apparatus, with the chambers 
connected by short tubes. Each mouse was first set in the middle chamber and allowed to explore 
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for five minutes. After the habituation period, the animal was removed and an unfamiliar male 
probe mouse (C57BL/6J strain) was set in one of the side chambers (the particular side alternated 
between trials). The probe mouse was enclosed in a small metal cage, which allowed nose 
contact between the bars. The test mouse was then returned to the middle chamber and allowed 
to freely explore for a ten-minute session. Measures were taken of the amount of time spent in 
each chamber of the apparatus for the first and second five minutes of the session. 
Histology. Mouse brains were carefully excised, gently rinsed, fixed in 4% paraformaldehyde for 
24 h, and then placed in 70% ethanol prior to embedding into paraffin. Five micron sections were 
processed for histology, and stained with either hematoxylin and eosin or cresyl violet for routine 
histological examination. Unstained sections were used to detect calbindin expression using 
immunohistochemistry. Slides were stained per the manufacturer instructions using the calbindin 
D1I4Q rabbit monoclonal antibody (Cell Signaling, 13176) with citrate antigen retrieval, 
SignalStain® Boost Detection Reagent (Cell Signaling, 8114), and SignalStain® DAB Substate 
Kit (Cell Signaling, 8059). Degenerating neurons were characterized via light microscopic level 
by cell body shrinkage, loss of Nissl substance and a small/shrunken darkly stained (pyknotic) 
nucleus as described 170. Human cerebellum, testes, and ovary sections were from the Human 
Protein Atlas tissue array 171 and were stained with anti-CHIP antibody (Sigma, C9243). 
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CHAPTER IV 
 
THE UNFOLDING TAIL OF CHIP MUTATION IN SCAR16 DISEASE PATHOLOGY: 
PARTIAL LOSS OF FUNCTION AS A DRIVER OF DISEASE 1 
  
 
Our findings and subsequent reports of human STUB1 mutation in various forms of 
ataxia have led to the establishment of a new disease designation, SCAR16 (Autosomal 
Recessive Spinocerebellar Ataxia-16), to describe spinocerebellar ataxia caused by homozygous 
or compound heterozygous mutation in the STUB1 gene that encodes the CHIP protein. Using 
recombinant proteins as well as in cell culture models, we previously demonstrated that 
introduction of the T246M mutation into CHIP is associated with SCAR16 and results in loss of 
CHIP ubiquitin ligase activity, and that CHIP-/- mice have behavioral and reproductive 
impairments that mimic some of the clinical features of GHS. However, due to the limitations of 
exogenous overexpression studies and our findings that CHIP-/- mice do not exactly phenocopy 
the diverse disease heterogeneity in SCAR16, we wanted to extend our initial findings and study 
the biophysical, cellular and in vivo repercussions of T246M CHIP mutation in a more disease-
relevant context.  
Using multiple biophysical approaches, we demonstrate that T246M mutation results in 
disorganization and misfolding of the CHIP U-box domain, which disrupts its dimerization and 
promotes both its aggregation and enhanced clearance by a proteasome-dependent mechanism. 
In addition to its role as an E3 ubiquitin ligase, CHIP has additional roles within the cell as a co-
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chaperone that contribute to PQC as well as emerging roles as a metabolic regulator and nuclear 
protein involved in DNA repair. Using both in vitro assays as well as a primary cell culture 
model, we demonstrate that while ubiquitin ligase activity is lost as a consequence of T246M 
mutation, T246M CHIP maintains some function in these other roles that may directly impact the 
cellular stress response and also contribute to SCAR16 pathophysiology. Furthermore, utilizing 
CRISPR/Cas genome editing technology, we established a mouse model (T247M) that mimics 
the human mutation and observed behavioral deficits attributable to cognitive cerebellar 
dysfunction not observed in our total loss of CHIP animal model, as well as deficits in learning 
and memory attributable to hippocampal dysfunction that are reflective of cognitive deficits 
reported in SCAR16 patients. We conclude that T246M mutation is not equivalent to total loss of 
CHIP and that specific CHIP mutations in SCAR16 likely have varying biophysical and 
functional consequences to CHIP that may directly correlate to clinical phenotype. Sadly, the 
therapeutic options for patients with ARCAs, including SCAR16 are severely limited. Our 
findings both further expand our basic understanding of CHIP biology and provide meaningful 
mechanistic insight underlying the molecular drivers of SCAR16 disease pathology, which may 
be used to inform the development of novel therapeutics for this devastating disease. 
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Introduction 
Our findings and subsequent reports of human STUB1 mutation in various forms of 
ataxia have led to the establishment of a new disease designation, SCAR16 (Autosomal 
Recessive Spinocerebellar Ataxia-16) to describe spinocerebellar ataxia caused by homozygous 
or compound heterozygous mutation in the STUB1 gene that encodes the CHIP protein. Sadly, 
the therapeutic options for patients with ARCAs, including SCAR16 are severely limited. 
Understanding the underlying molecular mechanisms associated with CHIP mutation in SCAR16 
will provide insight required for the development of effective therapies for this devastating 
degenerative disease.  
Using recombinant proteins, as well as in cell culture models, we demonstrated that 
introduction of the T246M mutation into CHIP associated with SCAR16 results in loss of CHIP 
ubiquitin ligase activity. However, the T246M CHIP protein does still bind chaperone proteins, 
suggesting it may retain some chaperone activity. Interestingly, we also showed that CHIP-/- 
mice have behavioral and reproductive impairments that mimic some of the clinical features of 
GHS. However, the complete genetic depletion of CHIP in these mice results in other phenotypic 
changes, including accelerated aging and metabolic complications. These additional changes 
may be caused by compensatory mechanisms in the mouse model or may be due to the total loss 
of all CHIP functions. 8, 155 While these studies provide powerful evidence that SCAR16 can be 
caused by a loss of function mutation in CHIP and further highlight the role of disordered 
ubiquitination and PQC in the pathogenesis of neurodegenerative disease, they are limited in 
their direct application to human pathophysiology by two important constraints. First, these cell-
based studies were all performed in the context of exogenous overexpression of T246M CHIP 
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protein. While these types of studies provided a powerful tool to begin to understand the biology 
of T246M CHIP in cells, their interpretation is limited because CHIP protein is not expressed at 
physiologic levels, and in some cases is being studied in cells that normally do not express CHIP 
protein. Second, while the CHIP-/- mice mimic some of the phenotypes of SCAR16 patients, they 
are not the appropriate model for understanding the in vivo repercussions of CHIP mutation in 
SCAR16. To date, 7 independent reports, including our own, have identified 10 STUB1 mutation 
genotypes in a diverse pool of ARCA patients.90, 162-166 These 10 genotypes feature 15 unique 
mutations that have led to disease pathology in patients harboring either compound heterozygous 
or homozygous mutations. The amino acid substitutions reported result in nonsense, missense, 
frameshift and splicing mutations and are predicted to significantly alter protein function. There 
is great clinical heterogeneity of the ARCA patients harboring these STUB1 mutations. This 
suggests that specific CHIP mutations may have varying biophysical and functional 
consequences to CHIP that may directly correlate to clinical phenotype. Clearly, in this context 
an animal model with a total loss of CHIP does not adequately represent the spectrum of human 
disease represented by SCAR16. For these reasons, we wanted to extend our initial findings and 
study the biophysical, cellular and in vivo repercussions of T246M CHIP mutation in a more 
disease-relevant context. 
Initially we hypothesized that the functional loss of CHIP ubiquitin ligase activity as a 
result of T246M mutation was the result of catalytic inactivation of the U-box domain. However, 
based upon our understanding of the CHIP structure-function relationship, several additional 
structural consequences of T246M CHIP could also result in functional loss of ubiquitin ligase 
activity. As described previously, CHIP has three important functional domains: the 
tetracopeptide repeat (TPR) domain, the charged coiled-coil (CC) domain, and the U-box 
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domain. The TPR domain is required for chaperone protein binding. Conversely, CHIP 
dimerization and structural conformational flexibility are required for activation of the bound E2 
conjugating enzyme and subsequent ubiquitin transfer. This dimerization and conformational 
flexibility are dependent upon both the U-box domain and CC domain. 79, 80 Importantly, while 
the CHIP mutations associated with ARCAs are present in all three of CHIP’s functional 
domains, the majority are concentrated in the charged domain and within the U-box domain, 
including T246M. This suggests that the structural consequences of T246M mutation may not be 
as straightforward as simple catalytic activation, but might instead reflect loss of CHIP 
dimerization ability or general destabilization of the U-box that results in a misfolded protein that 
may retain some normal functions or may instead be damaging. Here we utilize multiple 
biophysical methods and cell culture studies to evaluate the consequences of T246M mutation on 
CHIP dimerization status and U-box domain structure and stability in order to better define the 
structural implications of CHIP mutation in SCAR16. 
In addition to its role as an E3 ubiquitin ligase, CHIP has many additional roles within 
the cell. As a co-chaperone, CHIP interacts with Hsp-bound proteins to aid in substrate 
stabilization and refolding and regulates activation of the stress-chaperone response through 
activation of HSF1.72-74 Additionally, our laboratory has recently uncovered a range of new and 
unexpected functional roles for CHIP, including involvement in cardiac metabolic homeostasis 
(as a regulator of AMP-activated protein kinase (AMPK)) and DNA damage repair (as a 
regulator of Sirtuin-6 (SirT6)).8, 87 Because CHIP is such a multi-faceted protein, in order to fully 
appreciate how CHIP mutation drives disease pathology in SCAR16, we evaluated the 
consequences of CHIP mutation from multiple angles. Here we determine the effects of T246M 
mutation on CHIP function in its traditional roles as an E3 ubiquitin ligase and co-chaperone, as 
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well as on the emerging functions of CHIP as a direct chaperone and regulator of AMPK and as 
a nuclear protein involved in DNA damage repair.  
To evaluate the pathophysiological implications of T246M mutation in vivo, we 
generated a mouse model (T247M) that mimics the human mutation. We used this model to 
validate our biophysical studies and cellular models in the genomic context of the mutation vs. 
overexpression studies at super-physiological levels of protein in less disease-relevant cell types. 
Additionally, we performed an in-depth behavioral assessment of these mice to determine the 
effects of T246M mutation at a whole-animal level, begin to understand the pathophysiology of 
T246M in vivo and validate this animal model as a representative of SCAR16 human disease. 
Studying T246M mutation both in vitro and in vivo has allowed us a unique opportunity to begin 
to delineate the contribution of co-chaperone, ubiquitin ligase activity and other emerging CHIP 
activities to specific deficits observed in vitro and in vivo in a disease-relevant context. This 
biophysical, cellular and in vivo characterization of T246M mutation in SCAR16 will provide 
valuable insight required for the development of effective therapies for this devastating 
degenerative disease.  
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Results 
The T246M mutation destabilizes the CHIP U-box and promotes aggregate formation in vitro. 
Asymmetric homodimerization of CHIP as well as conformational flexibility are required for 
CHIP ubiquitin ligase activity. Critical to both the dimerization and conformational flexibility is 
an intact U-box domain 128, 172. T246, which is highly conserved across CHIP homologs, is 
located within the U-box domain of CHIP. Furthermore, T246 is located in the core of a 
conversed beta hairpin turn that lies at the interface between two dimerized CHIP molecules. We 
hypothesized that this amino acid substitution within the CHIP U-box domain may have overall 
structural consequences and/or affect its ability to form functional dimers, consequently reducing 
or abolishing CHIP’s ubiquitin ligase function towards both chaperone and non-chaperone 
substrates and leaving its ability to function as a chaperone intact. To test the effects of T246M 
substitution on U-box stability, we performed solution structure NMR on the isolated WT and 
T246M CHIP U-box domain. NMR has evolved as the main technique to obtain structural 
information at atomic resolution in solution on  proteins and allows for the determination of 
protein’s structures as well as their interactions. While the WT CHIP U-box showed distinct 
peaks across the N and H spectrums, consistent with a stable, structured protein, the T246M 
spectra revealed broad, fuzzy peaks, overlapping in the middle of the N and H spectrums 
consistent with misfolded or conformationally diverse molecules (Fig. 4.1A). This was 
confirmed by collecting spectra at additional temperature (data not shown) with similar results. 
Having demonstrated that NMR the T246M U-box spectrum was not consistent with a well-
folded protein regardless of temperature, we wanted to confirm this lack of stable structure by 
another method. Circular dichroism spectroscopy was collected for both WT and T246M CHIP 
U-box protein at 15°C in 10 mM sodium phosphate pH 7.0 with 20 mM NaCl and 1 mM DTT. 
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The protein was at 0.25 mg/mL in both cases according to UV absorbance at 280 nm. These 
conditions were chosen to optimize the spectrum of the WT protein, which demonstrates clear 
secondary structure including significant α-helical character (dips around 208 and 222 nm) (Fig. 
4.1B, left). The T246M mutant protein was at the same buffer conditions and protein 
concentration; however, the signal is much weaker and is consistent with more random coil or 
less stable protein. Further, we then monitored the protein melting temperature (Tm) at 222 nm, 
which corresponds to α-helical structures. The WT protein clearly shows a loss of signal as the 
temperature increases with a Tm around 30°C. Again, the T246M protein was not well-folded to 
begin with, and I observed no real change with temperature (Fig. 4.1B, left). Together these data 
suggest the T246M mutation destabilizes the U-box domain, resulting in a loss of secondary α-
helical structure and protein misfolding.  
To test the effects of T246M substitution on CHIP dimerization status, we purified full-
length WT, T246M, K30A and H260Q mutant recombinant protein and performed dynamic light 
scattering (DLS). DLS measures the intensity of light scattered by molecules as a function of 
time, such that in solutions of equal concentration one can determine the fraction of each sample 
that exists in various multimeric states (monomer, dimer, trimer, etc.). Interestingly, by DLS we 
observed that both WT and K30A CHIP exist primarily as dimer, with a small population of 
trimer and tetramer (which we were unable to resolve). However, T246M mutation as well as the 
other U-box domain mutation H260Q result in little to no detectable CHIP dimer and a dramatic 
shift to primarily large multimeric aggregates (Fig 4.1C). Together these data suggest that 
T246M mutation results in dramatic structural instability and disorganization of the CHIP U-box 
that inhibits dimer formation and promotes the formation of large multimeric aggregates, likely 
resulting in significant functional consequences particularly to CHIP ubiquitin ligase activity. 
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Figure 4.1 The T246M mutation in CHIP results in the formation of large multimeric aggregates 
in cells.  
A. 600-MHz 15N-1H transverse relaxation-optimized spectroscopy-HSQC spectra collected at 
293K for 2H,15N-labeled WT (left) and T246M (right) CHIP U-box (218-303). 
 
B. Circular dichroism spectroscopy data collected for both WT (blue) and T246M (red) CHIP 
U-box (218-303) at 0.25 mg/mL at 15°C in 10 mM sodium phosphate pH 7.0 with 20 mM 
NaCl and 1 mM DTT (left). Melting point (Tm) determination for WT and T246M CHIP U-
box (218-303) at 222 nm (right). 
 
C. Size distribution of full-length recombinant WT (red), T246M (blue), K30A (green) and 
H260Q (pink) CHIP at 0.5mg/mL as determined by DLS measurements. Peaks representing 
CHIP dimer, trimer/tetramer, and large, multimeric aggregates are indicated with 
corresponding molar mass values.  
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The T246M mutation in CHIP results in the formation of large multimeric aggregates in cells. 
As we observed in vitro, T246M mutation in CHIP dramatically destabilizes the CHIP U-box 
domain and results in a loss of secondary α-helical structure (Fig. 4.1A, B). Given that we 
observed the formation of large multimeric T246M CHIP aggregates in vitro (Fig. 4.1C), we 
hypothesized that the T246M substitution would also lead to the formation of multimeric CHIP 
aggregates in cells. To test the effect of the T246M substitution on CHIP’s dimerization status, 
we first expressed either myc-tagged wild-type CHIP (CHIP-WT) or CHIP engineered with a 
methionine substituted for threonine at residue 246 (CHIP-T246M) as well as a TPR-domain 
mutant K30A CHIP and an additional U-box domain mutant H260Q in COS-7 cells and 
performed blue native polyacrylamide gel electrophoresis (BN PAGE) and Western blotting for 
myc-tagged CHIP. As expected, both the WT and K30A proteins migrate at approximately 70 
kDa, as predicted for a CHIP dimer. However, both U-box domain mutants, T246M and H260Q 
are detected as higher molecular weight species, suggesting they exist in cells predominantly as 
large, multimeric aggregates (Fig. 4.2A). We subsequently performed immunocytochemistry for 
myc-tagged CHIP protein to observe CHIP localization and aggregation in the same model of 
exogenous CHIP expression in COS-7 cells. Not surprisingly, WT protein is detected as diffuse 
staining throughout the cytoplasm and within the nucleus, while T246M protein appears as 
punctate staining in the cytoplasm that we hypothesize represents accumulations of multimeric 
CHIP aggregates (Fig. 4.2B). Taken together, these data suggest that in cells T246M protein is at 
least partially misfolded as a result of disorganization of the U-box domain that results from the 
amino acid substitution. This inhibits proper dimerization between T246M CHIP molecules and 
likely contributes to the loss of ubiquitin ligase activity of T246M CHIP previously observed 
(Fig. 3.3).  
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Figure 4.2. The T246M substitution mutation in CHIP results in the formation of large 
multimeric aggregates in cells. 
A. COS-7 cells were co-transfected with the indicated vectors (transgenes, CTL=pcDNA3, 
WT=pcDNA3-myc tagged CHIP, T246M=pcDNA3-myc tagged CHIP-T246M, 
K30A=pcDNA3-myc tagged CHIP K30A, H260Q=pcDNA3-myc tagged CHIP-H260Q). Cells 
were collected on ice and total protein collected and freshly separated by BN PAGE and 
immunoblotted (IB) with the indicated antibodies. The same samples were also separated on a 
denatured reducing gel and immunoblotted with the indicated anti-myc CHIP antibody to detect 
total CHIP protein expression. 
B. COS-7 cells were co-transfected with the indicated transgenes. 24 hours post-transfection, 
cells were fixed and immunostained for myc-CHIP expression. (scale bars=20 μm) 
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Coexpression of WT CHIP with T246M CHIP does not rescue T246M aggregation or 
significantly disrupt WT CHIP dimerization and localization. Given the nature of GHS as an 
autosomal recessive CA, where mutation carriers who are heterozygous for CHIP mutation are 
clinically unaffected, we hypothesized that the coexpression of T246M CHIP with WT CHIP, as 
would exist in a heterozygote, would not result in WT-T246M heterodimers that would disrupt 
normal WT CHIP function. When exogenously expressed alone in COS-7 cells, T246M forms 
almost no detectable dimer, existing predominantly as large multimeric aggregates (Fig. 4.2). To 
test whether WT CHIP and T246M CHIP protein interact, we first expressed HA-tagged wild-
type CHIP (HA-WT) and myc-tagged T246M CHIP (Myc-T246M) alone or in combination in 
COS-7 cells and performed coimmunoprecipitation of HA-WT and Myc-T246M from purified 
cell lysates followed by gel electrophoresis and immunoblotting for HA, Myc or total CHIP. 
Interestingly, we observed that WT and T246M CHIP protein do interact when coexpressed in 
COS-7 cells, with each able to be coimmunoprecipitated by direct pull-down of the other. In 
lysate coexpressing HA-WT and myc-T246M, myc-T246M was detectable following 
immunoprecipitation of HA-WT and HA-WT was detectable following immunoprecipitation of 
myc-T246M (Fig. 4.3A). Furthermore, the amount of detectable HA-WT present in the input 
samples was lower in lysates also expressing myc-T246M than in lysates only expressing HA-
WT, which we hypothesize may be due to some portion of HA-WT becoming insoluble or being 
more rapidly turned over as a result of its association with myc-T246M (Fig. 4.3A). Next, to test 
whether this interaction between WT and T246M CHIP resulted in heterodimerization, we 
performed the same coexpression of HA-WT and Myc-T246M CHIP as in Fig. 4.3A but 24 
hours post-transfection, we instead directly separated the lysates by BN PAGE to observe the 
dimerization/aggregation status of CHIP. Interestingly, we observed that coexpression of HA-
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WT CHIP did not significantly increase the presence of Myc-T246M-containing dimers (Fig. 
4.3B, middle panel), but T246M resulted in a slight increase in higher molecular weight species 
of HA-WT CHIP (Fig. 4.3B, left panel). Given the lack of phenotype in WT-T246M 
heterozygotes, we hypothesized that WT CHIP localization would be largely unaffected by 
T246M coexpression, such that normal CHIP functions would remain intact by the maintenance 
of fully functional CHIP protein in the appropriate cellular compartments. To test whether WT 
CHIP localization is affected by coexpression of T246M CHIP, we again coexpressed HA-WT 
and Myc-T246M in Cos-7 cells and performed immunostaining for HA and Myc. As predicted, 
we observed that the localization of HA-WT was largely unaffected by coexpression of Myc-
T246M (Fig. 4.3C). Taken together, these data suggest that while WT and T246M CHIP interact 
and their coexpression may result in the aggregation/enhanced turnover of some small portion of 
total WT CHIP protein, the localization and dimerization status of WT CHIP is largely 
unaffected by the presence of T246M. Therefore, WT CHIP function likely also remains intact. 
Furthermore, the presence of WT CHIP does not appear to rescue the misfolding/structural 
disorganization of T246M CHIP and prevent T246M aggregation to allow formation of 
functional dimers. Rather, based upon this data, we hypothesize that in heterozygotes, the 
remaining WT CHIP is sufficient to maintain normal CHIP functions within the cell despite the 
presence of T246M CHIP. 
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Figure 4.3. Coexpression of WT CHIP with T246M CHIP does not rescue T246M aggregation 
or disrupt WT CHIP dimerization and localization. 
A. COS-7 cells were co-transfected with the indicated vectors (transgenes, HA-WT=pcDNA3-
HA-tagged CHIP, Myc-T246M=pcDNA3-myc tagged CHIP-T246M) or both. 24 hours post-
transfection, cell lysates were collected and immunoprecipitated with EZview Red Anti-HA 
Affinity Gel or EZview Red Anti-Myc Affinity Gel. The inputs and resulting precipitants (IP) 
were separated by SDS-PAGE and immunoblotted with the indicated antibodies.  
B. COS-7 cells were co-transfected with the indicated transgenes. 24 hours post-transfection, 
cells were collected on ice and total protein collected and freshly separated by BN PAGE and 
immunoblotted (IB) with the indicated antibodies. Approximate molecular weights in kilodaltons 
(kd) are also provided.  
C. COS-7 cells were co-transfected with the indicated transgenes. 24 hours post-transfection 
cells were fixed and immunostained for HA-WT CHIP (left panels) or Myc-T246M CHIP 
(center panels) expression/localization. DAPI nuclear staining is also shown (right panels). (scale 
bars=20 μm) 
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T246M CHIP is more rapidly turned over than WT CHIP, in part by a proteasome-dependent 
mechanism. We consistently observed lower levels of soluble CHIP protein when expressing 
equal amounts of transgenes for CHIP U-box domain mutant T246M relative to WT CHIP in 
COS-7 cells (data not shown). Additionally in this model, we also observed significant amounts 
of large molecular weight aggregates of T246M CHIP not observed with WT CHIP expression 
(Fig. 4.2). Taken together with our in vitro structural data where we observe disorganization and 
lack of secondary structure in the U-box of T246M, we believe T246M and other U-box domain 
mutations dramatically destabilize CHIP structure and likely result in the accumulation of 
misfolded protein aggregates. One mechanism by which cells attempt to eliminate these types of 
terminally misfolded proteins and reduce their accumulation in toxic aggregates is by way of the 
UPS. 173, 174 To test whether T246M CHIP is being degraded via the UPS, we transiently 
expressed his-tagged wild-type CHIP (WT CHIP) or his-tagged T246M CHIP (T246M CHIP) in 
COS-7 cells. Twenty-four hours post-transfection, we treated cells with 50 µg/ml cyclohexamide 
for 0, 1 or 2.5 hours in the presence or absence of 20 µM proteasome inhibitor MG132 and then 
performed SDS-PAGE and immunoblotting for His-CHIP and β-tubulin (Fig. 4.4A). As 
expected, the turnover rate of T246M CHIP observed in the presence of cyclohexamide was 
significantly greater than that observed for WT CHIP, with 50% of soluble T246M CHIP 
remaining after 2.5 hours of cyclohexamide chase relative to 80% of WT CHIP (Fig. 4.4B,C). 
Furthermore, when the proteasome was also blocked by MG132 co-treatment, T246M CHIP 
protein levels were restored to 75% of the untreated control levels whereas WT CHIP was fully 
restored to control levels (Fig. 4.4B,C).  
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This suggests that both WT CHIP and T246M CHIP are degraded by the UPS; however, while 
the turnover of WT CHIP appears to be entirely UPS-dependent, the turnover of T246M CHIP is 
both more rapid and is also only partially proteasomally regulated. This further suggests that 
other clearance mechanisms such as autophagy may also contribute to the more rapid turnover of 
T246M CHIP.  
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Figure 4.4. T246M CHIP is more rapidly turned over than WT CHIP, in part by a proteasome-
dependent mechanism  
A. COS-7 cells were co-transfected with the indicated vectors (transgenes, HA-WT=pcDNA3-
his-tagged CHIP, Myc-T246M=pcDNA3-his tagged CHIP-T246M). 24 hours post-transfection 
cells were treated with 50 µg/ml cyclohexamide for 0, 1 or 2.5 hours in the presence or absence 
of 20 µM proteasome inhibitor MG132 and lysates collected and separated by SDS-PAGE and 
immunoblotted with antibodies against His-CHIP and β-tubulin. 
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B. Quantitation of the ratio of total CHIP relative to total β-tubulin protein in immunoblots 
represented in Fig.4.4A calculated using Licor Image Studio Lite. 
C. Quantitation of the ratio of total CHIP relative to total β-tubulin protein as a percentage of this 
protein ratio in control cells not treated with cyclohexamide or MG132. 
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Expression of endogenous T247M CHIP protein in primary MEFs is dramatically reduced 
despite normal mRNA levels. While incredibly useful as an initial tool to understand the cellular 
effects of T246M CHIP mutation, the COS-7 cell model is significantly limited by potential 
artifacts of ectopic CHIP expression. Thus, utilizing CRISPR/Cas-mediated genome engineering, 
we generated mice homozygous for the single amino acid substitution T247M in CHIP (T246M 
in humans). From these mice, we harvested and cultured primary mouse embryonic fibroblasts 
(MEFs) and evaluated total CHIP protein and mRNA levels in these cells. Interestingly, total 
CHIP protein levels as detected by CHIP immunoblot were dramatically reduced in T247M 
MEFs isolated from 4 different T247M mouse embryos relative to WT MEFs from WT 
littermates (Fig. 4.5A). However, T247M STUB1 mRNA levels in lysates from the same MEFs 
as detected by SYBR green quantitative PCR showed no change relative to WT STUB1 mRNA 
(Fig. 4.5B). Together these data suggest that the reduction in detectable T247M protein is likely 
a result of post translational regulation, with probable mechanisms including proteasomal 
degradation and/or clearance by autophagy. miRNA regulation of CHIP/STUB1 translation has 
also been previously shown and may represent an additional mechanism of T247M CHIP protein 
downregulation175.  
Endogenous T247M CHIP is detected in a punctate immunostaining pattern in primary MEFs 
that exhibit slower growth rates. Ectopic expression of T246M CHIP in COS-7 cells resulted in 
notably punctate immunostaining of CHIP protein relative to a highly diffuse staining pattern 
observed with WT CHIP expression (Fig. 4.2B), which we hypothesize represents misfolded 
T246M CHIP protein aggregates. To test whether these aggregates are also present at 
endogenous protein expression levels, we performed CHIP immunostaining in T247M and WT 
CHIP MEFs. As expected, we observe a distinct punctate pattern of CHIP staining in T247M 
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MEFs, with the appearance of more focused regions of high intensity CHIP staining relative to 
the more diffuse pattern observed in WT MEFs (Fig. 4.5C). This suggests endogenous T247M 
CHIP may be forming multimeric aggregates or may potentially be accumulating in a particular 
cellular compartment or clearance vesicle such as an autophagosome. We subsequently measured 
growth rates of wildtype (WT), T247M and heterozygous (HET) primary MEFs to determine 
whether CHIP dysfunction as a result of T247M mutation and/or proteotoxicity associated with 
T247M CHIP expression might affect the growth rate of these cells in culture. We cultured WT, 
T247M and HET primary MEFs in parallel by tracking the population doubling time with the 
iCELLigence impedance-based system for real-time monitoring of cell growth under normal 
growth conditions. Interestingly, T247M MEFs exhibited a significantly slower growth rate 
relative to WT MEFs (T247M MEF doubling time=45 hours vs WT MEF doubling time=36 
hours) (Fig. 4.5D). Taken together these data suggest that when expressed at endogenous levels 
T247M accumulates within the cell in a distinct pattern relative to WT CHIP that may represent 
aggregation and/or misfolded protein clearance efforts by the cell. This phenotype may manifest 
to alleviate proteotoxicity associated with the aggregation and/or dysfunction of this abnormal 
protein that is, at the very least, negatively impacting cell growth. Given CHIP’s multi-faceted 
role within the cell, this T247M mutation alters multiple cellular processes.  
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Figure 4.5. Expression of endogenous T247M CHIP protein in primary MEFs is dramatically 
reduced despite normal mRNA levels and is detected in a punctate immunostaining pattern in 
primary MEFs that exhibit slower growth rates.  
A. Immunoblottting for CHIP and β-tubulin in P1 primary WT, T247M CHIP and Heterozygous 
(HET) MEFs. 
 
B. Relative quantitation of total STUB1 mRNA in P1 primary WT, T247M CHIP and 
Heterozygous (HET) MEFs. 
 
C. CHIP immunostaining in P2 primary WT and T247M CHIP MEFs. 
 
D. Cell growth of WT, T247M and HET MEFs was monitored over 72 hours utilizing the 
iCELLigence impedance-based system for real-time monitoring of cell growth under normal 
growth conditions. Electrode impedence is directly correlated to cell index and the 
population doubling time is the time required for the cell index to double and thus represents 
time when the whole cell population has performed at least 1 division. 
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Endogenous T247M CHIP is rapidly turned over and UPS inhibition dramatically increases 
T247M protein levels, particularly in the insoluble fraction. As described above, we observed 
more rapid rate of T246M CHIP protein turnover observed in the COS-7 cell ectopic expression 
model (Fig. 4.4) and the dramatic difference in soluble endogenous T247M CHIP protein 
observed in T247M MEFs relative to WT MEFs (Fig. 4.5A). Therefore, we wanted to evaluate 
the turnover rate of endogenous T247M CHIP in primary MEFs. To determine the rate of 
T247M CHIP protein turnover, we blocked protein synthesis in WT, T247M and CHIP knockout 
primary MEFs by treatment with 50µg/ml cycloheximide for 0, 2, 4 or 6 hours and measured 
CHIP protein expression. As expected, while the total soluble CHIP protein expression is 
dramatically reduced in the T247M MEFs as observed previously (Fig. 4.5A) (in fact, requiring 
separate exposure lengths to most clearly visualize the protein), the turnover rate of T247M 
CHIP is significantly faster than WT CHIP, with T247M CHIP completely undetectable by 6 
hours of cycloheximide chase compared to approximately 75% of WT CHIP remaining after 6 
hours (Fig. 4.6A). This suggests increased protein turnover likely contributes significantly to the 
lower levels of detectable soluble T247M CHIP. Our findings in vitro and in COS-7 cells when 
ectopically expressed demonstrate that T246M CHIP forms less functional dimers and instead 
may accumulate in large multimeric aggregates, (Fig. 4.1, 4.2). Therefore we hypothesized that 
another contributing factor to the low levels of detectable soluble T247M CHIP protein may be 
the accumulation of misfolded/aggregated T247M CHIP in the insoluble fraction. To evaluate 
the T247M fractional distribution and whether this distribution was effected by proteasome 
inhibition relative to WT, we treated WT and T247M primary MEFs with 20 µM MG132 or 
0.05% DMSO control for 4 hours. We then collected soluble, insoluble and total protein 
fractions from samples containing equal cell numbers. These samples were separated by SDS-
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PAGE and immunoblotted for CHIP and β-tubulin. To allow direct comparison of CHIP protein 
levels across fractions, we performed 660 nm protein assay to quantitate total protein/sample 
prior to SDS-PAGE and normalized protein load across fractions. We observed several 
interesting phenomenon that help us to understand the regulation of T247M CHIP. First, we 
observed that even when accounting for insoluble protein, total T247M protein 
(soluble+insoluble) is dramatically lower than total WT protein (Fig. 4.6B, C). Secondly, the 
change in total protein levels is dramatically higher with proteasome inhibition for T247M (4-
fold) protein than WT (<1-fold), suggesting dramatically more UPS-dependent turnover of 
T247M relative to WT (Fig 4.6C). Surprisingly though, proteasome inhibition did not restore 
T247M total protein levels to that of WT, suggesting another highly efficient mechanism of 
T247M turnover that dramatically reduces total T247M protein. We also observed that both the 
baseline and MG132 treatment-dependent distribution between soluble and insoluble fractions 
was significantly different for T247M relative to WT (Fig. 4.6D). At baseline WT CHIP appears 
to exist largely in the soluble fraction, and inhibition of the proteasome only slightly shifts the 
distribution from soluble to insoluble. This suggests that, as expected, only a small percentage of 
total WT CHIP is normally turned over by the proteasome under baseline conditions and this 
CHIP will accumulate in the insoluble fraction upon proteasome inhibition. Interestingly, T247M 
has > 2-fold greater distribution in the insoluble fraction at baseline relative to WT, and 
inhibition of the proteasome dramatically increases the total amount of T247M CHIP in both 
fractions but specifically increases T247M present in the soluble fraction by 2-fold and the 
insoluble fraction by 6-fold. This suggests that the proteasome appears to be responsible for 
clearing a large fraction of T247M CHIP that would otherwise accumulate as insoluble protein, 
but also clears some T247M CHIP that remains soluble but may be functionally defective and 
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therefore deleterious to the cell (Fig. 4.6D). Together these data suggest that T247M CHIP is 
rapidly cleared by the proteasome, and much of the protein degraded by the UPS will accumulate 
in the insoluble fraction, likely due to its misfolded nature. However, other efficient clearance 
mechanisms must exist within the cell to reduce the total T247M protein burden and prevent 
large amounts of accumulation of T247M CHIP protein both as soluble, potentially toxic protein 
as well as in damaging insoluble aggregates.  
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Figure 4.6. Endogenous T247M CHIP is rapidly degraded in part by the UPS, largely reducing 
accumulation of insoluble protein.  
A. Immunoblottting for CHIP and β-tubulin in soluble cell lysates from P2 primary WT, T247M 
CHIP and CHIP knockout (-/-) MEFs collected after 0, 2, 4 or 6 hours of protein synthesis 
inhibition by cyclohexamide chase. (light and dark exposure for total CHIP to allow easier 
visualization of poorly expressed T247M CHIP) 
 
B. P2 primary WT, T247M CHIP and CHIP knockout (-/-) MEFs were treated with 20 µM 
MG132 or 0.05% DMSO control for 4 hours. Cells were counted and divided into two equal 
samples that were then processed into soluble, insoluble and total protein lysates. Half of the 
cells were lysed directly in SDS sample buffer and sonicated (total protein) the other half 
were lysed in TritonX-100 lysis buffer. The TritonX-100 samples were then separated by 
centrifugation and the supernatant collected (soluble). The remaining pellet was then rinsed 
and lysed directly in SDS sample buffer and sonicated (insoluble). Samples were then 
quantitated by 660 nm protein assay and samples of equal protein concentration separated by 
SDS-PAGE and immunoblotted for CHIP and β-tubulin.  
 
C. Quantitation of total CHIP protein in each condition relative to total CHIP present in DMSO 
treated WT CHIP control cells in Fig. 4.6B.  
 
D. Quantitation of the relative distribution of total CHIP between soluble and insoluble fractions 
within each genotype in Fig. 4.6B. Prior to calculating the relative distribution, CHIP values 
were normalized for the percentage of each fraction loaded on the gel to allow comparison of 
CHIP expression across fractions of unequal total volume. 
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T246M CHIP does not ubiquitinate non-chaperone substrates but has enhanced E2 ligase 
binding. We have previously shown that both in vitro and in cells, T246M CHIP has virtually no 
detectable ubiquitin ligase activity towards chaperone substrates (Chapter III). We hypothesized 
that this would also be the case for non-chaperone substrates given the disorganization of the 
T246M CHIP U-box (Fig. 4.1). To test this, we evaluated the previously reported non-canonical 
monoubiquitination of non-chaperone neuronal substrate α-synuclein by in vitro ubiquitination 
assay176. As expected, we observed a loss of α-synuclein monoubiquitination as a result of 
T246M mutation (Fig. 4.7A). Since first observing the loss of ubiquitin ligase activity but 
preserved interaction with chaperone proteins (Chapter III) and the structural disorganization of 
the T246M U-box domain (Fig. 4.1), we hypothesized that T246M CHIP may still associate with 
E2 ligases that, when bound to CHIP, normally facilitate the transfer of ubiquitin to 
ubiquitination substrates, but that the transfer of ubiquitin may be impaired by the structural 
consequences of T246M mutation. To test whether T246M CHIP still binds to E2 ligases in 
cells, we transiently expressed myc-tagged wild-type CHIP (WT CHIP), myc-tagged T246M 
CHIP (T246M CHIP) or myc-tagged H260Q CHIP (H260Q) in COS-7 cells and performed co-
immunoprecipitation for CHIP and E2 ligase known to function with CHIP UbcH5c. 
Interestingly, we observe an enhanced association of U-box domain mutants, T246M CHIP and 
H260Q CHIP with UbcH5c relative to WT CHIP, suggesting the rate of association/dissociation 
between CHIP and the E2 enzyme may be impaired by the loss of ubiquitin transfer that results 
from U-box mutation (Fig. 4.7B). We hypothesize that this may reduce accessibility of the 
associated E2 ligase to other E3 enzymes, perhaps impairing ubiquitination reactions beyond 
only CHIP substrates. Together these data suggest that, while it can no longer ubiquitinate 
substrate proteins, T246M CHIP still binds many of its normal binding partners, but that the 
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dynamics of these interactions may be altered. This may have larger implications for additional 
enzymatic reactions outside of direct regulation of CHIP substrates, potentially further impairing 
the cell’s ability to maintain baseline cellular homeostasis and/or allowing the cell to respond to 
stress.  
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Figure 4.7. T246M CHIP does not ubiquitinate non-chaperone substrates but has enhanced E2 
ligase binding. 
A. Cell-free ubiquitination reactions containing recombinant α-synuclein and the indicated CHIP 
proteins resolved via SDS-PAGE and immunoblotted for an antibody recognizing α-synuclein. 
B. COS-7 cells were co-transfected with the indicated transgenes and immunoprecipitated with 
either a UbcH5c antibody, CHIP antibody or IgG. The inputs and resulting precipitants (IP) were 
immunoblotted (IB) with the indicated antibodies.  
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T246M CHIP promotes HSF1 translocation to the nucleus and activation of transcription. In 
addition to its role as a ubiquitin ligase, CHIP can also act as a co-chaperone through its direct 
interactions with cellular chaperones, including HSC70, HSP70, and HSP90 via CHIP’s 
tetratricopeptide repeat (TPR) domain.81, 128, 134, 153 Both a functional TPR and U-box domain are 
required for CHIP’s ability to directly impact PQC and attenuate the cellular stress response in 
large part through polyubiquitination of HSP chaperones.75, 79 Given that the T246M CHIP 
mutation resides in the U-box domain, we hypothesized that the T246M substitution would result 
in a loss of CHIP’s ubiquitin ligase activity, without affecting CHIP’s interaction and activities 
with cellular chaperones though the intact TPR domain. Through its interaction with HSP 
chaperones, CHIP also regulates the transcriptional activation of heat shock factor 1 (HSF1), 
which is normally under negative regulatory control by molecular chaperones Hsp70 and Hsp90. 
Furthermore, this activation of HSF1 confers protection from cellular stress and prevents 
apoptosis74. We demonstrated previously by co-immunoprecipitation assay that T246M 
substitution does not impair its ability to bind to chaperones (Fig. 3.3 and 3.4). To test whether 
CHIP’s regulation of HSF1 remains intact with T246M mutation, we first transiently expressed 
wildtype (WT) CHIP, T246M CHIP and TPR-domain mutant K30A CHIP in COS7 cells and 
measured the nuclear translocation of HSF1 induced by CHIP expression. As previously 
reported74, we observed that expression of WT CHIP drives HSF1 to the nucleus. As expected, 
expression of T246M CHIP also resulted in nuclear translocation of HSF1 while expression of 
TPR domain mutant did not (Fig. 4.8A). These data suggest that despite disruption of the CHIP 
U-box, T246M mutation leaves the TPR domain sufficiently intact to maintain this activity.  
To test whether HSF1 that is driven to the nucleus by T246M CHIP is transcriptionally 
active, we utilized the Promega HSF1 Dual-Luciferase Reporter (DLR) Assay System in COS7 
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cells to measure the transcriptional activation of HSF1 with CHIP expression. As previously 
reported,74 we observed that expression of WT CHIP results in activation of HSF1 transcriptional 
activity. Interestingly, expression of T246M CHIP as well as U-box domain mutant H260Q also 
resulted in activation of HSF1; however, that activation of HSF1 by U-box domain mutants was 
1-fold to 2.5-fold higher than that observed with WT CHIP. Importantly, we also observed no 
significant HSF1 activation by the expression of control protein β-galactosidase (β-gal) or TPR 
domain mutant K30A CHIP (Fig. 4.8B).  
The dramatic increase in HSF1 activation relative to WT CHIP observed with both U-box 
domain mutants that we have previously shown to form large multimeric aggregates in cells led 
us to hypothesize that perhaps the increased HSF1 activation was not a CHIP-specific effect but 
rather driven by a cellular-stress response to the presence of these aggregates. To test this 
hypothesis, we developed a CHIP double-mutant K30A-T246M CHIP containing the T246M 
mutation and also the TPR domain mutation K30A that disrupts CHIP-driven HSF1 nuclear 
translocation and activation. To first characterize the aggregation status of this double mutant, 
we transiently expressed it in COS-7 cells at both 1X and 2.5X concentrations alongside WT 
CHIP, T246M CHIP and H260Q CHIP, performed BN PAGE and CHIP immunoblotting. We 
observed that, like T246M CHIP, K30A-T246M CHIP also forms large multimeric aggregates 
when transiently expressed in COS7 cells (Fig. 4.8C). To test whether HSF1 activation by U-box 
domain mutants is driven by chaperone-mediated interaction of HSF1 with CHIP or is merely a 
consequence of the overexpression of aggregation-prone proteins, we measured HSF1 activation 
in the presence of K30A-T246M double mutant as well as previously reported misfolded, 
aggregation-prone derivative of BSA, cBSA177. Interestingly, we observed that expression of 
neither K30A-T246M CHIP nor cBSA promote HSF1 activation relative to WT CHIP, 
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suggesting that the enhanced potentiation of HSF1 activity by CHIP U-box mutants T246M 
CHIP and H260Q CHIP is specific and not solely due to their tendency towards forming large 
multimeric aggregates (Fig. 4.8B). 
In our COS-7 transient overexpression model, when transfecting in equal amounts of 
CHIP DNA across constructs, we consistently observed lower amounts of soluble CHIP protein 
when expressing T246M CHIP, H260Q CHIP and K30A-T246M CHIP relative to WT CHIP. 
We hypothesized that due to disorganization of the U-box domain, some portion of these 
expressed CHIP proteins was becoming insoluble, potentially as multimeric aggregates. To test 
this hypothesis, we performed SDS-PAGE and immunoblotting for CHIP comparing the soluble 
fraction (prepared by lysing cells in 1% Triton X-100 lysis buffer) and remaining insoluble pellet 
(solubilized by sonication in SDS-sample buffer). As expected, we observed significant amounts 
of T246M CHIP, H260Q CHIP and K30A-T246M CHIP in the insoluble pellet with no 
detectable WT or K30A CHIP present in the insoluble pellet (Fig. 4.8D).   
Based upon this observation that T246M CHIP, H260Q CHIP and K30A-T246M CHIP 
were all observed significantly in the insoluble fraction, we wanted to confirm that enhanced 
potentiation of HSF1 activation was specific to soluble CHIP and further confirm it was not 
aggregate driven. To test this, we repeated the experiment presented in Fig. 4.8B but now 
expressing higher amounts of T246M, H260Q and K30A-T246M CHIP such that the amount of 
soluble CHIP detectable by immunoblot was roughly equivalent to WT CHIP (Fig. 4.8E). As 
expected, we observed that under these conditions where there is likely to be both more soluble 
and insoluble CHIP, there remains no activation of HSF1 by K30A-T246M CHIP.  
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Furthermore, the increased expression of either T246M CHIP or H260Q resulted in even greater 
potentiation of HSF1 activation. Together these data suggest that HSF1 activation is driven by 
soluble CHIP in a dose-dependent manner and this potentiation is dramatically enhanced by U-
box mutants T246M and H260Q. 
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Figure 4.8. T246M CHIP promotes HSF1 translocation to the nucleus and activation of 
transcription. 
A. Immunoblottting for HSF1, CHIP, HP1α and MEK in cytosolic (C) and nuclear (N) fractions 
from COS7 cells transiently transfected with the indicated vectors (transgenes, CTRL=pcDNA3, 
WT=pcDNA3-myc tagged CHIP, T246M=pcDNA3-myc tagged CHIP-T246M, 
K30A=pcDNA3-myc tagged CHIP K30A) and treated with or without heat shock in 42°C water 
bath for 30 min as marked.  
B. Immunoblotting for CHIP, HSP70 and AMPKα in Triton X-100 soluble and insoluble 
fractions from COS7 cells transiently transfected with the indicated vectors (transgenes, 
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CTRL=pcDNA3, WT=pcDNA3-myc tagged CHIP, T246M=pcDNA3-myc tagged CHIP-
T246M, K30A=pcDNA3-myc tagged CHIP K30A, H260Q=pcDNA3-myc tagged CHIP-H260Q, 
K30A-T246M=pcDNA3-myc tagged K30A-T246M double mutant). 
C. Top, HSF1 transcription activity fold increase relative to control cells as detected by Promega 
HSF1 Dual-Luciferase Reporter (DLR) Assay System in COS7 cells transiently transfected with 
the indicated vectors (transgenes, CTRL=pcDNA3, WT=pcDNA3-myc tagged CHIP, 
T246M=pcDNA3-myc tagged CHIP-T246M, K30A=pcDNA3-myc tagged CHIP K30A, 
H260Q=pcDNA3-myc tagged CHIP-H260Q, K30A-T246M=pcDNA3-myc tagged K30A-
T246M double mutant, β-gal=pcDNA3 beta-galactosidase, cBSA=pcDNA3 cytosolic bovine 
serum albumin) at low (1X) and high (2X) expression levels. Bottom, immunoblotting for CHIP 
and β-tubulin of COS7 cells transfected in parallel with top DLR assay. 
D. Top, HSF1 transcription activity fold increase relative to control cells as detected by Promega 
HSF1 Dual-Luciferase Reporter (DLR) Assay System in COS7 cells transiently transfected with 
the indicated vectors (transgenes, CTRL=pcDNA3, WT=pcDNA3-myc tagged CHIP, 
T246M=pcDNA3-myc tagged CHIP-T246M, K30A=pcDNA3-myc tagged CHIP K30A, 
H260Q=pcDNA3-myc tagged CHIP-H260Q, K30A-T246M=pcDNA3-myc tagged K30A-
T246M double mutant, GFP=green fluorescent protein) at low (1X) and high (2X) expression 
levels. Here T246M CHIP, H260Q CHIP and K30A-T246M CHIP were each expressed at 
adjusted concentrations to produce relative soluble CHIP as that present with WT CHIP 
expression. Bottom, immunoblotting for CHIP and β-tubulin of COS7 cells transfected in 
parallel with top DLR assay. 
E. Immunoblotting for CHIP aggregation status under native, non-denatured, non-reduced 
conditions. COS-7 cells were transfected with the indicated vectors (transgenes, CTL=pcDNA3, 
WT=pcDNA3-myc tagged CHIP, T246M=pcDNA3-myc tagged CHIP-T246M, 
K30A=pcDNA3-myc tagged CHIP K30A, H260Q=pcDNA3-myc tagged CHIP-H260Q, K30A-
T246M=pcDNA3-myc tagged K30A-T246M double mutant at equal and 2.5X WT 
concentration). Cells were collected on ice and total protein collected and freshly separated by 
BN PAGE and immunoblotted (IB) with the indicated antibodies. The same samples were also 
separated on a denatured reducing gel and immunoblotted with the indicated anti-myc CHIP and 
β-tubulin antibodies to detect total CHIP protein expression. 
F. Immunoprecipitation of ubiquitinated Hsp70. COS-7 cells were co-transfected with the 
indicated vectors (transgenes, CTRL=pcDNA3, WT=pcDNA3-CHIP, T246M=pcDNA3-CHIP-
T246M and K30A-T246M=pcDNA3-CHIP K30A-T246M double mutant) in addition to HA-
tagged ubiquitin and FLAG-Hsp70. HSP70 was immunoprecipitated (IP) with FLAG beads and 
the resulting precipitants as well as inputs were immunoblotted (IB) with the indicated 
antibodies. CTRL lanes shown are (left to right) CTRL=HA-tagged ubiquitin and pcDNA3, 
CTRL= HA-tagged ubiquitin+pcDNA3+FLAG-Hsp70 
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T247M CHIP chaperone interactions and co-chaperone activities remain intact and may be 
enhanced in T247M primary MEFs. We have previously shown that when expressed transiently 
in COS-7 cells T246M CHIP maintains interactions with chaperone proteins (Fig. 3.3) and 
promotes chaperone-mediated activities, including the translocation and activation of HSF1 
(Fig.4.8A, B, E). To test whether T247M CHIP expressed endogenously in T247M primary 
MEFs still interacts with chaperone proteins and still maintains previously reported CHIP 
chaperone functions, particularly under stress conditions, we first performed co-
immunoprecipitation (IP) of endogenous CHIP and endogenous Hsc70 from purified P2 primary 
cell lysates followed by gel electrophoresis and immunoblotting (IB) for CHIP or Hsc70 in the 
remaining precipitants and input samples (Fig.4.9A). As expected, immunoprecipitation of both 
WT and T247M CHIP resulted in co-isolation of Hsc70, demonstrating that T247M CHIP 
maintains its interaction with Hsc70 when expressed endogenously. Interestingly, the amount of 
Hsc70 isolated with T247M CHIP was proportionally greater than the amount of Hsc70 isolated 
with WT CHIP. Interestingly, the immunoprecipitation of Hsc70 resulted in detectable levels of 
co-isolated WT CHIP; however, T247M CHIP was not detectable. Based upon our detection of 
Hsc70 in the CHIP immunoprecipitation, we hypothesize that this is a reflection of the very low 
levels of soluble T247M CHIP present in these cells such that it is not detectable by this method 
and not a true lack of interaction between T247M CHIP and Hsc70. After confirming T247M 
CHIP chaperone interactions are intact and perhaps even enhanced, we next tested whether this 
interaction is functional, such that T247M CHIP retains its normal co-chaperone functions. It has 
been previously shown that CHIP not only enhances Hsp70 induction during acute stress but also 
mediates its turnover during the stress recovery process, with the former a result of its co-
chaperone activities and the later mediated by its ubiquitin ligase activity75. To test whether one 
136 
 
or both of these activities remains intact despite T247M mutation we subjected WT, T247M and 
CHIP knockout (CHIP-/-) primary MEFs to heat shock (HS) in a 42°C water bath for 10 min and 
then collected total cell lysates after 0, 4 and 20 hours of recovery under normal growth 
conditions. As expected, we observed that in the presence of WT CHIP, Hsp70 expression is 
significantly increased and then is dramatically reduced again by 20 hours post-HS. Also as 
expected, we observed that in the absence of CHIP the induction of Hsp70 at 4 hours post-HS is 
dramatically reduced. Interestingly, in the presence of T247M CHIP the induction of Hsp70 is 
not only preserved, but is enhanced relative to WT, while the return of Hsp70 to baseline levels 
is slowed, with more Hsp70 remaining after 20 hours of recovery relative to WT CHIP cells (Fig. 
4.9B). In order to further evaluate the regulation of Hsp70 following heat shock in the presence 
of T247M CHIP, we again subjected WT and T247M primary MEFs to heat shock (HS) in a 
42°C water bath for 10 min and then collected total cell lysates in a more extensive timecourse, 
collecting cells after 0, 2, 4, 8, 12, 16, 20 and 24 hours of recovery under normal growth 
conditions. As expected, in the presence of WT CHIP, Hsp70 expression was increased 
following HS, reaching a peak at 12 hours post-HS and returning to near baseline levels by 24 
hours post-HS. Interestingly, in the presence of T247M CHIP, Hsp70 expression was induced 
more rapidly and to a great extent than WT, with a significant increase over baseline levels by 
just 8 hours post-HS. Furthermore, in the presence of T247M CHIP, the increased expression of 
Hsp70 was prolonged, as we observed significantly elevated protein levels even at 24 hours post-
HS (Fig. 4.9C). Together these data suggest that when expressed at endogenous levels in primary 
MEFs, like WT CHIP, T247M CHIP interacts with chaperone proteins. Furthermore, via these 
chaperone interactions, T247M CHIP maintains its ability to enhance Hsp70 induction during 
acute stress, and in fact may more greatly enhance Hsp70 expression than WT CHIP. However, 
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its ability to mediate Hsp70 turnover during the stress recovery process is impaired, likely due to 
its loss of ubiquitin ligase activity. We hypothesize that the observed enhanced induction of 
Hsp70 expression during stress may be a result of a change in binding kinetics between T247M 
CHIP and Hsp70 due to changes in T247M protein structure caused by the U-box domain 
mutation.  
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Figure 4.9. T247M CHIP chaperone interactions and co-chaperone activities remain intact and 
may be enhanced in T247M primary MEFs. 
A. CHIP and Hsc70 immunoblot of P2 primary WT and T247M MEF cell lysates collected and 
immunoprecipitated with a HSC70 antibody or CHIP antibody. The inputs and resulting 
precipitants (IP) were separated by SDS-PAGE and immunoblotted with the indicated 
antibodies. Control samples (CTRL) contained a mix of 50% WT lysate and 50% T247M lysate 
and were immunoprecipitated with either rat IgG or rabbit IgG. 
B. CHIP and Hsp70 immunoblot of P2 primary WT, T247M and CHIP knockout (CHIP-/-) MEFs 
treated without heat shock (NHS) or with heat shock (HS) in a 42°C water bath for 10 min. HS 
cells were then returned to normal growth conditions and total cell lysates collected after 0, 4 or 
20 hours of recovery. Cleared lysates were separated by SDS-PAGE and immunoblotted with the 
indicated antibodies. 
C. CHIP and Hsp70 immunoblot of P2 primary WT and T247M (T247M or TM) MEFs heat 
shocked (HS) in a 42°C water bath for 10 min. HS cells were then returned to normal growth 
conditions and total cell lysates collected after 0, 2, 4, 8, 12, 16, 20 or 24 hours of recovery. 
Cleared lysates were separated by SDS-PAGE and immunoblotted with the indicated antibodies. 
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T246M disrupts CHIP regulation of SIRT6 and does not protect primary MEFs from UVC-
induced cell death. We have recently uncovered a connection between CHIP and the nuclear 
lysine deacetylase/ADP ribosylase SIRT6, which is an essential regulator of inflammatory gene 
expression and DNA repair CHIP stably interacts with SIRT6 and CHIP-mediated non-canonical 
ubiquitination promotes SIRT6 protein stability. In the absence of CHIP, SirT6 is subject to 
canonical ubiquitination and proteasome-mediated degradation, dramatically reducing SIRT6 
half-life, reducing DNA repair capacity, and increasing expression of inflammatory genes.87 
Furthermore, our additional preliminary data demonstrate that stress-induced nuclear 
accumulation of CHIP results in CHIP’s association with not only SIRT6, but also other nuclear 
proteins, including several DNA repair proteins (data unpublished). GHS patients with T246M 
CHIP mutation have significant loss of cerebellar mass with associated cerebellar ataxia (Fig. 
3.1), and CHIP-/- mice have significant degeneration of cerebellar Purkinje cells where CHIP is 
highly expressed (Fig. 3.7). Apoptosis of these neuronal populations may be a direct 
consequence of impaired DNA repair as a result of T246M CHIP mutation. We hypothesized 
that the clinical pathology of T246M CHIP mutation is in part caused by an impairment of 
CHIP-mediated DNA repair mechanisms by disruption of CHIP protein interactions or CHIP-
mediated non-canonical ubiquitination of DNA-repair protein substrates. To test whether CHIP-
mediated DNA-repair mechanisms remain intact after T246M mutation we first evaluated 
T246M CHIP regulation of SIRT6 in vitro and in cells. We performed cell free in vitro 
ubiquitination reactions containing SIRT6 and WT or T246M CHIP. As expected, we observed 
that T246M CHIP is unable to ubiquitinate SIRT6 in vitro (Fig. 4.10A). We next performed 
immunoprecipitation of FLAG-SIRT6 to test whether SIRT6 interaction is preserved after 
T246M CHIP mutation when expressed in COS-7 cells and evaluated the ubiquitination status of 
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SIRT6 in the presence of T246M CHIP in these cells. Interestingly, we observed that T246M 
CHIP maintains its interaction with SIRT6 and, in fact, this interaction appears to be enhanced, 
with more T246M CHIP precipitating with FLAG-SIRT6 than WT CHIP. Additionally, not only 
does expression of T246M CHIP result in less ubiquitinated FLAG-SIRT6 relative to that 
observed in the presence of WT CHIP expression, but in fact, the ubiquitination of FLAG-SIRT6 
is reduced relative to control cells with no CHIP expression. Together, these data suggest that 
T246M CHIP does interact with but does not ubiquitinate SIRT6 in vitro or in cells and may 
inhibit access to SIRT6 by the competing E3. This likely would result in significantly impaired 
SIRT6 regulation that we hypothesize may negatively impact the DNA repair capacity in cells 
expressing T246M CHIP.  
UVC-radiation has previously been shown to induce apoptosis in DNA-repair deficient 
cell-models178. To test whether T246M mutation inhibits the DNA repair capacity of cells, we 
subjected WT, T247M and CHIP knockout (CHIP-/-) primary MEFs to 10J/m2 UVC-radiation 
and measured viability 24 hours later using MTT cell viability assay. As expected, we observed 
that WT MEF viability was unaffected but both T247M and CHIP-/- MEF viability was 
significantly reduced by ~20-25% following exposure to 10J/m2 UVC-radiation (Fig. 4.10C). 
Notably, at higher UVC doses, WT MEFs did also exhibit a reduction in viability as measured by 
MTT assay, but the loss of viability in T247M and CHIP-/- MEFs was always greater than that 
observed with WT up to doses of 30J/m2 (data not shown). This suggests significant impairment 
of DNA repair capacity in primary MEFs either by total loss of CHIP or as a result of 
dysregulation of DNA repair proteins, such as SIRT6, as a result of T247M CHIP mutation. 
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Figure 4.10. T246M disrupts CHIP regulation of SIRT6 and does not protect primary MEFs 
from UVC-induced cell death. 
 
A. Cell-free ubiquitination reactions containing recombinant SIRT6 and the indicated CHIP 
proteins resolved via SDS-PAGE and immunoblotted for antibodies recognizing SIRT6 and 
CHIP. 
B. Immunoprecipitation of ubiquitinated FLAG-SIRT6. COS-7 cells were co-transfected with 
the indicated vectors (transgenes, CTL=pcDNA3, WT=pcDNA3-CHIP and T246M=pcDNA3-
CHIP-T246M) in addition to HA-tagged ubiquitin and FLAG-HSP70. HSP70 was 
immunoprecipitated (IP) with FLAG beads and the resulting precipitants as well as inputs were 
immunoblotted (IB) with the indicated antibodies. CTRL lane 1 (far left) contains no FLAG-
SIRT6. 
C. MTT cell viability in WT, T247M and CHIP knockout (CHIP-/-) P2 primary MEFs 24 hours 
after exposure to 10J/m2 UVC radiation. % viability calculated relative to untreated cells of the 
same genotype.  
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T246M CHIP potentiates AMPK activity in vitro and interacts with AMPK in cells, protecting 
them from oxidative stress but does not ubiquitinate upstream AMPK-regulator LKB1. We 
recently uncovered a link between proteolytic and metabolic pathways with our discovery that 
CHIP serves as an autonomous chaperone for AMP-activated kinase (AMPK)8. AMPK is a 
global metabolic sensor, activated by reduced ATP levels to limit energy-consuming processes 
and promote ATP synthesis179-181. The AMPK holoenzyme consists of three subunits: the 
catalytic α subunit (α1 or α2) and the β and γ regulatory subunits. AMPK is regulated both by 
phosphorylation of the α subunit, principally mediated by liver kinase B1 (LKB1), and 
allosterically through the AMP/ATP binding domain found in the γ subunit182. CHIP regulation 
of AMPK is proposed to involve two-fold promotion of AMPK activity during cellular stress, 
first by enhancing its phosphorylation by upstream kinase LKB1 and by acting as a direct 
chaperone, binding to AMPK to affect its tertiary structure, agonizing AMPK activity followed 
by recovery in which CHIP-mediated ubiquitination and subsequent degradation of LKB1 
restores AMPK activity to baseline levels8. The importance of an intact CHIP U-box domain in 
these regulatory roles remains incomplete, although FRET studies suggest that the CHIP U-box 
still binds AMPK but only partially induces changes in its tertiary structure that may mediate 
CHIP’s direct agonism of AMPK activity8. Our data suggests that T246M mutation in the CHIP 
protein disrupts its ubiquitin ligase activity but leaves at least some of its endogenous protein-
protein interactions and chaperone functions intact (Figs. 3.3, 3.4, 4.7-4.10). Therefore, we 
hypothesized that T246M CHIP maintains its ability to bind AMPK and agonize AMPK activity. 
Furthermore, we hypothesized that this activation is sufficient to protect cells from acute 
oxidative stress, especially because AMPK activation may be prolonged as a result of loss of 
CHIP-mediated LKB1 ubiquitination and degradation.  
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To test whether T246M CHIP regulation of AMPK upstream regulator, LKB1 is 
preserved we performed cell free in vitro ubiquitination reactions containing LKB1 and WT or 
T246M CHIP. As expected, we observed that T246M mutation results in loss of CHIP-mediated 
LKB1 monoubiquitination (Fig. 4.11A). We have previously shown that when expressed 
transiently in COS-7 cells, T246M CHIP maintains interactions with chaperone proteins (Fig. 
3.3) and promotes chaperone-mediated activities, including the translocation and activation of 
HSF1 (Fig.4.8A, B, E). To test whether T246M also maintains its interaction with AMPKα, we 
transiently expressed myc-tagged WT and T246M CHIP in COS-7 cells and performed co-
immunoprecipitation of CHIP and AMPKα1. As expected, we observed that T246M CHIP 
precipitates with AMPKα1 and, in fact as we observed with other CHIP interacting proteins, the 
association between AMPKα1 and T246M CHIP appears to be enhanced (Fig. 4.11B). 
CHIP binding to AMPKα1 has previously been shown to potentiate AMPK kinase 
activity8, therefore to test whether the intact/enhanced binding of T246M CHIP to AMPK also 
potentiates AMPK, we performed an in vitro kinase activity assay utilizing recombinant CHIP, 
AMPK and Z’LYTE peptide substrate (Invitrogen). Interestingly, we observed that like WT 
CHIP, T246M CHIP potentiates AMPK substrate phosphorylation in a dose-dependent manner 
(Fig. 4.11C). Notably, as indicated by the right-shifted dose-response curve, the potentiation 
appears to be reduced with T246M CHIP relative to WT CHIP. However it is important to point 
out that the physiological significance of this observation is unclear given the likely large 
difference in the distribution of WT and T246M CHIP between soluble dimer and multimeric 
aggregates as indicated by our biophysical characterization of recombinant WT and T246M 
CHIP. such that the concentration of CHIP protein participating in this potentiation of AMPK 
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may not truly be equivalent (Fig. 4.1). Based upon this data we can however conclude that 
T246M CHIP does maintain its ability to potentiate AMPK activity. 
AMPK activation has been previously shown to protect cells from acute oxidative stress 
and we have previously demonstrated that CHIP is required for this AMPK activation8, 183. 
Having observed that the interaction of AMPK and CHIP is preserved and CHIP-mediated 
potentiation of AMPK is maintained in spite of T246M mutation, we hypothesized that this 
activation will be sufficient to protect cells from acute oxidative stress, especially because while 
potentially diminished in amplitude AMPK activation may be prolonged as a result of loss of 
CHIP-mediated LKB1 ubiquitination and degradation. To test this, utilizing the iCelligence 
impedance-based system for cell-based assays, we cultured and monitored the growth over time 
of HEK293 cells that had been stably depleted of WT CHIP by shRNA knockdown (shCHIP) as 
well as control HEK293 cells expressing wildtype CHIP (shCTRL). WT or T246M CHIP was 
then reintroduced in these cells by transient transfection, followed by exposure to 0 µM or 200 
µM H2O2 for 24 hours beginning at 24 hours post-transfection (Fig. 4.11D). As expected, in 
HEK293 cells stably depleted of WT CHIP, 200 µM H2O2 resulted in a dramatic reduction in the 
recorded delta cell index relative to vehicle treated cells as well as relative to shCTRL cells also 
treated with 200 µM H2O2. The delta cell index is a reflection of the change in total cells over 
time, thus suggesting that in the absence of CHIP, oxidative stress dramatically inhibits cell 
proliferation and/or promotes cell death. Interestingly, reintroduction of both WT and T246M 
partially rescued this loss of cell proliferation/viability, confirming that like WT CHIP, T246M 
CHIP is protective against oxidative stress, perhaps via its regulation and activation of AMPK 
activity.      
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Figure 4.11. T246M CHIP potentiates AMPK activity in vitro and interacts with AMPK in cells, 
protecting them from oxidative stress but does not ubiquitinate AMPK-regulator LKB1. 
A. Cell-free ubiquitination reactions containing recombinant LKB1 and the indicated CHIP 
proteins resolved via SDS-PAGE and immunoblotted for an antibody recognizing LKB1. 
B. In vitro kinase assay measuring AMPK kinase activity towards Z’LYTE peptide substrate in 
the presence of increasing amounts of recombinant CHIP protein and IgG protein control. 
C. Co-immunoprecipitation of myc-CHIP and AMPKα1. COS-7 cells were co-transfected with 
the indicated vectors (transgenes, CTL=pcDNA3, WT=pcDNA3-CHIP and T246M=pcDNA3-
CHIP-T246M). myc-CHIP or AMPKα1 was then immunoprecipitated (IP) with CHIP or 
AMPKα antibody. The inputs and resulting precipitants (IP) were separated by SDS-PAGE and 
immunoblotted (IB) with the indicated antibodies. IgG indicates control immunoprecipitation of 
cell lysates utilizing rabbit or goat IgG. 
D. Delta cell index recorded by iCelligence impedence-based cell monitoring system as a 
measure of cell proliferation/viability in HEK293 cells stably depleted of CHIP with and without 
the reintroduction of WT or T246M CHIP in the presence and absence of 200 µM H2O2. 
HEK293 cells were stably depleted of WT CHIP by shRNA knockdown (shCHIP). Control cells 
were HEK293 cells expressing wildtype CHIP stably transfected with control shRNA (shCTRL). 
WT or T246M CHIP was then reintroduced in these cells by transient transfection, followed by 
exposure to 0 µM or 200 µM H2O2 for 24 hours beginning at 24 hours post-transfection. Delta 
cell index (Delta CI) was calculated as the change in cell index before and after exposure to 0 
µM or 200 µM peroxide.  
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T247M CHIP interacts with and regulates AMPK phosphorylation in primary MEFs that are 
protected from oxidative stress perhaps through an AMPK-mediated mechanism. We observed 
that in vitro and when expressed transiently in cells, T246M CHIP maintains interactions with 
AMPK and potentiates AMPK activity, likely promoting the protection of cells from oxidative 
stress (Fig. 4.11B-D). However, the relationship between T247M CHIP and AMPK when 
expressed T247M CHIP was expressed endogenously was still unknown. To address this, we 
utilized WT and T247M primary MEFs to test whether T247M CHIP interacts with AMPK and 
whether this interaction results in enhanced phosphorylation of AMPK under conditions of 
oxidative stress and whether expression of T247M protects cells from oxidative stress-induced 
cell death as is observed in the presence of WT CHIP. We performed co-immunoprecipitation of 
CHIP and AMPK from WT and T247M MEF whole cell lysates. As expected, we observed that 
like WT CHIP, endogenous T247M CHIP interacts with AMPKα1. Interestingly, similar to what 
we observed with exogenous expression of T246M CHIP in COS-7 cells, while the amount of 
soluble CHIP isolated by immunoprecipitation was significantly higher from WT MEFs vs. 
T247M MEFs, the amount of co-precipitated AMPK was not significantly different (Fig. 4.12A). 
This suggests that the amount of soluble T247M CHIP present, while dramatically reduced 
relative to WT CHIP, is sufficient to accomplish the same AMPK binding. This may reflect a 
change in T247M CHIP binding kinetics as a consequence of mutation-induced structural 
changes and/or may result in reduced availability of T247M CHIP to other binding partners.  
CHIP has previously been shown to promote AMPK activity during acute oxidative stress by 
enhancing its phosphorylation by upstream kinase LKB18. Having confirmed AMPK-T247M 
interaction in this endogenous expression model, we next wanted to evaluate whether the 
functional consequences of this interaction remain intact. To test this we exposed WT and 
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T247M primary MEFs to 0, 200 and 400 µM H2O2 to induce acute oxidative stress and measured 
the phosphorylation of AMPKα. Interestingly, the phosphorylation of AMPKα in the presence 
of T247M CHIP was not significantly different relative to that observed in the presence of WT 
CHIP (Fig. 4.12B, C). This suggests that despite loss of CHIP-mediated LKB1 ubiquitination 
and/or changes in T247M CHIP-AMPK binding dynamics, the functional interaction at the level 
of AMPKα phosphorylation under stress remains intact.  
We observed in shCHIP HEK293 cells that re-introduction of T247M CHIP could rescue 
loss of cell proliferation/viability caused by oxidative stress (Fig. 4.11D). To confirm that like 
WT CHIP, endogenous T247M CHIP protects cells from oxidative stress we exposed WT, 
T247M CHIP and CHIP knockout (CHIP-/-) primary MEFs to 0 or 500 µM H2O2 and utilized the 
iCelligence impedence-based cell monitoring system to measure the change in cell index 
recorded as a measure of cell proliferation/viability over time before and after H2O2 or vehicle 
exposure. Primary MEFs lacking CHIP (CHIP-/-) had a dramatic reduction in the change in cell 
index during H2O2 exposure, indicating a loss of cell proliferation/viability in response to 
oxidative stress. However, this loss of proliferation/viability was not observed in MEFs 
expressing either WT or T247M CHIP, suggesting that CHIP mediates this protection of 
oxidative stress and, importantly, T247M CHIP is also sufficient to protect primary MEFs from 
oxidative stress (Fig. 4.12D). Taken together, these data suggest that while some aspects of 
AMPK regulation by CHIP are affected by T247M mutation either by loss of its ubiquitin ligase 
activity or changes in its binding dynamics, T247M CHIP is still sufficient to regulate AMPK 
activity and promote cell survival during oxidative stress.  
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Furthermore, T247M mutation is a partial-loss of function mutation that results in an inability of 
the mutant protein to ubiquitinate its substrates, but other functions that are integral to CHIP’s 
role in the cellular stress response that may not be dependent on CHIP ubiquitin ligase activity 
remain intact. 
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Figure 4.12. T247M interacts with AMPK in cells, protecting them from oxidative stress and 
promotes phosphorylation of AMPK during acute oxidative stress. 
A. Co-immunoprecipitation of CHIP and AMPKα1. Purified whole cell lysates from WT and 
T247M CHIP P2 primary MEFs were immunoprecipitated (IP) with CHIP or AMPKα antibody. 
The inputs and resulting precipitants (IP) were separated by SDS-PAGE and immunoblotted (IB) 
with the indicated antibodies. IgG indicates control immunoprecipitation of cell lysates utilizing 
rabbit or goat IgG. 
B. Immunoblot of purified whole cell lysates from WT and T247M primary MEFs following 10 
min exposure to 0, 200 or 400 µM H2O2 to induce acute oxidative stress. Lysates were separated 
by SDS-PAGE and immunoblotted (IB) with the indicated antibodies. 
C. Quantitation of phosphorylated AMPKα relative to total AMPKα as shown in representative 
immunoblot in Fig. 4.12B. 
D. Delta cell index recorded by iCelligence impedence-based cell monitoring system as a 
measure of cell proliferation/viability in WT, T247M CHIP and CHIP knockout (CHIP-/-) P2 
primary MEFs in the presence of 0 µM or 500 µM H2O2. Delta cell index (Delta CI) was 
calculated as the change in cell index before and after exposure to 0 µM or 500 µM peroxide for 
24 hours.  
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T247M protein is significantly reduced while mRNA remains unchanged in mouse tissues. 
T247M protein levels are significantly reduced relative to WT CHIP in T247M CHIP primary 
MEFs (Fig. 4.5A), while T247M CHIP mRNA levels are unchanged (Fig. 4.5B). Additionally, 
patient fibroblasts from SCAR-16 patients with other CHIP mutations also have significantly 
reduced CHIP protein expression184. However, the expression of SCAR-16 related mutant CHIP 
in animal tissue was unknown. To test this, we isolated protein and mRNA from brains, testes, 
livers and hearts of T247M CHIP male mice and their wildtype littermates. Tissue homogenates 
were separated by SDS-PAGE and immunoblotted for CHIP and β-tubulin. Confirming what we 
observed in primary MEFs, in all 4 tissue types, T247M CHIP protein expression was 
dramatically reduced relative to WT CHIP (Fig. 4.13A). Reduced protein expression may be the 
direct result regulation at the transcriptional level. Therefore, we also isolated mRNA from the 
same tissues and performed quantitative real-time polymerase chain reaction (qRT-PCR) to 
evaluate STUB1 (CHIP) mRNA levels. Despite the dramatic difference in protein expression, we 
measured no significant difference in WT vs. T247M CHIP mRNA levels across all 4 tissues 
(Fig. 4.13B). Together these data suggest that T247M CHIP protein expression is differentially 
regulated when compared to WT CHIP, but that this regulation does not occur at the mRNA 
level. Our primary MEF data showing enhanced T247M turnover, that is at least in part 
dependent on proteasomal degradation (Fig 4.6) provides one possible mechanism underlying 
this observed difference in CHIP protein levels. Additionally, cellular mechanisms for clearing 
large insoluble aggregates such as autophagy may also be involved. However, it is important to 
note that while levels of soluble T247M CHIP are dramatically reduced relative to WT CHIP, 
T247M CHIP mutation does not phenocopy total loss of CHIP.  
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Instead, the remaining T247M CHIP is sufficient to maintain many of CHIP’s normal functions 
such that T247M CHIP likely results in only a partial-loss of function mutation but changes in 
protein binding dynamics may also, in some contexts cause T247M CHIP to behave as a 
dominant negative.  
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Figure 4.13. T247M protein is significantly reduced while mRNA remains unchanged in mouse 
tissues. 
A. Immunoblottting for CHIP and β-tubulin in WT and T247M male mouse brain (B), testes (T), 
liver (L) and heart (H) tissue homogenates. T247M tissue homogenates were evaluated loading 
both 10 µg and 50 µg of total protein to allow for visualization of T247M CHIP. 
B. Relative quantitation of total STUB1 mRNA isolated from WT and T247M male mouse brain 
(B), testes (T), liver (L) and heart (H) tissue. 
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T247M homozygous mutant mice exhibit dysregulation of inhibitory processes governing 
activity, exploration, and sensorimotor gating, and to impaired learning and memory. We 
reported previously that both siblings homozygous for the CHIP T246M substitution have 
profound cerebellar ataxia as well as selective cognitive impairments. Additional reports of 
CHIP mutation in other cases of SCAR16 feature cerebellar dysfunction (ataxia) with an 
additional range of clinical features associated with disease, including a heterogeneity of 
additional neurological deficits.90 The profound cerebellar ataxia exhibited in SCAR16 suggests 
that CHIP plays a critical role in maintaining cerebellar function. And in fact when we examined 
our CHIP-/- mouse line in a battery of cognitive assessments, we observed that total loss of CHIP 
expression has a selective impact in motoric, sensory, and cognitive function, in particular with 
tasks attributed to cerebellar function (Figs. 3.5 and 3.6). However, the results of our biophysical 
and cell based models suggest that T246M mutation is not functionally equivalent to total loss of 
CHIP, thus in order to determine the pathophysiological implications of T246M mutation in vivo 
we generated a mouse model (T247M) that mimics the human mutation. We first wanted to 
assess the neurological behavior of the T247M CHIP mice to determine if this mutation found in 
human SCAR16 patients leads to neurological impairments associated with SCAR16. Given the 
autosomal recessive nature of CHIP deficiency in SCAR16, we examined both T247M 
homozygous and heterozygous mice as well as their wildtype littermates in a battery of 
neurological assessments.  
The rotarod test is extensively used in mouse models to detect cerebellar dysfunction by 
testing motor coordination and motor learning on a rotating dowel. The performance of CHIP-/- 
mice on the rotarod demonstrated a severe motoric impairment, and we hypothesized that given 
the severe ataxia associated with cerebellar dysfunction in SCAR16 patients we would observe 
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similar deficits in the homozygous T247M mice. However, neither the heterozygous nor 
homozygous T247M mice exhibited any significant deficits in motor coordination on an 
accelerating rotarod when tested in 4 different trials at 9-10, 22, 27-28 and 31 weeks of age (Fig. 
4.14). While these results are surprising, we predict that this may be a strain dependent effect as 
strain differences have been reported with the rotarod test in other studies of mouse models of 
neurdegeneration185, and when comparing the wildtype animals tested previously against our 
CHIP-/- mice (C57/Bl6 x 129SVEV) vs. the wildtype tested here (C57/Bl6) the latency to fall 
from the accelerating rotarod of the C57/Bl6 WT mice is more than 4X longer than the C57/Bl6 
x 129SVEV WT animals (Fig 3.5A and 4.14). This suggests that the C57/Bl6 mouse strain may 
be particularly well-adapted to this task, such that to observe a degenerative deficit may require 
further advanced aging of the mice. This hypothesis is further supported by the variable age of 
onset of motor deficits reported previously in additional mouse models of cerebellar degenerative 
disorders.186  
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Figure 4.14. Latency to fall from an accelerating rotarod. Maximum trial length was 300 sec. 
Trials 4 and 5 were given 48 hours after the first 3 trials, when mice were 9-10 weeks (Wk) in 
age. 
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Next, to assess auditory function, reactivity to environmental stimuli, and sensorimotor 
gating the mice were examined in the acoustic startle and prepulse inhibition test. CHIP-/- mice 
had previously demonstrated significantly reduced magnitude of the startle response as well as a 
delayed reaction time with no change in prepulse inhibition when evaluated at 25 weeks of age 
(Fig. 3.5C, D). However, no effects of T247M genotype were observed for acoustic startle 
amplitudes at either age of testing, 11-13 weeks or 33 weeks (Fig. 4.15A and 4.15B). Similarly, 
the three genotypes demonstrated comparable levels of prepulse inhibition in the first test (Fig. 
4.15C). Interestingly, in the second test, the T247M mutant mice exhibited significant decreases 
in percent inhibition across every prepulse sound level, indicating the emergence of sensorimotor 
deficits by age 33 weeks [main effect of genotype, F(2,41)=9.62, p=0.0004, genotype x decibel 
interaction, F(8,164)=2.08, p=0.0406] (Fig. 4.15D). These degenerative deficits in prepulse 
inhibition are consistent with other mouse models of cerebellar degeneration with profound 
Purkinje cell loss.187 
 In addition to this deficit in prepulse inhibition attributed to cerebellar dysfunction, the 
mutant mice demonstrated both hyperactivity and increased impulsivity in an open field test. As 
shown in Table 4.1, highly significant effects of genotype were found for distance traveled, 
rearing, and center time at both ages tested (Fig. 4.16). In the first test at age 8-9 weeks, the 
CHIP mutant mice had increased levels of locomotor activity in comparison to WT and HET 
mice at most intervals in the 1-hr session (Fig. 4.16A). By the second test, the mutant mice were 
overtly hyperactive across the entire test (Fig. 4.16B). In fact, data from one female mutant 
mouse was removed from the analysis, because of extreme activity levels (i.e. distance 
traveled=7,230 cm at the 50 min interval). A different pattern emerged for rearing movements, a 
measure of vertical activity. At both 8-9 weeks and 32 weeks, the mutant mice had significantly 
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reduced levels of rearing at the beginning of each session (Fig. 4.16C, D), indicating a deficit in 
the initial exploration of the open field. In the second open field test, higher levels of rearing 
emerged in the mutant group in the last half of the session, in line with a hyperactive phenotype 
(Fig. 4.16D). In both open field tests, the disruption of CHIP led to increased time spent in the 
center region, suggesting a reduction in typical cautionary avoidance of the open area (Figure 
4.16E, F). Together these data suggest T247M CHIP expression led to more impulsive and risky 
exploration, as observed in mouse models for mania and impulsivity188, 189 and overt 
hyperactivity. Interestingly, both impulsivity and hyperactivity have been attributed to cognitive 
cerebellar dysfunction in humans190-192. Surprisingly, when we then evaluated the T247M CHIP 
mutant mice in the elevated plus maze (EPM) test for anxiety-like behavior, no significant 
effects of genotype were observed. We hypothesize that this may be because the mice were only 
evaluated in the EPM at 7-8 weeks at which point overt cognitive cerebellar decline may not 
have yet occurred and significant differences in anxiety-like behavior would be observable 
(Table 4.2). 
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Figure 4.15. Magnitude of startle responses and prepulse inhibition in an acoustic startle test. 
Trials included no stimulus (NoS) trials and acoustic startle stimulus (AS) alone trials. 
 
A.-B. Magnitude of startle response of WT, T247M HET and T247M homozygous mutant mice 
at 11-13 weeks (A) and 33 weeks (B). 
 
C.-D. Prepulse inhibition of WT, T247M HET and T247M homozygous mutant mice at 11-13 
weeks (C) and 33 weeks (D). 
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Table 4.1. Statistical analysis of open field data. F values, degrees of freedom, and p values 
from a repeated measures ANOVA, with the factors genotype and time (5-min intervals across a 
1 hour test). In the second test, data from one female mutant mouse was removed from analysis, 
due to extreme levels of hyperactivity.  
_____________________________________________________________________________ 
 
Measure and Age at Testing            Main Effect of Genotype     Genotype x Age Interaction 
________________________________________________________________________________ 
Distance traveled 
  8-9 weeks     F(2,45)=7.41, p=0.0017          F(22,495)=2.00, p=0.0047 
  32 weeks     F(2,40)=25.96, p<0.0001 F(22,440)=1.05, p=0.3971 
Rearing movements 
  8-9 weeks     F(2,45)=0.09, p=0.9160         F(22,495)=3.38, p<0.0001 
  32 weeks     F(2,40)=0.82, p=0.4495          F(22,440)=3.12, p<0.0001 
Time spent in center region 
  8-9 weeks     F(2,45)=3.37, p=0.0434         F(22,495)=4.00, p<0.0001 
  32 weeks     F(2,40)=19.21, p<0.0001 F(22,440)=2.60, p=0.0001 
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Figure 4.16. Distance traveled, rearing movements and time in spent in the center in two open 
field tests at ages 8-9 weeks and 32 weeks.  *p<0.05, comparison to WT, **p<0.05, comparison 
to both WT and HET. 
 
A.-B. Distance traveled in open field test of WT, T247M HET and T247M homozygous mutant 
mice at 8-9 weeks (A) and 32 weeks (B). 
 
C.-D. Number of rearing movements (vertical activity) in open field test of WT, T247M HET 
and T247M homozygous mutant mice at 8-9 weeks (C) and 32 weeks (D). 
 
E.-F. Time spent in the center in open field test of WT, T247M HET and T247M homozygous 
mutant mice at 8-9 weeks (E) and 32 weeks (F). 
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Table 4.2. Performance of WT, HET and T247M CHIP mutant mice in an elevated plus maze 
test for anxiety-like behavior, a marble-burying assay for exploratory digging, and a buried food 
test for olfactory function.  
______________________________________________________________________________ 
 
                 WT       HET           Mutant 
______________________________________________________________________________ 
 
Elevated plus maze 
   Percent open arm time  32 ± 3     30 ± 4   36 ± 4     
   Percent open arm entries  39 ± 2     41 ± 2      42 ± 3   
   Total number of entries  28 ± 2     27 ± 2   28 ± 3   
 
Number of marbles buried in 30 min 
   First test (age 12 weeks)  16 ± 0.6  18 ± 0.4  11 ± 1.7** 
   Second test (age 32 weeks)  17 ± 0.4  16 ± 0.7  13 ± 1.3** 
 
Olfactory test 
   Latency to find food (sec)  267 ± 74  189 ± 52   289 ± 95 
   Percent of group finding food      80%       95%        89% 
__________________________________________________________________________________ 
**p<0.05, comparison to both WT and HET. 
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In addition to the deficits attributed to cerebellar dysfunction, the T247M also 
demonstrated highly significant impairment in both contextual and cue-dependent learning in the 
conditioned fear procedure, perhaps suggesting hippocampal dysfunction, resulting in 
impairment of learning and memory as a result of T247M CHIP mutation. On Day 1, the training 
day, all of the genotype groups had similar, very low levels of freezing before any exposure to 
the aversive foot shock (Fig. 4.17A). In contrast, during the test for context learning on Day 2, 
the mutant mice exhibited significantly less freezing than either the WT or HET mice at every 
time point [main effect of genotype, F(2,45)=18.46, p<0.0001; genotype x time interaction, 
F(10,225)=3.3, p=0.0005] (Fig. 4.17A). These learning deficits were still evident in the mutant 
group 2 weeks later, during the second test [main effect of genotype, F(2,45)=12.17, p<0.0001] 
(Fig. 4.17B). Strong genotype effects were also observed for cue-dependent learning (Fig. 4.17C, 
D). For both tests, the mutant mice failed to demonstrate a sharp increase in freezing typically 
observed with the onset of the auditory cue [Test 1, main effect of genotype, F(2,45)=4.4, 
p=0.018; genotype x time interaction, F(8,180)=3.48, p=0.0009; and Test 2, main effect of 
genotype, F(2,45)=11.75, p<0.0001; genotype x time interaction, F(8,180)=2.78, p=0.0063]. This 
lack of response could not be attributed to hearing impairment, since the mutant mice had normal 
performance in the acoustic startle test. Together these data suggest significant impairment in 
learning and memory as a result of homozygous T247M CHIP expression. 
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Figure 4.17. Context-dependent and Cue-dependent conditioned fear testing in WT, HET and 
T247M CHIP mutant mice at age 14-18 weeks. **p<0.05, comparison to both other groups. 
 
 
A. Context-dependent learning, Test 1. Baseline levels of freezing behavior before shock 
exposure were determined on Day 1 (the training day). Contextual learning was evaluated 
across 5 min on Day 2 of testing. 
B. Context-dependent learning, Test 2. Test for retention of contextual learning was conducted 2 
weeks following the first test.  
C. Cue-dependent learning, Test 1. An 80 decibel acoustic stimulus (Cue) was presented 2 min 
after mice were placed in the conditioned fear chambers.  
D. Cue-dependent learning, Test 2. Test 2 was conducted 2 weeks after Test 1.  
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Additional testing in the 3-chamber choice test found altered social behavior as a result of 
T247M CHIP expression, such that T247M mutant mice had increased preference for social 
novelty (Fig. 4.18). During the social novelty phase of testing the T247M mutant mice had a 
shift in preference towards the newly-introduced stranger 2 [within-genotype repeated measures 
ANOVAs, following overall significant effect of side, F(1,44)=8.08, p=0.0068] (Fig. 4.18B) and 
the mutant mice made significantly more entries than either the WT or HET mice into the side 
containing stranger 2 [genotype x side interaction, F(2,44)=4.92, p=0.0118, effect of side, 
F(1,44)=11.05, p=0.0018] (Fig. 4.18D).  
Further behavioral testing revealed the T247M mutant mice also had reduced marble 
burying, indicating a decrease in exploratory digging (Table 4.2). However, no effects of 
genotype were observed for olfactory ability in a buried food test (Table 4.2). Overall, the CHIP 
mutation did not lead to overt signs of poor health; however, both the male and female mutant 
mice had significantly lower body weights than the WT and HET groups at almost every time 
point during the behavioral study (Fig. 4.19). Overall, the results of the battery of behavioral 
assessments performed suggest that homozygous T247M CHIP mutation leads to the 
dysregulation of inhibitory processes governing activity, exploration, and sensorimotor gating, 
and to impaired learning and memory in tests for conditioned fear. Interestingly, impaired 
conditioned fear and decreased marble-burying have also been reported in mice with deletion of 
maternal E3 ubiquitin ligase Ube3a, a model for Angelman syndrome193.  Surprisingly, testing at 
ages up to 31 weeks did not reveal significant motor impairment indicative of cerebellar ataxia as 
a result of T247M mutation; however, other behavioral deficits attributable to cognitive 
cerebellar dysfunction were observed as well as deficits in learning and memory attributable to 
hippocampal dysfunction that are reflective of cognitive deficits sometimes observed in SCAR16 
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patients. Interestingly, we have observed some behavioral deficits that overlap with those 
observed in our mouse model of total loss of CHIP; however, the majority were unique to 
T247M mutation, supporting our cell-based data suggesting T247M mutation and total loss of 
CHIP are not equivalent. Additional efforts to compare these mouse strains on the same genetic 
background are on-going to better enable this comparison. Furthermore, it is notable that the 
deficits observed occur largely in the homozygous mutation setting as would be predicted based 
upon the recessive inheritance pattern of SCAR16.  
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Figure 4.18. Social approach in a 3-chamber choice test of WT, HET and T247M mutant mice at 
10-13 weeks of age. * p < 0.05, within-genotype comparison between stranger 1 side and 
opposite side. ## p < 0.05, comparison to same measure in both other genotypes. 
 
A.-C. 3-chamber choice test of sociability of WT, HET and T247M mutant mice at 10-13 weeks 
of age. Time spent with stranger 1 (A) and number of entries into side containing stranger 1 (C). 
 
B.-D. 3-chamber choice test of social novelty of WT, HET and T247M mutant mice at 10-13 
weeks of age. Time spent with already-investigated stranger 1 vs. novel stranger 2 (B) and 
number of entries into side containing already-investigated stranger 1 vs. novel stranger 2 (D). 
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Figure 4.19. Body weights across the behavioral study. Data are missing from one male mutant 
mouse for the first weight measure. *p<0.05, comparison to WT. **p<0.05, comparison to both 
WT and HET. 
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Discussion 
Our biophysical, cellular and in vivo characterization of T246M mutation in SCAR16 
both in vitro and in vivo has allowed us a unique opportunity to begin to delineate the 
contribution of co-chaperone, ubiquitin ligase activity and other emerging CHIP activities to 
specific deficits observed in vitro and in vivo in a disease-relevant context. Initially we had 
hypothesized that the functional loss of CHIP ubiquitin ligase activity as a result of T246M 
mutation was the result of catalytic inactivation of the U-box domain. However, our structural 
and biophysical data suggest that T246M mutation leads to dramatic destabilization and 
misfolding of the CHIP U-box that results in a loss of CHIP’s ability to form dimers and 
promotes the formation of large, multimeric CHIP aggregates both in vitro and in cells. 
Furthermore, when T246M is expressed endogenously across multiple tissues and cell types the 
amount of total soluble protein is dramatically reduced. Additionally, the rate of turnover of 
T246M is greatly enhanced relative to WT CHIP protein, suggesting that the destabilization of 
the U-box promotes the clearance of this structurally misfolded mutant CHIP, likely in an effort 
by the cell to reduce the accumulation of insoluble toxic aggregates, in part through a 
proteasome-dependent mechanism. Importantly when expressed with WT CHIP, T246M CHIP 
does not disrupt WT CHIP dimerization status or localization and conversely the presence of WT 
CHIP does not rescue the misfolding/structural disorganization of T246M CHIP. This data 
supports the recessive inheritance pattern of SCAR16 and may explain why the heterozygous 
T246M mutant carriers do not have any disease phenotype.  
Interestingly, a small population of soluble, partially-functional endogenous T246M 
CHIP protein remains. It is particularly fascinating to us that T246M CHIP’s E3 ubiquitin ligase 
activity towards a variety of substrates is completely abolished but T246M CHIP retains the 
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ability to function in some of CHIP’s critical cellular roles in PQC as a co-chaperone and as an 
autonomous chaperone promoting the phosophorylation and potentiating the activity of AMPK, 
protecting cells from oxidative stress. This is particularly intriguing given the very low levels of 
soluble T246M expressed endogenously. Importantly, while T246M CHIP retains co-chaperone 
activities, binding chaperone proteins and inducing HSF1 nuclear translocation and Hsp70 
expression following stress, both chaperone binding and the induction of Hsp70 are enhanced, 
possibly suggesting abnormal binding kinetics that result from the structural disorganization of 
the CHIP U-box that may alter normal CHIP-mediated regulation of the chaperone-mediated 
stress response. CHIP-/- mice are highly stress intolerant74; therefore, it will be fascinating to 
elucidate whether the abnormal aspects of T246M CHIP co-chaperone activity we have observed 
are functionally deleterious or advantageous in our T247M CHIP mice in in vivo stress models. 
As one might expect due to the multifaceted nature of CHIP activity in cells, our studies suggest 
that the functional consequences of T246M mutation under stress are stress-specific, as we 
observed T246M CHIP protects cells from oxidative stress, but similar to total loss of CHIP, 
T246M mutation does not protect cells from UVC-induced cell death. These data further support 
our conclusion that T246M mutation is not functionally equivalent to total loss of CHIP.  
In order to best understand this distinction when T246M is expressed in a genomic 
context and to evaluate the pathophysiological implications of T246M mutation in vivo, we 
generated a mouse model (T247M) that mimics the human mutation. Surprisingly, testing at ages 
up to 31 weeks did not reveal significant motor impairment indicative of cerebellar ataxia as a 
result of T247M mutation, however other behavioral deficits attributable to cognitive cerebellar 
dysfunction were observed as well as deficits in learning and memory attributable to 
hippocampal dysfunction that are reflective of cognitive deficits reported in SCAR16 patients. 
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These data further support our previous findings from CHIP-/- mice that CHIP plays a critical 
role in cerebellar maintenance. Interestingly, while we have observed some behavioral deficits 
that overlap with those observed in our mouse model of total loss of CHIP, the majority were 
unique to T247M mutation, further validating our cell-based data that suggest T246M mutation 
and total loss of CHIP are not functionally equivalent. We hypothesize that the phenotypic 
differences observed between CHIP-/- mice and T247M mice are likely reflective of our cell-
based and in vitro findings that while T247M CHIP no longer functions as an E3 ubiquitin 
ligase, other CHIP functions remain intact despite this mutation. And in fact, perhaps even more 
intriguingly, T247M mutation may in some cases modify CHIP’s co-chaperone activities in a 
functionally advantageous or, more likely, deleterious manner, similar to a dominant-negative 
mutation. These data further support our previous findings that highlight the role of aberrant 
ubiquitination in the pathogenesis of SCAR16 however suggest that loss of CHIP ubiquitin 
ligase activity alone may not fully explain the molecular mechanisms underlying the diverse 
pathophysiology observed in the heterogeneity of SCAR16 disease. As such, it appears that 
T246M mutation in SCAR16 is best described as a partial loss of function mutation. 
The CHIP mutations that have been associated with SCAR16 are present in all three of 
CHIP’s functional domains, although interestingly the majority are concentrated in the charged 
domain and the U-box domain, supporting disruption of CHIP ubiquitin ligase activity as a likely 
driver of disease. Our data clearly support this role of aberrant ubiquitin ligase function in the 
pathophysiology of SCAR16 but suggest that this is not mechanism whereby CHIP mutation 
drives disease. Given the diversity of reported mutations and the clinical heterogeneity of the 
ARCA patients harboring these STUB1 mutations, we originally hypothesized that the affected 
protein domain may directly correlate to clinical phenotype. For example, cognitive impairment 
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occurs in 5 out of 6 genetic signatures harboring mutations in the U-box domain, such that 
residual CHIP activity involving a defective or truncated U-box domain but intact TPR domain 
could directly correlate to specific clinical symptoms in some patients. Our extensive behavioral 
analysis of the T247M CHIP mouse model provides direct evidence to support this hypothesis, 
demonstrating that particular cognitive deficits are in fact associated in vivo with a U-box 
domain point mutation that has been demonstrated in vitro and in cells to have a partially 
functionally intact TPR domain. The development of additional animal models with isolated 
domain mutations may help to further validate this hypothesis and identify how the 
multifunctional roles of CHIP contribute to particular clinical pathologies. It seems clear, 
however, that while disordered ubiquitination contributes to SCAR16 pathology, CHIP mutation 
as a driver of disease is not limited to loss of ubiquitin ligase activity but may represent a more 
multi-faceted disruption of CHIP-mediated PQC.  
To date, we have only begun to fully evaluate the in vivo consequences of T247M 
mutation. The results of our behavioral assessment of these mice are fascinating and raise many 
questions about the underlying pathological, cellular and biochemical changes that are occurring 
to drive this phenotype. At a cellular level, future studies will aim to elucidate this by evaluating 
changes in cell signaling pathways that result from T247M mutation in vivo. Additionally, 
having observed significant cerebellar deficits we are interested in evaluating the health of the 
cerebellum in T247M mice, particularly to evaluate its structure and identify signs of atrophy, 
quantitate and evaluate localization of CHIP expression, identify the presence of aggregates 
indicative of proteotoxicity and evaluate Purkinje cell pathology. It will be particularly 
fascinating to compare these data to our previous data evaluating many of these parameters in 
vivo in the context of total loss of CHIP.  
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Within the spectrum of disease phenotypes represented by SCAR16, patients with GHS 
represent a unique group where cerebellar ataxia characteristic of SCAR16 is paired with 
neuroendocrine deficits and resulting reproductive impairments associated with hypogonadism. 
We previously observed CHIP-/- mice recapitulate many of the reproductive impairments 
characteristic of GHS. While developing the T247M mouse model and establishing the mouse 
colony we have observed impaired breeding of T247M homozygous mice. Additionally, 
preliminary hormonal studies of male T247M mice suggest abnormal circulating hormone levels 
and an impairment of the pituitary’s ability to respond to stimulation with gonadotropin releasing 
hormone, similar to that observed in hypogonadism associated with GHS (data not shown). 
Future studies will seek to characterize the neuroendocrine deficits and reproductive impairments 
associated with T247M. Both by comparison to the CHIP-/- animals as well as to additional 
SCAR16 point mutant mice we may be able to delineate the contribution of particular CHIP 
functions to this unique disease phenotype. 
These studies represent the first in vivo characterization a CHIP mutation relevant to 
human disease. Loss of CHIP function has long been associated with protein misfolding and 
aggregation in several genetic mouse models of neurodegenerative disorders; however, a role for 
CHIP in human neurological disease had never been identified. In light of the identification of 
T246M CHIP mutation and subsequent designation of SCAR16, the establishment of the T247M 
mouse model of SCAR16 represents a novel and important tool to finally evaluate CHIP 
dysfunction in vivo in a disease-relevant context. Our biophysical, cellular and in vivo 
characterization of T246M mutation in SCAR16 has provided significant insight into both the 
molecular mechanisms driving disease pathology in SCAR16 as well as basic CHIP biology, by 
shedding new light on the structure-function relationship, particularly how it contributes to the 
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multifaceted activities of CHIP within the cell. Furthermore, we are hopeful these studies have 
provided valuable insight required for the future development of effective therapies for this 
devastating degenerative disease.  
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Experimental Procedures 
Expression plasmids and recombinant proteins. Mammalian expression plasmids pcDNA3-myc-
CHIP, pcDNA3-myc-CHIP-K30A, pcDNA3-myc-CHIP-H260Q, HA-Ubiquitin, FLAG-SIRT6, 
FLAG-HSP70, β-galactosidase, GFP and cBSA were used as described previously 75, 87, 128, 135, 
177. CHIP, CHIP-H260Q, CHIP-K30A, CHIP-T246M and AMPK recombinant proteins were 
produced in Escherichia coli BL21(DE3) as His-tagged fusion proteins by induction with 0.1mM 
isopropyl-1-thio-β-D-galactopyranoside overnight at 18°C followed by purification with 
HisTrap™ HP columns (GE Healthcare), concentrated, and stored in in 20 mM HEPES pH 7.4 
with 150 mM NaCl.  
Mutagenesis. A point mutation of threonine to methionine at position 246 of CHIP was created 
for generation of single T246M point mutant and K30A-T246M double point mutant by site-
directed mutagenesis using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, 
E0554S) according to manufacturer’s instructions using previously described pcDNA3-myc-
CHIP template or pcDNA3-myc-K30A CHIP template128 and mutagenic primers 5’-
CCGTGCATCATGCCCAGTGGC-3’ and 5’-CTCCCGCATCAGCTCAAAGC-3’ 
(BaseChanger software, New England Biolabs). The myc-CHIP-T246M and myc-CHIP-K30A-
T246M expression plasmids were produced by transformation in Escherichia coli DH5α, 
purified, and the single-base pair substitution was verified by DNA sequencing.  
In vitro ubiquitination reactions. In vitro ubiquitination reactions were carried out as previously 
described 128. Briefly, bacterially-expressed 4uM LKB1 (Sigma, SRP0246), 1uM α-synuclein 
(ab123758) or 1 µM SIRT6 (Sigma, SRP0120) was incubated in the presence of 2.5 μM CHIP or 
CHIP mutants, 50 nM purified Ube1 (Boston Biochem, E305), 2.5 μM purified UbcH5c 
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(BostonBiochem, E2-627) and 0.25 μM ubiquitin (BostonBiochem, U100H) in 50 mM Tris pH 
7.5, 600 μM DTT, 2.5 mM MgCl2-ATP (BostonBiochem, B20) in a total volume of 10 μl for 1 h 
at 37°C. Samples were analyzed by 4-12% Bis-Tris SDS-PAGE and immunoblotting was 
performed with either anti-LKB1 (Santa Cruz, SC32245), anti-SIRT6 (Abcam, Ab62739) or 
anti-α-synuclein (Abcam, ab138501) antibodies. 
Dynamic Light Scattering. The solution molecular weights of WT CHIP, K30A, H260Q and 
T246M point mutant CHIP were determined using size exclusion chromatography followed by 
multi-angle light scattering (SEC-MALS). The SEC-MALS system consisted of a GE Superdex 
200 column connected to Wyatt DAWN HELEOS-II multi-angle light scattering instrument and 
a Wyatt T-Rex refractometer (Wyatt Technology, Santa Barbara, CA, USA). 100 µl of 0.5 
mg/ml of each sample was loaded onto the column, and the light scattering and refractive index 
data were collected as the eluted samples passed through light scattering system. The molar 
masses of the samples eluting in various peaks were calculated from these data using ASTRA 6 
software (Wyatt Technology). 
Nuclear Magnetic Resonance Spectroscopy. Human WT and T246M U-box (amino acid residues 
212-303) recombinant proteins were purified as previously described for WT CHIP U-box.194 
NMR spectra were recorded at 600 MHz (1H) and 20°C in buffer containing 20 mM HEPES (pH 
7.5), 50 mM NaCl, and 1 mM DTT as previously described194. NMR data were processed with 
NMRPipe195 and analyzed with SPARKY.196  
Circular Dichroism Spectroscopy. CD spectra of WT and T246M U-box CHIP were collected as 
previously described197 at 0.25 mg/mL and 15°C in 10 mM sodium phosphate pH 7.0 with 20 
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mM NaCl and 1 mM DTT. Tm for WT and T246M U-box CHIP was additionally determined by 
CD at 222 nm.  
T247M mouse generation and off-target site mutation anaylsis. Guide RNA Cloning. Guide 
RNA protospacer (target) sequences were cloned into a T7 promoter vector in context with guide 
RNA structural elements, allowing T7-mediated in vitro transcription to produce the full guide 
RNA molecule. A guanine was added to the 5’ end of protospacer sequences that do not have a 
native 5’ guanine to allow T7 in vitro transcriptional initiation, which requires a 5’ guanine 
residue. T7 ligation mixtures were transformed into Stellar competent cells. Miniprep DNA was 
sequence-verified. 
Guide RNA In Vitro Transcription. Guide RNA plasmids were linearized by digestion with DraI, 
which cleaves at the end of the guide RNA sequence. Linearized material was purified by silica 
column (Qiaquick) and used as template for T7 in vitro transcription using the NEB HiScribe T7 
kit. Reactions included 1000 ng linear guide RNA plasmid in a standard reaction recommended 
by the kit provider. Reactions were incubated at 37°C overnight followed by addition of DNAse 
I and 30 min additional incubation at 37°C to remove plasmid DNA. Guide RNAs were then 
purified using Qiagen RNEasy mini kit, eluted in 30 µl RNAse-free microinjection buffer (5 mM 
Tris-Cl pH7.5, 0.1 mM EDTA) and quantitated on a Nanodrop spectrophotometer. 
Guide RNA Activity Test. The Cas9/guide RNA target region was PCR amplified from wild-type 
C57BL/6 DNA using primers Stub1-ScF1 (5’-GGAGACAGGAGTTGCCCACACA-3’) and 
Stub1-ScR1 (5’- CAGTTCAGAACCCATCAGCAGG-3’). PCR product was purified on a silica 
minicolumn and eluted in 10 mM Tris-Cl pH8.5. 
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In Vitro Cleavage Assay. Guide RNAs were tested for activity in an in vitro cleavage assay, 
which included 1x NEB restriction buffer 3, 1 mg/ml BSA, 30 µg/ml Cas9 protein, 300 ng target 
DNA and 600 ng guide RNA in a 20 µl reaction volume. A control reaction was performed in 
parallel with all components except guide RNA. Reactions were incubated at 37°C 1 hr, 80°C 10 
min, then 4°C until gel analysis. Reaction mixes were separated on 2% Agarose TAE gels with 
ethidium bromide and imaged using a standard ethidium bromide gel imaging system. Guide 
RNA Stub1-g82T (GAACCCTGCATTACACCCAGTGG, protospacer associated motif NGG 
underlined) produced nearly 100% target site cleavage and was selected for embryo 
microinjection to produce Stub1-T247M knock-in animals.  
Mouse production. Genome editing was performed using CRISPR/Cas technology with the 
modification of mouse sequence NM_019719 at positions #740 and #741: ACAATG, 
resulting in change of Threonine247 to Methionine. Founder animals were produced by 
microinjection of C57BL/6J embryos with a mixture of 100 ng/ul Cas9 mRNA, 50 ng/ul Stub1 
guide RNA g82T and 100 ng/ul donor oligonucleotide Stub1-T247M-T (5’-
TGACTACTTGTGTGGCAAGATTAGCTTTGAGCTGATGCGGGAACCCTGCATTATGCC
CAGTGGTATCACCTATGACCGCAAGGACATTGAGGAGCACCTGCAGGTAAG-3’) in 5 
mM Tris pH7.5, 0.1 mM EDTA. Injected embryos were surgically implanted in CD-1 
pseudopregnant recipients and resulting pups were genotyped by PCR amplification of the Stub1 
T246 region followed by Sanger sequencing. Animals harboring the Stub1 T246M codon change 
were identified by deconvolution of sequence traces. Founder animals were mated to wild-type 
C57BL/6J animals and F1 animals harboring the T246M mutation were intercrossed to generate 
homozygous animals. 
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Off-target analysis. For off-target analysis, guide RNAs were checked for predicted off-target 
sites using the web server crispr.mit.edu. The top 10 predicted off-target sites were PCR 
amplified from the founder biopsy DNA and PCR products were sequenced to detect the 
presence of mutations at each off-target site. Mutations were detected based on the presence of 
multiple peaks in the sequence traces. 
Cell culture and transfection. CHIP+/+, CHIP−/− and T247M CHIP mouse embryonic fibroblasts 
(MEFs) were cultured as previously described74. COS-7 and shCTRL and shCHIP HEK293 cells 
were maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% 
fetal bovine serum (Sigma) at 37°C in an atmosphere of 5% CO2. Cell transfections were 
performed using X-tremeGENE 9 (Roche) with the indicated plasmid DNA at a 1:3 DNA to X-
tremeGENE 9 ratio. 
iCelligence Population Doubling/Cell Proliferation/Viability. For determination of primary MEF 
growth rates, cells were plated on iCelligence E-Plates L8. Cell attachment, spreading, and 
proliferation were continuously monitored every 30 min for 72 hours using the iCELLigence 
System (Acea Biosciences). The electronic readout of cell-sensor impedance is displayed 
continuously in real time as the Cell Index (CI). The CI value at each time point is defined as Rn-
Rb/Rb, where Rn is the cell-electrode impedance of the well with the cells, and Rb is the 
background impedance of the well with media alone. Population doubling was determined from 
the exponential phase of the growth curve and calculated using the iCELLigence RTCA software 
(Roche Applied Science) according to manufacturer’s protocol. For determination of cell 
proliferation/viability of HEK293 cells in the presence of 200 µM H2O2 HEK293 cells stably 
depleted of CHIP or shCTRL were used as previously described.87 Cells were plated in E-plates 
L8 at 40,000 cells/well and CI continuously monitored for the duration of the experiment. 24 
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hours later WT or T246M CHIP was reintroduced by transient transfection as described above. 
Cells were then exposed to 0 µM or 200 µM H2O2 for 24 hours beginning at 24 hours post-
transfection. Delta cell index (Delta CI) was calculated as the change in cell index before and 
after exposure to 0 µM or 200 µM peroxide utilizing iCELLigence RTCA software as per 
manufacturer’s instructions. For determination of cell proliferation/viability of WT, T247M and 
CHIP-/- primary MEFs in the presence of 500 µM H2O2 cells were plated in E-plates L8 at 
30,000 cells/well and CI continuously monitored for the duration of the experiment. 24 hours 
post-plating, cells were exposed to 0 µM or 500 µM H2O2 for 24 h. Delta cell index (Delta CI) 
was calculated as the change in cell index before and after exposure to 0 µM or 500 µM peroxide 
utilizing iCELLigence RTCA software as per manufacturer’s instructions. 
 
mRNA analysis. CHIP mRNA levels in primary MEFs were determined using the SingleShot™ 
SYBR® Green Kit (Biorad, 1725085) and Roche LightCycler 480 with PrimePCR SYBR green 
primer assays targeting the indicated genes (Biorad) listed below. Relative expression values 
were calculated using the ΔCT method correcting for PCR efficiency and mean centered across 
the three genotypes. Expression was normalized to the geometric mean of Actb and Hprt, the two 
most stable reference genes across genotypes as determined via Normfinder198 (also tested 
Gapdh and Tbp). 
Table 4.3. qPCR Primers                
 
Gene  Biorad Assay ID 
Act  qMmuCED0027505 
Gapdh  qMmuCED0027497 
Hprt  qMmuCED0045738 
Stub1  qMmuCED0001075 
Tbp  qMmuCID0040542 
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Protein and mRNA isolation/analysis from mouse tissue. Liver, heart, brain and testes were 
isolated from anesthetized 4 month old WT, HET and T247M male littermates. Tissue was 
stored frozen in RNAlater solution (Ambion) until protein and mRNA were isolated using the 
Ambion PARIS Kit (Ambion, AM1921) as per manufacturer’s instructions. Tissue disruption 
prior to protein/RNA isolation was performed with Ambion PARIS Kit Cell Disruption Buffer 
and Qiagen TissueLyser LT with 5 mm steel beads. Any contaminating DNA was removed from 
RNA prepared by PARIS Kit by treatment with TURBO DNA-free™ Kit (Ambion) and mRNA 
was reverse transcribed using Iscript cDNA synthesis kit (Bio-Rad). Real-time PCR was 
performed using Roche LightCycler 480 and Sso Advanced Universal SYBR Green Supermix 
(Biorad) with PrimePCR SYBR green primer assays targeting the indicated genes (Biorad) listed 
above. Relative expression values were calculated using the ΔCT method correcting for PCR 
efficiency and mean centered across the three genotypes. Expression was normalized to the 
geometric mean of Actb and Gapdh, the two most stable reference genes across genotypes as 
determined via Normfinder198 (also tested Hprt and Tbp). 
Cell lysate collection/nuclear fractionation/isolation of total, soluble and insoluble fractions. For 
all assays unless otherwise noted, cell lysates were prepared by first washing cells in cold PBS 
and lysing in Cell Lytic M (Sigma) containing 1X HALT protease/phosphatase inhibitor (Pierce) 
and 50 µM PR619 (Lifesensors). Lysates were clarified by centrifugation at 15,000 x g for 10 
min at 4°C. Total protein concentration was determined by BCA protein assay (Pierce). 
Alternatively, cells were lysed on ice for 15 m in Triton X-100 cell lysis buffer (50 mM Tris, pH 
7.4, 150 mM NaCl, 1% Triton X-100, 1mM EDTA, protease inhibitor [Complete; Roche], 50 
µM PR-619 (LifeSensors)). Triton X-100 insoluble material was collected by solubilization of 
the insoluble pellet following 15,000 x g centrifugation by resuspension in 2X Laemmeli Sample 
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buffer (Biorad), brief sonication and heating for 5 m at 100°C. Nuclear fractions were prepared 
using the NE-PER kit (Pierce), as per manufacturer’s instructions. Total, soluble and insoluble 
fractions as shown in Fig. 4.6 were prepared by first trypsinizing and counting P2 primary MEFs 
grown on 15-cm tissue-culture treated dishes to near 100% confluency. Cells were then divided 
equally between two tubes, spun at 500 x g, pellet rinsed in PBS and spun again at 500 x g. Cells 
for total protein fraction (tube 1) were then lysed in 2X Laemmeli SDS sample buffer (65mM 
Tris-HCl, 10% Glycerol, 2%SDS), sonicated briefly on ice and boiled at 100°C for 5 m. The cell 
pellet in tube 2 was then lysed for collection of soluble and insoluble fractions. This pellet was 
lysed in Triton X-100 cell lysis buffer as described above and soluble protein collected following 
centrifugation at 15,000 x g for 10 m at 4°C. The Insoluble pellet was then rinsed once in lysis 
buffer and spun again at 15,000 x g for 10 m at 4°C. The pellet was then solubilized in 2X 
Laemmeli SDS sample buffer (65mM Tris-HCl, 10% Glycerol, 2%SDS), sonicated briefly on ice 
and boiled at 100°C for 5 min. Total protein concentrations in each fraction were then 
determined by 660nm Protein Assay (Thermo Scientific) and samples of equal total protein 
prepared for SDS-PAGE by addition of final concentrations of 0.025% bromophenol blue and 
100mM DTT.  
Polyacrylamide gel electrophoresis, Blue native polyacrylamide gel electrophoresis, gel 
immunoblotting, and densitometry. For reduced and denatured conditions, protein samples were 
resolved on NuPAGE Novex® Bis-Tris Gels (Life Technologies) using the MOPS/LDS buffer 
system or Mini-PROTEAN® TGX Precast Gels (Bio-Rad) using the Tris/Glycine/SDS buffer. 
Native protein samples were resolved on 4-16% NativePAGE Novex® Gels (Life Technologies) 
using 0.001% G-250 cathode buffer. Proteins were transferred to PVDF membranes and 
incubated with primary antibodies overnight (see following table for antibody information) and 
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detected with either anti-rabbit or anti-mouse (GE Healthcare), or anti-goat (Sigma) HRP-
conjugated antibodies and visualized with ECL Advance substrate (GE Healthcare) using the 
EC3™ Imaging System (UVP). For quantification of relative protein levels, densitometry 
analysis was performed using LI-COR Image Studio Lite.  
Immunoprecipitation/Co-immunoprecipitation of FLAG-HSP70/CHIP, FLAG-SIRT6/CHIP, HA 
WT-CHIP/MYC T246M-CHIP from COS-7 cells. COS-7 cells were cultured and transiently 
transfected as described above with the indicated transgene vectors. 24 h post-transfection cells 
were treated with 20 μM MG132 or DMSO for 2.5 hours prior to harvest. Cells were washed in 
cold PBS and lysed in Cell Lytic M (Sigma) containing 1X HALT protease/phosphatase 
inhibitor (Pierce) and 50 µM PR619 (Lifesensors). Lysates were clarified by centrifugation at 
15,000 x g for 10 min. Total protein concentration was determined by BCA protein assay 
(Pierce) and 1 mg total protein clarified lysate incubated overnight at 4°C with 20 μg of 
EZview™ Red ANTI-FLAG® M2, EZview™ Red ANTI-MYC® M2 or EZview™ Red ANTI-
HA® M2 (Sigma). The gel was then washed 5 times with Tris-Buffered Saline with 0.5% 
Nonidet P-40; subsequently, proteins were eluted in reducing SDS-sample buffer and analyzed 
by SDS-PAGE and western blotting was performed using anti-FLAG HRP (Sigma, A8592), anti-
HA HRP (Sigma, A6533) and anti-myc HRP (Sigma, A5598) antibodies. 
Immunoprecipitation/Co-immunoprecipitation of UbcH5c/CHIP, AMPKα1/CHIP, Hsc70/CHIP 
from COS-7 cells or Primary MEFs. COS-7 cells were cultured and transiently transfected as 
described above with the indicated transgene vectors. Primary MEFs were cultured as previously 
described and plated in 2 15cm tissue culture dishes and incubated overnight under normal 
growth conditions. 24 h post-transfection (COS-7) or plating (Primary MEFs) cells were treated 
with 20 μM MG132 or DMSO for 2.5 h prior to harvest. Cells were washed 1X in cold PBS and 
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lysed in Cell Lytic M (Sigma) containing 1X HALT protease/phosphatase inhibitor (Pierce) and 
50 μM PR619 (LifeSensors). Lysates were clarified by centrifugation at 15,000 x g for 10 min. 
Total protein concentration was determined by BCA protein assay (Pierce) and 1.5 mg total 
protein clarified lysates were incubated overnight at 4°C with 10 μg anti-UbcH5c (Cell Signaling 
Technologies, 4330S), anti-AMPKα1 (R and D Systems, AF3197), anti-CHIP (Abcam, ab4447), 
anti-Hsc70 (Enzo, ADI-SPA-815), rat IgG, rabbit IgG or goat IgG antibodies. 120 μl Protein-G 
Dynabeads (Invitrogen) were then added to each sample and incubated for 0.5 h at room 
temperature with rotation. Beads were washed four times with Phosphate-Buffered Saline with 
0.05% Tween-20; subsequently, proteins were eluted in SDS-sample buffer and analyzed by 
SDS-PAGE and western blotting using anti-UbcH5c (Cell Signaling Technologies, 4330S), anti-
CHIP (Sigma, S1073), anti-AMPKα1/2 (Cell Signaling Technologies, 2532) or anti-Hsc70 
(Enzo, ADI-SPA 815) antibodies. 
Myc-CHIP and endogenous CHIP Immunofluorescence: CHIP Immunofluorescence was 
performed as previously described199 with the following modifications. Cells were fixed in 4% 
paraformaldehyde for 10 min, then incubated in permeabilization buffer (PBS, 0.5% Triton X-
100, 1% BSA) for 10 min. Primary and secondary antibodies were prepared at dilutions of 1:500 
(CHIP-Sigma HPA043531) or (anti-c-myc, Sigma M4439) and 1:800 (Alexa-Fluor Goat anti-
rabbit or Goat anti-mouse), respectively, in blocking buffer (PBS, 0.05% Triton X-100, 1% 
BSA). Coverslips were mounted using Vectashield Hardset with Dapi (Vector Laboratories). 
Cells were visualized using a Zeiss LSM 710 spectral confocal. 
HSF1 Luciferase Reporter Assay. COS-7 cells were cultured, plated at 5000cells/well in clear-
bottom white 96-well plates (Thermo Scientific, 165306) and transiently transfected as described 
above with the indicated transgene vectors and the Qiagen Cignal Heat Shock Response Reporter 
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(luc) Kit (CCS4023L) as per manufacturer’s instructions. 24 h post-transfection cells were lysed 
and luciferase assays were performed using a Dual-Luciferase® Reporter Assay System 
(Promega, Madison, WI) on a BMG Labtech CLARIOstar dual-injection plate reader following 
the manufacturer’s protocol. Transfection of each construct was performed in triplicate in each 
assay and a total of 3 assays were performed on 3 separate days. Empty vector was transfected in 
each plate in triplicate to be used for normalization purposes. Ratios of Renilla luciferase 
readings to Firefly luciferase readings were taken for each experiment and triplicates were 
averaged. The average values of the tested constructs were normalized to the activity of the 
empty construct. Bars represent the averages of the normalized values with error bars indicating 
the range. 
Cyclohexamide chase. COS-7 cells were co-transfected with the indicated vectors and 24 h post-
transfection treated with 50 µg/ml cyclohexamide for 0, 1 or 2.5 h in the presence or absence of 
20 µM proteasome inhibitor MG132 and lysates collected and separated by SDS-PAGE and 
immunoblotted with antibodies against His-CHIP and β-tubulin as described above. Primary 
MEFs were plated and incubated for 24 h under normal growth conditions. Cells were then 
treated with for 0, 2, 4 or 6 h with 50 µg/ml cyclohexamide and lysates collected and separated 
by SDS-PAGE and immunoblotted with antibodies against CHIP (ab4447) and β-tubulin as 
described above. 
 
Heat Stress and Recovery. Two models of heat stress and recovery were utilized. For measures 
of heat stress/CHIP-induced nuclear translocation of HSF1 in COS-7 cells, cells were heat 
shocked in a water bath for 30 min at 42°C prior to lysate collection and nuclear fractionation as 
previously described.74 For Hsp70 induction and recovery assays in primary T247M and WT 
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MEFs, cells were heat shocked in a water bath for 10 min at 42°C prior to recovery at 37°C 
under normal growth conditions for the indicated times.  
AMPK in vitro activity assay. Recombinant proteins CHIP, CHIP point mutants and AMPKα2 in 
20 mM HEPES pH 7.4 with 150 mM NaCl prepared as described above and as previously 
described 8 were diluted to final concentrations of 730nM (pAMPKα2) or 7 point 5X serial 
dilution curve starting from 2.8 µM in 1X kinase buffer A (50 mM HEPES pH7.5, 1 mM EGTA, 
0.01%Brij-35 and 10mM MgCl2) and pre-incubated together at 30°C for 30 min with gentle 
shaking. Invitrogen Z’-LYTE Kinase Assay Kit-Ser/Thr 23 Peptide was then utilized as per 
manufacturer’s instructions to determine pAMPKα2 enzymatic activity in the presence of CHIP 
with each condition measured in triplicate in 3 independent assays. 
Acute oxidative stress. WT and T247M Primary MEFs were exposed to 0, 200 or 400 µM H2O2 
for 10 min under normal growth conditions as previously described8 and lysates collected and 
separated by SDS-PAGE and immunoblotted with antibodies against pAMPKα1/2 –T172 (Cell 
Signaling Technologies, 4188) and total AMPK(Cell Signaling Technologies, 2532) as described 
above. Relative protein levels of phosphorylated AMPKα-T172 normalized to total AMPK are 
expressed as mean ± SEM from 3 independent experiments. *P < 0.05 via Dunnett’s comparison 
to wild-type 0 µM H2O2 condition. 
UVC Viability Assay. Fresh never frozen primary MEFs (P3) were plated at 5,000 cells/well in 
96-well plates 24 h prior to treatment. Cells were then rinsed once with warm PBS and placed in 
100 µl of warm PBS and placed uncovered under a UV lamp emitting primarily 254 nm 
radiation at a fluency rate 0 or 10J/m2/s as previously described.200 Cells were then placed back 
in normal growth media and allowed to recover for 20 hours under normal growth conditions 
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prior to measuring viability by Promega CellTiter 96® AQueous One Solution Cell Proliferation 
and Viability MTS assay. 
Mouse behavioral assessments.  
Table 4.4. Behavioral testing regimen 
 
 
Age (weeks)  Procedure 
 
   7-8    Elevated plus maze test for anxiety-like behavior   
First wire-hang test for grip strength 
    8-9     First open field test (1 hour) 
   9-10     First and second rotarod tests for motor coordination 
   10-13  Social approach in a 3-chamber choice task  
   11-13 First marble-bury assay and acoustic startle test (index of sensorimotor 
gating) 
   12-14  Buried food test for olfactory ability  
   14-16  Conditioned fear (contextual and cue-dependent learning, first tests) 
   16-18  Retention test for conditioned fear (2 weeks following first test) 
   22 (5 months) Third rotarod test 
   27-28  Fourth rotarod test 
   31    Fifth rotarod test, second wire-hang test 
   32    Second activity test, second marble-bury test 
   33   Second acoustic startle test  
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Table 4.5.  Number of mice in study.  Four mice were taken for histology following the first 
round of testing (before the third rotarod test). 
_____________________________________________________________________________ 
              WT    HET               Mutant 
______________________________________________________________________________ 
 
First behavioral tests 
   Male      7    9   5 
   Female    13   10   4 
 
Follow-up tests 
   Male      6    7   4 
   Female    13   10   4 
______________________________________________________________________________ 
 
Data analysis. For each procedure, measures were taken by an observer blind to mouse genotype 
(CHIP WT, HET, or mutant). Behavioral data were analyzed using one-way or repeated 
measures Analysis of Variance (ANOVA). Fisher's protected least-significant difference (PLSD) 
tests were used for comparing group means only when a significant F value was determined. For 
all comparisons, significance was set at p < 0.05. Data presented in figures and tables are means 
(± SEM). 
 
Wire-hang test for grip strength. Mice were suspended from a cage lid for the maximum trial 
time of 60 sec.  
 
Elevated plus maze for anxiety–like behavior. This procedure is based on a natural tendency 
of mice to actively explore a new environment, versus a fear of being in an open area. Mice were 
given one 5 min trial on the plus maze, which had two walled arms (the closed arms, 20 cm in 
height) and two open arms. The maze was elevated 50 cm from the floor, and the arms were 30 
cm long. Animals were placed on the center section (8 cm x 8 cm), and allowed to freely explore 
the maze. Measures were taken of time on, and number of entries into, the open and closed arms 
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Marble-burying assay. Mice were tested in a Plexiglas cage located in a sound-attenuating 
chamber with ceiling light and fan. The cage contained 5 cm of corncob bedding, with 20 black 
glass marbles (14 mm diameter) arranged in an equidistant 5 x 4 grid on top of the bedding. 
Subjects were given access to the marbles for 30 min. Measures were taken of the number of 
buried marbles (two thirds of the marble covered by the bedding). 
 
Buried food test for olfactory function. Several days before the olfactory test, an unfamiliar 
food (Froot Loops, Kellogg Co., Battle Creek, MI) was placed overnight in the home cages of 
the mice. Observations of consumption were taken to ensure that the novel food was palatable. 
Sixteen to twenty hours before the test, all food was removed from the home cage. On the day of 
the test, each mouse was placed in a large, clean tub cage (46 cm L x 23.5 cm W x 20 cm H), 
containing paper chip bedding (3 cm deep), and allowed to explore for 5 min. The animal was 
removed from the cage, and 1 Froot Loop was buried in the cage bedding. The animal was then 
returned to the cage and given 15 min to locate the buried food. Measures were taken of latency 
to find the food reward. 
 
Open field test. Exploratory activity in a novel environment was assessed by a one-hour trial in 
an open field chamber (41 cm x 41 cm x 30 cm) crossed by a grid of photobeams (VersaMax 
system, AccuScan Instruments). Counts were taken of the number of photobeams broken during 
the trial in 5-min intervals, with separate measures for ambulation (total distance traveled) and 
rearing movements. Time spent in the center region of the open field was measured as an index 
of anxiety-like behavior. Mice were tested at two ages: 8-9 weeks and 32 weeks. 
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Rotarod. Subjects were tested for motor coordination and learning on an accelerating rotarod 
(Ugo Basile, Stoelting Co., Wood Dale, IL). For the first test session, animals were given 3 trials, 
with 45 seconds between each trial. Two additional trials were given 48 hours later. Rpm 
(revolutions per min) was set at an initial value of 3, with a progressive increase to a maximum 
of 30 rpm across 5 min (the maximum trial length). Measures were taken for latency to fall from 
the top of the rotating barrel. Additional tests (2 trials per test) were conducted at 3 other time 
points during the behavioral study.  
 
Sociability in a 3-chamber choice test. Mice were evaluated for the effects of Chip deficiency 
on social preference. The test session consisted of 3 10-min phases: a habituation period, a test 
for sociability, and a test for social novelty preference. For the sociability assay, mice were given 
a choice between being in the proximity of an unfamiliar conspecific (“stranger 1”), versus being 
alone. In the social novelty phase, mice were given a choice between the already-investigated 
stranger 1, versus a new unfamiliar mouse (“stranger 2”). The social testing apparatus was a 
rectangular, 3-chambered box fabricated from clear Plexiglas. Dividing walls had doorways 
allowing access into each chamber. An automated image tracking system (Noldus Ethovision) 
provided measures of entries and duration in each side of the social test box, as well as time in 
spent within 5 cm of the Plexiglas cages (the cage proximity zone).  
At the start of the test, the mouse was placed in the middle chamber and allowed to 
explore for 10 min, with the doorways into the two side chambers open. After the habituation 
period, the mouse was enclosed in the center compartment of the social test box, and an 
unfamiliar, sex-matched C57BL/6J mouse (stranger 1) was placed in one of the side chambers. 
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The stranger mouse was enclosed in a small Plexiglas cage drilled with holes, which allowed 
nose contact, but prevented fighting. An identical empty Plexiglas cage was placed in the 
opposite side of the chamber. Following placement of the stranger and the empty cage, the doors 
were re-opened, and the subject was allowed to explore the entire social test box for 10 min. 
Measures were taken of the amount of time spent in each chamber and the number of entries into 
each chamber by the automated tracking system. At the end of the sociability phase, stranger 2 
was placed in the empty Plexiglas container, and the test mouse was given an additional 10 min 
to explore the social test box. 
 
Acoustic startle and prepulse inhibition. This procedure was used to assess auditory function, 
reactivity to environmental stimuli, and sensorimotor gating. The test was based on the reflexive 
whole-body flinch, or startle response, that follows exposure to a sudden noise. Measures were 
taken of startle magnitude and prepulse inhibition, which occurs when a weak prestimulus leads 
to a reduced startle in response to a subsequent louder noise. Mice were tested at two ages: 11-13 
weeks and 33 weeks.  
For each test, mice were placed into individual small Plexiglas cylinders within larger, 
sound-attenuating chambers. Each cylinder was seated upon a piezoelectric transducer, which 
allowed vibrations to be quantified and displayed on a computer. The chambers included a 
ceiling light, fan, and a loudspeaker for the acoustic stimuli. Background sound levels (70 dB) 
and calibration of the acoustic stimuli were confirmed with a digital sound level meter (San 
Diego Instruments). Each session consisted of 42 trials that began with a 5-min habituation 
period. There were 7 different types of trials: the no-stimulus trials, trials with the acoustic startle 
stimulus (40 msec; 120 dB) alone, and trials in which a prepulse stimulus (20 msec; either 74, 
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78, 82, 86, or 90 dB) occurred 100 ms before the onset of the startle stimulus. Measures were 
taken of the startle amplitude for each trial across a 65-msec sampling window, and an overall 
analysis was performed for each subject's data for levels of prepulse inhibition at each prepulse 
sound level (calculated as 100 - [(response amplitude for prepulse stimulus and startle stimulus 
together / response amplitude for startle stimulus alone) x 100].  
 
Fear conditioning. Mice were evaluated for learning and memory in a conditioned fear test, 
using the Near-Infrared image tracking system (MED Associates, Burlington, VT). The 
procedure had the following phases: training on Day 1, a test for context-dependent learning on 
Day 2, and a test for cue-dependent learning on Day 3. Follow-up tests for retention of learning 
were conducted 2 weeks later. 
Training. On Day 1, each mouse was placed in the test chamber, contained in a sound-
attenuating box, and allowed to explore for 2 min. The mice were then exposed to a 30-sec tone 
(80 dB), followed by a 2-sec scrambled foot shock (0.4 mA). Mice received 2 additional shock-
tone pairings, with 80 sec between each pairing.  
Context- and cue- dependent learning. On Day 2, mice were placed back into the original 
conditioning chamber for a test of contextual learning. Levels of freezing (immobility) were 
determined across a 5-min session. On Day 3, mice were evaluated for associative learning to the 
auditory cue in another 5-min session. The conditioning chambers were modified using a 
Plexiglas insert to change the wall and floor surface, and a novel odor (dilute vanilla flavoring) 
was added to the sound-attenuating box. Mice were placed in the modified chamber and allowed 
to explore. After 2 min, the acoustic stimulus (an 80 dB tone) was presented for a 3-min period. 
Levels of freezing before and during the stimulus were obtained by the image tracking system. 
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Two weeks following each test, mice were given second tests to evaluate retention of context- 
and cue- dependent learning. 
 
Study approval. All animal procedures were approved by the Institutional Animal Care and Use 
Committee of The University of North Carolina at Chapel Hill. 
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Throughout the lifetime of an organism all cells must respond to changes in their 
environment, including a plethora of physiologic and pathologic stresses, in order to maintain 
homeostasis and survive. Protein homeostasis is particularly critical to cell survival because of 
the central role proteins play in so many cellular processes. Both under basal conditions and in 
response to stress, cells utilize multiple highly specialized and integrated methods of PQC to 
ensure that proteins are appropriately folded and terminally misfolded proteins are eliminated to 
prevent proteotoxicity. This is particularly crucial to post-mitotic organs such as the heart and 
brain, with their very limited capacity for self-renewal. PQC depends on an elegant collaboration 
between molecular chaperones and the ubiquitin-proteasome system (UPS). Disruption of PQC 
and subsequent proteotoxicity has long been considered an underlying molecular phenotype in 
disease pathologies in the brain and is being increasingly recognized as such in disease 
pathologies in the heart as well. Using a multifaceted approach, we focused on understanding the 
molecular mechanisms underlying diseases where disruption of PQC is central to disease 
pathology. Specifically, we focused on understanding the function of E3 ubiquitin ligases and 
how mutations in these key players in the UPS can drive disease pathology in the heart and brain. 
Chapter II described and validated a novel method for the identification of E3 ubiquitin ligase 
substrates addressing a significant technological limitation in the field. In Chapter III, I described 
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the first discovery of human mutation in the E3 ubiquitin ligase, CHIP in a form of 
spinocerebellar ataxia, Gordon Holmes Syndrome, that has led to the establishment of a new 
disease designation, SCAR16 to describe spinocerebellar ataxia caused by homozygous or 
compound heterozygous mutation in CHIP. In Chapter IV, I expanded upon this discovery to 
define the structural and functional consequences of CHIP mutation in SCAR16 and explored the 
deficits associated with this mutation in a genomic context utilizing a mouse model system 
providing the first definition of partial CHIP dysfunction and assignment of specific in vivo 
deficits that result as a consequence of partial but not total loss of CHIP function. In this chapter, 
I will consider how these observations can guide future investigations.  
 
E3 Ubiquitin Ligase Substrate Identification 
 In Chapter II, we described a novel method for the identification of E3 ubiquitin ligase 
substrates. The development of this methodology addresses a significant gap in our ability to 
study these key PQC components as existing methods to identify their substrates have relied 
heavily upon non-physiologic in vitro methods, impeding the unbiased discovery of 
physiological substrates in relevant model systems. In order to validate this methodology, we 
utilized it to identify physiological substrates of MuRF1 in cardiomyocytes. MuRF1 has recently 
been shown to be an important regulator of mitochondrial function in vivo201. Not only did this 
work validate our methodology, but also identified several very intriguing MuRF1 substrates, 
including mitochondrial proteins Hspd1 and Atp5b. MuRF1has been shown both in vitro and in 
vivo to be cardioprotective in models of global ischemia-reperfusion injury, and given the pivotal 
role of mitochondria in ischemia-reperfusion injury, further characterization of MuRF1 
195 
 
regulation of these novel substrates in mitochondria may provide important mechanistic clues 
towards this dramatic cardioprotection.  
 With the robust, flexible nature of the protocol we have described in Chapter II, we are 
hopeful that this method can be easily adapted to fit the needs, technical expertise and resource 
availability of many users. For example, due to the limitations of  2D-DIGE/MALDI-TOF as 
discussed in Chapter II, with minimal modification this method could be used with gel-free 
quantitative proteomics strategies such Tandem Mass Tags (TMT) or Isobaric Tags for Relative 
and Absolute Quantification (iTRAQ) to identify and quantitate proteins in each of the collected 
eluate and supernatant samples.125 Furthermore, it is our hope that this protocol will be broadly 
applied to the study of both ubiquitin ligases and DUBs. In fact, applying this methodology to 
the identification of novel CHIP substrates, particularly in the cerebellum, could provide 
important mechanistic understanding of the underlying drivers of SCAR16 disease pathology.   
 
 CHIP in SCAR16 
 In Chapters III and IV we reported the first discovery of CHIP mutation in GHS 
(T246M), which led to the SCAR16 disease designation and began to elucidate the biophysical 
and functional consequences of CHIP mutation in SCAR16 in vitro, in cells and in vivo. In 
Chapter III and IV, it was determined that T246M point mutation results in loss of CHIP 
ubiquitin ligase activity that is likely a result of dramatic destabilization and misfolding of the 
CHIP U-box that results in a loss of CHIP’s ability to form dimers and promotes the formation of 
large, multimeric CHIP aggregates both in vitro and in cells. The CHIP mutations that have been 
associated with SCAR16 are present in all three of CHIP’s functional domains and there is great 
clinical heterogeneity within SCAR16 disease. Therefore, the extension of the biophysical, 
structural and in vitro studies to include additional SCAR16 CHIP mutations both within the U-
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box domain and elsewhere will provide valuable insight into the structure-function relationship. 
This will allows us to better understand how mutations across multiple structural domains may 
uniquely affect CHIP function but result in the same disease. Importantly, this provides insights 
in how these structural and resulting functional changes may directly correlate to specific aspects 
of the disease phenotype to result in the observed clinical heterogeneity. 
 In Chapter IV, we observed that T246M CHIP is prone to aggregation and likely in an 
attempt to prevent the accumulation of insoluble toxic aggregates the turnover of this protein is 
dramatically increased relative to WT CHIP. Furthermore, we observed that the expression of 
soluble T246M CHIP in primary MEFs and across multiple tissues is dramatically reduced, in 
part through a proteasome-dependent mechanism. However, inhibition of the proteasome only 
partially blocks this turnover of T246M CHIP, suggesting other cellular mechanisms are at work 
to remove this damaged protein before its accumulation becomes damaging to the cell. We do 
not believe this is unique to T246M CHIP mutation. Of the many mutations associated with 
SCAR16, only one is a truncating mutation, and we can assume that in the majority of these 
cases the mutated CHIP protein is also being translated and then must be cleared by the cell. In 
fact, similar to what we observed with T246M mutation in our mouse model, in another reported 
case of SCAR16, soluble mutant CHIP protein expression was also dramatically reduced in 
primary patient fibroblasts.184  Autophagy is one possible mechanism known to clear protein 
aggregates and has even been shown to be activated to clear ubiquitinated proteins in a 
compensatory manner when the UPS cannot meet the proteolytic demands of the cell.202 
Evaluating the turnover of T246M CHIP in primary MEFs in the presence of autophagy inhibitor 
bafilomycin as well as evaluating markers of autophagy such as LC-3 and p62 would allow us to 
197 
 
further understand the molecular mechanisms the cell is utilizing to eliminate this damaging 
protein. 
In Chapters III and IV, we determined that T246M mutation results in the loss of CHIP 
ubiquitin ligase activity while retaining the ability to function in some of CHIP’s critical cellular 
roles in PQC as a co-chaperone and as an autonomous chaperone promoting the 
phosophorylation and potentiating the activity of AMPK, protecting cells from oxidative stress. 
Importantly, while T246M CHIP retains co-chaperone activities, binding chaperone proteins and 
inducing HSF1 nuclear translocation and Hsp70 expression following stress, both chaperone 
binding and the induction of Hsp70 are enhanced. This suggests that while it remains partially 
intact ,T246M mutation may alter normal CHIP-mediated regulation of the chaperone-mediated 
stress response in a deleterious manner. These data and our findings in our analysis of behavioral 
deficits in the T246M mice demonstrate that T246M mutation is not equivalent to total loss of 
CHIP. In order to better understand this distinction at a molecular mechanistic level, we 
performed preliminary protein microarray studies comparing protein expression and 
phosphorylation of over 800 proteins in lysates from primary WT, CHIP-/- and T246M MEFs. 
While there was a subset of overlapping changes in protein expression and 
phosphorylation, the majority of detectable changes relative to WT cells were unique to total loss 
of CHIP or T246M CHIP point mutation. This supports our functional data that total loss of 
CHIP and T246M mutation are not equivalent and suggests that, in fact, this can be dissected 
down to the level of protein expression and cell signaling. Validation of the protein changes 
identified in this preliminary study as well as additional protein microarray studies comparing 
genotypes in the context of different cellular stresses would provide valuable insight into 
important cellular signaling pathways that contribute to T246M disease pathology. Particularly 
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evaluating the changes in cell signaling following oxidative stress and UVC-induced damage, 
where we have observed functional differences between total loss of CHIP and T246M CHIP 
would provide insight into the distinct molecular mechanisms that underlie this difference in 
phenotype. Furthermore, exploring the key signaling pathways uniquely affected by T246M 
CHIP mutation both under basal conditions and during stress has the potential to provide 
additional downstream therapeutic targets for modulation of SCAR16 disease.  
 In Chapters III and IV, we demonstrated that CHIP-/- mice have behavioral and 
reproductive impairments that mimic some of the clinical features of SCAR16. However, these 
mice do not directly phenocopy the diverse disease heterogeneity in SCAR16, leading us to 
establish a point mutant mouse model (T247M) that mimics the human mutation in order to 
study the in vivo repercussions of T246M CHIP. We observed behavioral deficits attributable to 
cognitive cerebellar dysfunction not observed in our total loss of CHIP animal model, as well as 
deficits in learning and memory attributable to hippocampal dysfunction that are reflective of 
cognitive deficits reported in SCAR16 patients. We concluded that T246M mutation is not 
equivalent to total loss of CHIP, and that specific CHIP mutations in SCAR16 likely have 
varying biophysical and functional consequences to CHIP that may directly correlate to clinical 
phenotype. Surprisingly, testing of these mice at ages up to 31 weeks did not reveal significant 
motor impairment in the accelerating rotarod test indicative of cerebellar ataxia as a result of 
T246M mutation. We hypothesize that this may be a strain-dependent effect, as even the WT 
mice are particularly skilled at this task and other studies have suggested strong strain-
dependence in the ability of the mice to perform this task and consequently to detect deficits by 
this measure.185, 203 Additionally, variable age of onset of motor deficits has been reported 
previously in additional mouse models of cerebellar degenerative disorders.186  For these reasons, 
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retesting of our animals at a more advanced age as well as performing additional measures of 
motor dysfunction including the parallel rod floor test reported to have significantly less strain-
dependence204 will allow us to determine with confidence the presence or absence of cerebellar 
ataxia in the T246M mouse model. 
In Chapter III, we observed motor dysfunction in CHIP-/- mice as well as cellular loss 
throughout the various lobes of the cerebellum, specifically in the Purkinje cell layer with 
noticeable degeneration, mimicking the observation of Purkinje cell loss identified in the 
neuropathological analysis in a deceased GHS patient with disordered ubiquitination (RNF216 
and OTUD4 mutations). 136 Together, these data suggest CHIP is required for cerebellar 
maintenance. In Chapter IV, we described behavioral deficits attributable to cognitive cerebellar 
dysfunction in our T246M mouse model, many of which unique to this model and not present in 
our total loss of CHIP animal model. In order to fully appreciate the distinction between T246M 
CHIP mutation and total loss of CHIP, as well better understand the molecular mechanisms 
underlying SCAR16 disease pathophysiology, a careful analysis of brain pathology should 
accompany the behavioral analysis we have already performed. These studies would include 
longitudinal MRI studies to assess progressive cerebellar atrophy in T246M mice as well as 
histological staining of the cerebellum using hematoxylin and eosin stain to detect 
morhphological changes. Additionally, they would include immunohistochemical staining of the 
cerebellum for CHIP to evaluate CHIP expression and localization, calbindin staining to evaluate 
Purkinje cell health, morphology and abundance and Congo red staining to evaluate for signs of 
proteotoxic protein aggregation. Given our observation of additional functional deficits in the 
T246M mice attributable to other brain regions, such as deficits in learning and memory related 
to hippocampal dysfunction and reports of similar deficits in SCAR16 patients, these studies may 
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be extended to other brain regions including the hippocampus as well in order to determine 
whether observed changes in brain pathology as a result of T246M mutation occur similarly 
throughout affected brain regions and/or whether these changes directly correlate to functional 
deficits. Careful and thorough analysis of the brain pathology associated with T246M mutation 
in mice and the accompanying behavioral deficits would not only provide important mechanistic 
clues into disease pathology but also provide validation of this model for use in the development 
of SCAR16 therapies and may suggest important study endpoints for the preclinical validation of 
these future clinical candidates.  
In Chapter III, we observed that CHIP-/- mice recapitulate many of the reproductive 
impairments characteristic of GHS. Within the spectrum of disease phenotypes represented by 
SCAR16, patients with GHS represent a unique group where cerebellar ataxia characteristic of 
SCAR16 is paired with neuroendocrine deficits and resulting reproductive impairments 
associated with hypogonadism. While developing the T247M mouse model and establishing the 
mouse colony, we have observed impaired breeding of T247M homozygous mice. Additionally, 
preliminary hormonal studies of male T247M mice suggest abnormal circulating hormone levels 
and an impairment of the pituitary’s ability to respond to stimulation with gonadotropin releasing 
hormone (GnRH), similar to that observed in hypogonadism associated with GHS (data not 
shown). Future studies to characterize the neuroendocrine deficits and reproductive impairments 
associated with T246M, both by comparison to the CHIP-/- animals as well as to additional 
SCAR16 point mutant mice, would have the potential to allow us to delineate the contribution of 
particular CHIP functions to this unique disease phenotype within the SCAR16 disease 
spectrum. In order to fully assess neuroendocrine deficits and reproductive impairments 
associated with T246M in mice, these studies would include measurements of circulating 
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hormone levels of the hypothalamic-pituitary axis, including lutenizing hormone, follicle 
stimulating hormone, testosterone, estrogen and progesterone, assessment of pituitary function 
by GnRH stimulation test, pathological and morphological evaluation of  the pituitary and sex 
organs, including immunohistochemical staining for CHIP expression and localization, and 
observation and quantitation of reproductive patterns of these mice. Together these studies would 
bring to light the neuroendocrine deficits and reproductive impairments associated with T246M 
mutation in mice and begin to describe an as-yet unexplored aspect of CHIP biology in hormonal 
signaling, pituitary function and reproductive health.  
In Chapters III and IV, we report neurobehavioral deficits associated with total loss of 
CHIP and T246M mutation in mice. However, importantly previous studies of CHIP-/- mice have 
revealed significant cardiac deficits in multiple models of cardiac disease as well as dramatically 
reduced longevity and stress-intolerance as a result of genetic depletion of CHIP.8, 83-87, 155  While 
the studies presented in Chapters III and IV highlight the importance of fully functional CHIP 
protein in the brain, these previous reports also strongly suggest the particular importance of 
CHIP as a regulator of PQC in the heart and elsewhere. Studying the T246M mice in the context 
of cardiac disease and stress models as well as evaluating their longevity would allow us to more 
fully characterize this model in terms of our existing knowledge of CHIP biology, as well as gain 
further insight into SCAR16 disease pathology. Furthermore, in Chapter IV, we determined that 
T246M CHIP’s E3 ubiquitin ligase activity towards a variety of substrates is completely 
abolished, but T246M CHIP retains the ability to function in some of CHIP’s critical cellular 
roles in PQC as a co-chaperone and as an autonomous chaperone towards AMPK. Thus, by 
direct comparison of results observed with T246M mice in cardiac disease models and other 
models of stress to those observed with total genetic depletion of CHIP would provide a unique 
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opportunity to a unique opportunity to delineate the contribution of co-chaperone, ubiquitin 
ligase activity and other emerging CHIP activities to these specific deficits observed in vivo in a 
disease-relevant context. 
 
Implications for SCAR16 therapeutics 
Recently there has been increasing interest in modulation of the UPS as a therapeutic 
strategy to treat many disease indications, particularly neurodegeneration, cancer and 
immunological disorders, and some clinical success in doing so. In Chapters III and IV, we 
defined T246M as a causative mutation in SCAR16 and began to uncover the underlying 
structural and functional changes in CHIP that result from its mutation and serve as the 
molecular drivers of SCAR16 disease pathogenesis. Furthermore, we established and evaluated 
neurobehavioral deficits of a mouse model of human CHIP mutation in SCAR16.  This 
biophysical, cellular and in vivo characterization of T246M mutation in SCAR16 provides 
valuable insight required for the development of effective therapies for this devastating 
degenerative disease.  
Central to any successful therapeutic development process is the identification of 
druggable therapeutic targets. The data we have presented in Chapters III and IV clearly validate 
CHIP as a driver of SCAR16 disease pathogenesis and suggest that loss of CHIP ubiquitin ligase 
activity as a consequence of structural misfolding of the U-box domain is central to disease. In 
light of this, one potential therapeutic strategy would be the direct modulation of mutant CHIP to 
prevent the disorganization of the U-box domain and restore CHIP ubiquitin ligase activity. 
Crispr-mediated gene editing is being increasingly utilized pre-clinically and is actively being 
developed for use therapeutically in humans. Application of this technology is particularly 
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attractive for SCAR16, as it would provide a mechanism to restore normal CHIP sequence at the 
genomic level, restoring normal CHIP protein expression and function and could be done early 
in disease before significant degeneration occurs potentially curing and at the very least halting 
disease progression.  
While repairing the disease-causing CHIP mutation is ideal, many hurdles still exist 
before this technology is likely to be successfully applied in humans. In the meantime, our data 
suggests other strategies for modulating CHIP activity as well. In Chapter IV, we demonstrated 
that T246M mutation results in only partial loss of CHIP function, such that while ubiquitin 
ligase function is completely lost, many of CHIP’s other integral cellular functions remain intact. 
If SCAR16 disease is largely driven by loss of CHIP ubiquitin ligase function as this suggests, 
then activating CHIP ubiquitin ligase activity may be sufficient to prevent disease. Thus, 
activating CHIP ubiquitin ligase activity, independent of CHIP itself, may be a viable strategy to 
treat SCAR16. In terms of specific therapeutic targets, this could include the activation of other 
E3 ubiquitin ligases that could ubiquitinate CHIP substrates in a compensatory manner. 
Identification of disease relevant CHIP substrates utilizing methodology as described in Chapter 
II would likely aid in this pursuit.  
Activation of other E3 ubiquitin ligases may not represent the only path to modulating 
CHIP without directly targeting CHIP. Utilizing a whole-genome cDNA overexpression and/or 
siRNA screening strategy to identify other genes that when overexpressed or depleted rescue the 
phenotype associated with T246M mutation (for example, UVC-induced cell death) would be a 
useful approach to begin to identify additional therapeutic targets. Furthermore, additional 
protein microarray studies comparing the protein expression and phosphorylation profile of 
T246M expressing cells to WT cells both under basal conditions and during stress has the 
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potential to provide additional downstream therapeutic targets for modulation of SCAR16 
disease. Extending these studies to identify changes in protein expression in the cerebellums of 
T247M mice relative to wildtype mice by SILAC studies may also provide valuable in vivo 
cerebellum-specific therapeutic targets. By these efforts targets may even be identified for which 
clinically approved or pre-clinical well-validated specific chemical entities already exist that can 
be applied to this novel disease indication. 
 Our understanding of CHIP and its role in SCAR16 disease pathogenesis as detailed in 
this thesis is ongoing, yet the data presented here represents validation of CHIP’s importance in 
human disease and makes great strides towards explaining the molecular mechanisms underlying 
SCAR16 disease pathology. Interestingly, it highlights similarities but also some distinct and 
likely clinically relevant differences between total and partial loss of CHIP function (Fig. 5.1), 
deepening both our basic understanding of CHIP biology and SCAR16 and potentially guiding 
future therapeutic strategies. More broadly, this work extends our understanding of the UPS and 
its role in disease pathogenesis that will undoubtedly drive successful investment, innovation, 
preclinical investigation and clinical study design to treat patients suffering from not only 
SCAR16 but many other devastating diseases.   
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Figure 5.1. Phenotypic effects of total vs. partial loss of CHIP function in humans and mice. 
A. The effects of CHIP genetic depletion in the CHIP KO mouse model (left), clinical 
phenotype of humans with SCAR16 CHIP partial loss of function mutations (center) and the 
effects of CHIP partial loss of function in the T247M mouse model (right). 
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